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Abstract
The aim of this thesis was a biopharmaceutical characterization of oral nanocrystal formulations. Crys-
talline nanosuspensions (nanocrystals) are one of the most promising and successful formulation ap-
proaches for the bioavailability enhancement of poorly water soluble drugs. Crystalline nano- and mi-
crosuspensions of fenofibrate and the Merck Serono Compound AS were prepared by wet media milling.
The suspensions covered a wide particle size range (100 nm to 8 µm) and exhibited narrow particle size
distributions.
It was challenging to determine the solubility and dissolution of nanocrystal formulations. Very small
particles with rapid dissolution kinetics complicated the separation of solid from dissolved material.
Therefore, an in situ noninvasive analytical method based on the monitoring of light scattering intensi-
ties was developed. It avoided the critical separation step, both in solubility and dissolution testing. The
determination of solubilities revealed that the solubility was slightly increased only by the smallest sized
nanocrystals (10 − 20 % for particle size < 200 nm).
The dissolution assessment by the light scattering technique had a high temporal resolution, sensitivity,
and reproducibility. A straightforward and small scale experimental setup was an additional advantage.
The ideal applicability was observed for particle diameters of 100−500 nm. Dissolution times as short as
90 s could be determined. The method was still applicable for dissolution of particles with up to 1 µm in
size and a good correlation to a conventional dissolution setup (USP II apparatus with sample filtration)
was demonstrated for suspensions in this size range. Biexponential modeling of the dissolution curves
was successful and allowed for analysis of the dissolution kinetics. The experimental dissolution results
were in good agreement to the Noyes-Whitney theory of dissolution.
The next step of biopharmaceutical characterization was the permeability assessment of drug substances
formulated as crystalline suspensions with various particle sizes. The permeabilities were measured
across Caco-2 cell monolayers. An assay with vertical monolayer arrangement was compared to the
classical horizontal assay. The vertical setup did not improve the discriminative power and the adjust-
ment of standardized experimental conditions was difficult. Therefore, the horizontal setup was selected
for further experiments. A variation of apical transport medium by using a biorelevant medium instead
of a classical buffered salt solution did not alter the permeabilities essentially.
A nanosuspension (150 nm) of the Merck Serono Compound AS enabled a higher permeability with
reference to larger sized suspensions (860 nm and 7 µm). This correlated well with an observed acceler-
ated dissolution and an observed slight increase in solubility of the nanosuspension. On the contrary, a
positive effect of size reduction on permeability was not detected for fenofibrate. This unexpected result
might be due to the enzymatic fenofibrate conversion to fenofibric acid, a better soluble and evenly per-
meable metabolite. A correlation of permeability with apical fenofibric acid concentration dominated the
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correlation of permeability with particle size. The metabolization interfered with the effects of particle
size reduction. However, this phenomenon was not explicitly investigated in this study.
The biopharmaceutical investigation was completed by pharmacokinetic studies on the oral administra-
tion of suspensions to rats. Nanosuspensions of both drug substances improved the bioavailability with
reference to microsuspensions.
The presented work covers a thorough particle size distribution analysis, solubility, dissolution, perme-
ation and in vivo pharmacokinetic investigation of micro- and nanosuspensions of two drug substances.
These data are very useful to investigate the in vitro-in vivo relation of oral nanocrystal formulations. In
this work a good linear correlation of the logarithmic dissolution times to the bioavailability was demon-
strated. Furthermore plasma concentration-time profiles were successfully simulated using the Advanced
Compartmental Absorption and Transit (ACAT) model. For nanocrystal formulations the fit of simulated
to observed profiles was improved by applying the nanofactor effect implemented in the ACAT model.
Zusammenfassung
Ziel dieser Arbeit war eine biopharmazeutische Charakterisierung von oralen nanokristallinen For-
mulierungen. Kristalline Nanosuspensionen (Nanokristalle) sind einer der erfolgreichsten Ansätze zur
Verbesserung der Bioverfügbarkeit von schwer wasserlöslichen Arzneistoffen. Kristalline Nano- und
Mikrosuspensionen des Arzneistoffes Fenofibrat und des Merck Serono Wirkstoffes AS wurden mittels
Nassvermahlung hergestellt. Die Partikelgröße wurde schrittweise reduziert um einen breiten Größen-
bereich abzudecken (100 nm bis 8 µm). Die Suspensionen zeigten eine enge Partikelgrößenverteilung.
Die Messung der Löslichkeit und Freisetzung von Nanokristall Formulierungen bergen besondere Her-
ausforderungen. Da es sich um äußerst kleine Partikel mir sehr schneller Auflösungskinetik handelt, ist
die Abtrennung der festen Partikel vom gelösten Material schwierig. Deshalb wurde eine nichtinvasive
analytische Methode basierend auf der Messung der Intensität des Streulichtes entwickelt. Sowohl für
die Löslichkeits- als auch für die Freisetzungsbestimmung konnte der kritische Separationsschritt durch
die neue Methode vermieden werden. Die Löslichkeitsmessungen ergaben, dass nur die Löslichkeit der
kleinsten Nanokristalle geringfügig gesteigert wurde (10 − 20 % für Partikel < 200 nm).
Die Freisetzungsmessung mittels der Lichtstreumethode zeigte eine hohe zeitliche Auflösung, Sensitiv-
ität und Reproduzierbarkeit. Ein unkomplizierter experimenteller Aufbau im Kleinstmaßstab war ein
weiterer Vorteil. Der optimalen Anwendungsbereich lag im Partikelgrößenbereich von 100 − 500 nm.
Auflösungszeiten bis zu minimal 90 s konnten bestimmt werden. Auch für die Freisetzungsmessung
im Partikelgrößenbereich bis zu 1 µm war die Methode anwendbar. Eine gute Übereinstimmung
der Ergebnisse mit einer konventionellen Freisetzungsbestimmung (Blattrührer Apparatur und Proben-
filtration) konnte für diesen Größenbereich gezeigt werden. Die Freisetzungskurven konnten durch
eine biexponentielle Funktion erfolgreich beschrieben werden und dies ermöglichte die Analyse der
Auflösungskinetik. Die experimentellen Ergebnisse stimmten gut mit der Noyes-Whitney Theorie der
Freisetzung überein.
Einen weiterer Baustein der biopharmazeutischen Charakterisierung war die Permeabilitätsmessung der
als kristalline Suspensionen formulierten Wirkstoffe. Das Caco-2 Zellkulturmodel wurde für die Be-
stimmung der Permeabilitäten verwendet. Ein vertikaler wurde mit einem klassischen horizontalen Ver-
suchsaufbau verglichen. Keine positive Auswirkung des vertikalen Aufbaus auf die Unterscheidbarkeit
von Formulierungen wurde festgestellt und die Einstellung standardisierter experimenteller Bedingung-
en im vertikalen System war schwierig. Folglich wurde der horizontale Aufbau für die weiteren Ver-
suche gewählt. Die Verwendung eines biorelevanten Transportmediums als alternatives apikales Medium
beeinfusste die Permeabilitäten nur unwesentlich im Vergleich mit einer klassischen gepufferten Salz-
lösung.
Eine Nanosuspension des Wirkstoffes AS mit 150 nm mittlerem Teilchendurchmesser zeigte eine höhere
XPermeabilität als Suspensionen mit größeren Partikeln (860 nm und 7 µm). Dies korreliert mit der
Beobachtung einer schnelleren Auflösung und einer leicht erhöhten Löslichkeit der Nanosuspension.
Dahingegen wurde für Fenofibrat kein positiver Einfluss der Partikelgrößenreduktion auf die Per-
meabilität beobachtet. Dieses unerwartete Ergebnis ist möglicherweise durch die enzymatische Ester-
spaltung von Fenofibrat zu Fenofibrinsäure bedingt, welche im Caco-2 Versuch auftritt. Fenofibrin-
säure ist besser löslich und ebenso permeabel wie Fenofibrat. Die Korrelation von Permeabilität mit der
apikalen Fenofibrinsäurekonzentration war deutlicher als die Korrelation von Permeabilität und Partikel-
größe. Die Metabolisierung überlagerte den Einfluss der Partikelgrößenreduktion. Jedoch wurden diese
Zusammenhänge in der vorliegenden Arbeit nicht systematisch untersucht.
Abgerundet wurde die biopharmazeutische Untersuchung durch in vivo Pharmakokinetikstudien, in de-
nen Suspensionsformulierungen oral an Ratten verabreicht wurden. Nanosuspensionen beider Wirkstoffe
verbesserten die Bioverfügbarkeit im Vergleich zu Mikrosuspensionen.
Diese Arbeit umfasst eine gründliche Untersuchung der Partikelgrößenverteilung, eine Bestimmung
der Löslichkeit, Freisetzung, Permeation und in vivo Pharmakokinetik für Mikro- und Nanosuspen-
sionen zweier verschiedener Wirkstoffe. Diese Daten sind sehr wertvoll für eine Untersuchung der
in vitro-in vivo Beziehung von oralen kristallinen Nanosuspensionen. In der vorliegenden Arbeit
wurde eine gute lineare Korrelation der logarithmischen Auflösungszeit zur Bioverfügbarkeit gezeigt.
Weiterhin konnten Plasma Konzentrations-Zeit Verläufe erfolgreich mittels des erweiterten Absorptions-
Kompartimentmodel (ACAT) simuliert werden. Für nanokristalline Formulierungen wurde die Über-
einstimmung simulierter und experimenteller Daten durch die Anwendung des Nanofaktor Effektes im
ACAT Model verbessert.
Contents
1 Introduction 1
1.1 Nanocrystal technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Biopharmaceutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2.1 Dissolution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2.2 Permeation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.2.3 Pharmacokinetic modeling & simulation . . . . . . . . . . . . . . . . . . . . . 11
1.3 Light Scattering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.4 Aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2 Materials and Methods 15
2.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.1.1 Model compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.1.2 Chemicals and reagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.1.3 Instruments and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.2 Manufacturing of micro- and nanosuspensions . . . . . . . . . . . . . . . . . . . . . . . 20
2.3 Physical state characterization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.3.1 Differential scanning calorimetry . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.4 Light scattering measurements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.4.1 Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.5 Determination of particle size and morphology . . . . . . . . . . . . . . . . . . . . . . 23
2.5.1 Dynamic light scattering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.5.2 Static light scattering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.5.3 Scanning electron microscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.6 Concentration determination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.6.1 Fluorescence spectroscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.6.2 High pressure liquid chromatography . . . . . . . . . . . . . . . . . . . . . . . 24
2.6.3 Plasma extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.7 Solubility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.7.1 Drug substance solubility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.7.2 Nanosuspension solubility by light scattering method . . . . . . . . . . . . . . . 25
2.8 Dissolution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
XII CONTENTS
2.8.1 Dissolution media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.8.2 Conventional method: Sampling and separation . . . . . . . . . . . . . . . . . . 26
2.8.3 Dialysis method: Continuous separation . . . . . . . . . . . . . . . . . . . . . . 27
2.8.4 Noninvasive analytical techniques . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.9 Dissolution by light scattering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.9.1 Experimental setup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.9.2 Method development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.9.3 Data evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.9.4 Application to a market drug product . . . . . . . . . . . . . . . . . . . . . . . 32
2.10 In vitro permeability studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.10.1 Cell culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.10.2 Transport media for permeability studies . . . . . . . . . . . . . . . . . . . . . 32
2.10.3 Monolayer characterization and validation of transport study protocol . . . . . . 34
2.10.4 Horizontal permeability assay . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.10.5 Vertical permeability assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.10.6 Data evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.11 In vivo pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.11.1 Study setup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.11.2 Intravenous formulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.11.3 Oral formulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.11.4 Data evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.11.5 Pharmacokinetic modeling & simulation . . . . . . . . . . . . . . . . . . . . . 38
2.12 Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3 Results and Discussion 41
3.1 Micro- and nanosuspensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.1.1 Particle size and morphology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.1.2 Suspension production process . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.1.3 Physical state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.1.4 Stability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Dissolution media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.3 Light scattering measurements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.3.1 Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.4 Solubility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4.1 Drug substances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4.2 Nanosuspensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4.3 Summary and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.5 Dissolution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.5.1 Conventional method: Sampling and separation . . . . . . . . . . . . . . . . . . 54
3.5.2 Dialysis method: Continuous separation . . . . . . . . . . . . . . . . . . . . . . 54
CONTENTS XIII
3.5.3 Noninvasive analytical techniques . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.5.4 Summary and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.6 Dissolution by light scattering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.6.1 Method development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.6.2 Comparison of light scattering and conventional dissolution method . . . . . . . 61
3.6.3 Fenofibrate nanocrystal dissolution . . . . . . . . . . . . . . . . . . . . . . . . 62
3.6.4 Compound AS nanocrystal dissolution . . . . . . . . . . . . . . . . . . . . . . . 64
3.6.5 Nanocrystal dissolution by light scattering method: Discussion . . . . . . . . . . 64
3.6.6 Data evaluation according to the Noyes-Whitney dissolution model . . . . . . . 67
3.6.7 Are nanocrystal dissolution data recorded by the light scattering method predic-
tive for microcrystal dissolution? . . . . . . . . . . . . . . . . . . . . . . . . . . 72
3.6.8 Application to a market drug product . . . . . . . . . . . . . . . . . . . . . . . 72
3.6.9 The use of the biorelevant dissolution medium FaSSIF . . . . . . . . . . . . . . 73
3.6.10 Summary and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.7 In vitro permeability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.7.1 Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.7.2 Comparison of permeability assays . . . . . . . . . . . . . . . . . . . . . . . . 77
3.7.3 Permeability of APIs formulated as crystalline micro- and nanosuspensions . . . 81
3.7.4 Permeability of fenofibrate formulations in literature . . . . . . . . . . . . . . . 87
3.7.5 Summary and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
3.8 In vivo pharmacokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
3.8.1 The effect of fenofibrate and compound AS particle size reduction on pharma-
cokinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
3.8.2 The in vivo effects of particle size reduction: Discussion . . . . . . . . . . . . . 90
3.8.3 In vitro-in vivo correlation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
3.8.4 Pharmacokinetic modeling & simulation . . . . . . . . . . . . . . . . . . . . . 94
3.8.5 Summary and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
4 Summary and Outlook 103
Bibliography 107
List of Abbreviations 119
Acknowledgments / Danksagung 121
XIV CONTENTS
1
Introduction
1.1 Nanocrystal technology
Many new drug candidates exhibit poor water solubility and thus low bioavailability after oral admin-
istration. This forms a major challenge for formulation scientists and the nanocrystal technology has
emerged as a valuable tool to build the bridge between drug discovery and (pre)clinical application (Lip-
inski 2002; Rabinow 2004; Kesisoglou et al. 2007). The oral administration of nanosuspensions offers the
advantages of enhanced bioavailability, reduced variability and diminished food effect (Rabinow 2004;
Kesisoglou et al. 2007; Muller 2000; Van Eerdenbrugh et al. 2010; Quinn et al. 2012). In the following
a short introduction will be given into preparation methods, market products and the physico-chemical
properties leading to favorable in vivo performance of nanocrystals.
Crystalline nanosuspensions are defined as colloidal aqueous dispersions of submicron sized active phar-
maceutical ingredient (API) crystals and are stabilized by electrostatic and steric stabilizers (Rabinow
2004; Kesisoglou et al. 2007; Muller 2000). There are two main approaches to produce nanosized API
crystals: the ‘top down’ and the ‘bottom up’ technologies. The term ‘bottom up’ summarizes controlled
precipitation/crystallization techniques. The ‘top down’ approach is applied more often. API crystals
are downsized by crushing and mechanical attrition. This is realized by high-pressure homogenization
(e.g. the DissoCubes R© technology) or by wet media milling (e.g. the NanoCrystal R© technology). Stabi-
lizers which adsorb to the particle surface are required to prepare a stable formulation. They protect the
submicron sized particles against inter-particle forces leading to aggregation. Polymers (e.g. cellulose
derivatives) are used as steric stabilizers and anionic surfactants (e.g. sodium laurylsulfate or dioctyl
sulfosuccinate) typically function as electrostatic stabilizers. In Table 1.1 the currently available market
products based on nanocrystalline API are listed (Kesisoglou et al. 2007; Van Eerdenbrugh et al. 2008).
2 Introduction
Table 1.1: Marketed pharmaceutical products based on nanocrystalline drug substance.
Product Drug substance Company Technology Approved1
RAPAMUNE R© Sirolimus Wyeth NanoCrystal R©2 2000
EMEND R© Aprepitant Merck NanoCrystal R© 2003
TriCor R© Fenofibrate Abbott NanoCrystal R© 2004
MEGACE R© ES Megestrol acetate PAR Pharmaceuticals NanoCrystal R© 2005
TriglideTM Fenofibrate SkyPharma3 IDD R©-P4 2005
1 Date of Approval by the US Food and Drug Administration. 2 Elan Drug Delivery NanoCrystal R©.
3 Shionogi/First Horizon Pharmaceuticals 4 Insoluble Drug Delivery-Microparticle.
The improvement in bioavailability by orally administered nanocrystalline API is attributed to an en-
hanced dissolution rate through enlarged surface area and to an increased solubility. A high curvature,
the creation of high energy surfaces and a less ordered structure of molecules in nanocrystals have been
suggested to give further contributions (Van Eerdenbrugh et al. 2010). Two equations are most often
quoted to provide the physico-chemical background of these phenomena. The Noyes-Whitney equation
with modifications by Nernst and Brunner (Noyes and Whitney 1897; Nernst 1904; Brunner 1904; Costa
and Sousa Lobo 2001) describes a proportional increase in dissolution rate with increasing surface area
(Eq. 1.2). The increase in saturation solubility is described by the Ostwald-Freundlich equation (Ostwald
1900; Freundlich 1923; Kesisoglou et al. 2007):
CS ,r = CS ,∞ exp
(
2γM
rρRT
)
(1.1)
where CS ,r is the saturation solubility of a particle with radius r, CS ,∞ is the saturation solubility
of infinitely large particle, γ is the particle medium interfacial tension, M is the compound molecular
weight, ρ is the particle density, R the universal gas constant and T the absolute temperature. However,
recent publications report solubility increases of not more than 15%, which is in good agreement with
the Ostwald-Freundlich equation. An only small solubility increase highlights the role of an enhanced
dissolution rate for the bioavailability improvement by nanocrystals (Jinno et al. 2006; Kesisoglou and
Wu 2008; Van Eerdenbrugh et al. 2010).
1.2 Biopharmaceutics
In the development of drug substances and drug products not only pharmacology but also biopharma-
ceutics is an integral component. Biopharmaceutics relates pharmacodynamics (effect of the drug on the
organism) to pharmacokinetics (effect of the organism on the drug). It deals with the interdependence
of biological aspects of the living organism and physical-chemical characteristics of the drug substance
and formulations. The processes of absorption (A), distribution (D), metabolism (M) and elimination
(E) are important for the in vivo performance of a drug. They are often summarized in the term ADME.
Additionally the liberation of drug molecules from solid dosage forms has been recognized to influence
pharmacokinetics, since drug molecules are required to be in the solution phase for absorption (Langguth
et al. 2004; Krishna and Yu 2008).
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Figure 1.1: A schematic representation of the factors that determine the fraction of drug absorbed across
the intestinal mucosa. Reproduced from Dressman et al. (1998) with kind permission from Springer
Science and Business Media.
The bioavailability is one of the principal in vivo pharmacokinetic parameters of a drug or drug formula-
tion. Bioavailability is defined as the rate and extent to which a drug or its active moiety is absorbed and
reaches the systemic circulation, thereby accessing the side of action (Langguth et al. 2004; Krishna and
Yu 2008). The rate limiting factors to oral drug absorption were summarized by Dressman et al. (1998)
and are illustrated in Figure 1.1. Incomplete absorption can be referred to
• incomplete dissolution at the gastrointestinal (GI) sites where it is well absorbed
• decomposition in the GI tract or formation of nonabsorbable complexes
• insufficient transport across the GI wall
• first pass metabolization or elimination.
In 1995 Amidon et al. (1995) introduced the biopharmaceutical classification system (BCS), which is
based on the understanding that the rate and extent of intestinal absorption is controlled by the solubility
and permeability of a drug. Both the amount of drug in solution at the epithelial barrier and the ability
of that drug to diffuse across the gastrointestinal wall determine absorption. According to the BCS drugs
are classified into four groups: BCS I (high solubility, high permeability), BCS II (low solubility, high
permeability), BCS III (high solubility, low permeability) and BCS IV (low solubility, low permeability).
The BCS has implications on the development of new drug products. For drugs with low solubility (BCS
II and IV) formulation factors influencing dissolution rate or solubility have a great potential to influ-
ence the absorption. These factors may for example be the drug particle size or solubilizing excipients.
Kawabata et al. (2011) recently reviewed the basic approaches and practical applications of the BCS in
formulation development. An in vitro-in vivo correlation based on the dissolution rate can most likely be
established for BCS II drugs, since dissolution is most often the rate-limiting step of absorption (Amidon
et al. 1995).
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In vitro dissolution and permeation tests are continuously modified to closely simulate physiological con-
ditions and to meet the requirements of innovative dosage forms. The aim is to predict the rate and extent
of drug absorption in vivo. In the following the basics and current developments in in vitro dissolution
and permeation testing will be reviewed.
1.2.1 Dissolution
Dissolution is the process by which drug molecules are liberated from a solid phase and enter into a
solution phase. In vitro dissolution studies are especially important in the development of every oral
dosage form. They are not only used to predict how drug products will perform in patients. In vitro
drug release kinetics are also an integral component of quality control testing (Sinko 2005). Furthermore
in vitro dissolution testing plays a role in bioequivalence studies. The Food and Drug Administration
(FDA) defines criteria under which in vitro dissolution testing can fully replace in vivo studies for BCS
I drugs (FDA Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for
Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System).
The forthcoming sections will provide an outline of mathematical dissolution models and experimental
dissolution methods with the focus on nanoparticle dissolution.
Theories and mathematical models of dissolution
The dissolution process consists of two consecutive steps. The first step is the interfacial reaction, mean-
ing the liberation of molecules from the solid surface. The second step is the transport of solutes from
the solid-liquid interface into the bulk solution (Lee et al. 2008).
The diffusion layer model assumes that the interfacial reaction happens instantaneously and that the dis-
solution process is controlled by diffusion of liberated molecules through the stagnant liquid film layer
surrounding the particle (diffusion layer) into the bulk solution. This model, which is based on the Fick´s
first law, was developed by Noyes and Whitney and was modified by Nernst and Brunner (Noyes and
Whitney 1897; Nernst 1904; Brunner 1904).
dm
dt
=
A0D
h
(CS −C) (1.2)
where dm/dt is mass rate of dissolution, A0 is the total surface area, D is the diffusion coefficient,
h is the effective boundary layer thickness, CS is the saturation solubility and C is the concentration of
solute in the bulk solution at time t.
In this model the total surface area A0 and the effective boundary layer thickness h are held constant
during dissolution. Many authors describe that for particle dissolution, and especially for nanoparticle
dissolution, this assumptions need to be refined. In the Higuchi-Hiestand equation the boundary layer h
decreases proportionally with particle size r (Higuchi and Hiestand 1963; Higuchi et al. 1963). Johnson
and coworkers specified this concept. They developed a theoretical model to describe the dissolution of
polydisperse powders under non-sink conditions. They introduced a transition particle radius rtransition.
Below this radius the diffusion layer thickness equals the particle radius (h = r) and above this radius
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the diffusion layer thickness reaches a maximum value of hmax irrespective of particle size (Hintz and
Johnson 1989; Johnson 2012). The following equations are derived:
dXS i
dt
= −
3DX1/30i X
2/3
S i
ρhir0i
(
CS i −
XdT
V
)
(1.3)
with
ri =
(
3XS i
4piρN0i
)1/3
(1.4)
where the subscript i denotes a particle size fraction and where XS i is the mass of solid drug in
particle size fraction i, X0i is the initial mass of solid drug, D is the diffusion coefficient, ρ is the drug
density, hi is the particle size dependent diffusion layer thickness, r0i is the initial radius of particles, ri
is the radius of particles, CS i is the particle size dependent solubility of drug particles (calculated by the
Ostwald-Freundlich equation (Eq. 1.1)), XdT is the total mass of drug in solution from all size fractions, V
is the dissolution volume, and N0i is the initial number of particles. The Johnson dissolution model takes
into account changes in particle radius, diffusion layer and solubility. Additionally every size fraction of
a particle size distribution is modeled individually.
An experimental confirmation that the particle radius is approximately equal to the boundary layer thick-
ness was presented by Galli (2006) for particles with diameters of 0.5 − 5.9 µm. However, Wang and
Flanagan (1999) proposed a general solution for diffusion-controlled dissolution of spherical particles,
which assumes a constant diffusion layer thickness. Both models have been successfully applied to
model experimental data (Johnson 2012).
The Johnson and the Wang-Flanagan equations consider many parameters. With the cube-root law and
the Weibull function two more simple and often applied models will be shortly summarized. Hixson and
Crowell (1931) considered that the surface area of a particle or dosage form diminishes during dissolu-
tion. They derived a cube-root law
W1/30 −W1/3t = κ ∗ t (1.5)
where W0 is the initial amount of drug, Wt is the remaining solid amount of drug at the time t and κ
is a constant incorporating the surface-volume relation (Costa and Sousa Lobo 2001).
The Weibull function is a general empirical equation and was adopted to model dissolution curves (Lan-
genbucher 1972). It has ubiquitous applicability to dissolution curves obtained under versatile conditions.
Recently attempts have been made to assign some mechanistic / kinetic meaning to the empirical Weibull
parameters (Dokoumetzidis et al. 2006).
The presented models provide a first insight into the field of dissolution theories and modeling. The
interested reader will find additional models in literature, for example in Langguth et al. (2004); Costa
and Sousa Lobo (2001); Lee et al. (2008); Judefeind and Villiers (2009).
6 Introduction
Figure 1.2: The principles and operation steps of different dissolution techniques (left boxes) and their
suitability for nanocrystal dissolution testing (right boxes). (above) Compendial/conventional methods
categorized as sampling and separation or membrane diffusion techniques and (below) in situ noninvasive
techniques with examples of potential analytical methods.
In vitro dissolution testing
Various techniques are applied for dissolution testing of drug substances and pharmaceutical dosage
forms. Most commonly the methods of the European and United States Pharmacopoeias (Ph. Eur. and
USP) are used. For testing of immediate-release oral solid dosage forms the closed systems basket (USP
I) and paddle (USP II) apparatus are the methods of choice. The apparatus consists of a rotating basket or
paddle in a large vessel filled with 500−1000 ml of dissolution medium. Usually samples are withdrawn
and the undissolved material is filtered off to spectroscopically quantify the dissolved fraction of the dose.
The reciprocating cylinder (USP III) and the flowthrough cell (USP IV) are alternative methods. They
can be operated as closed or open systems and are most commonly used for modified-release systems,
however, are not dedicated to this applications (Sinko 2005). Figure 1.2 summarizes the operation steps
of the compendial/conventional dissolutions methods.
Commonly used media are aqueous salt solutions or buffers with or without the addition of surfactants.
More physiological media are required to set up meaningful in vitro-in vivo correlations. As biorelevant
dissolution media fasted state-simulated intestinal fluid (FaSSIF) or fed state-simulated intestinal fluid
(FeSSIF) containing bile salts and phospholipids are frequently used (Galia et al. 1998; Kleberg et al.
2010).
Experimental methods for in vitro nanoparticle dissolution testing
The analytical question of determining the dissolution rate of nanoparticles was raised by Heng et al.
(2008) who asked ‘What is a suitable dissolution method for drug nanoparticles?’. Basically the disso-
lution methods proposed in literature can be categorized as (a) being based on sampling and separation,
(b) consisting of a membrane diffusion setup, or (c) true in situ analytical techniques (Fig. 1.2).
(a) The sampling and separation technique prevails in many published studies where filtration, (ultra-)
centrifugation or centrifugal-filtration are used to separate undissolved nanoparticles from dissolved API
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(Xia et al. 2010; Shono et al. 2010; Jinno et al. 2008; Laaksonen et al. 2011; Li et al. 2011). Juenemann
et al. (2011b) focused on the filtration step and concluded that pore sizes of ≤ 0.1µm result in predictive
dissolution profiles. Shortcomings of all applied separation techniques are that they are slow and inef-
ficient when applied to rapidly dissolving particles. It is challenging to separate particles that are less
than a hundred nanometers in size, which shrink during the dissolution process. Furthermore, invasive
separation steps, in which the systems to be analyzed are subjected to different forces, might alter the
dissolution process. Due to the poor solubility of APIs, the dissolved concentrations are usually in the
lower µg/ml range. Taking this limitation into account, it is not favorable to perform a dissolution ex-
periment which exposes the API to large surfaces and is therefore inevitably accompanied by adsorptive
loss of API.
(b) The concept of membrane diffusion covers dialysis or reverse dialysis methods (Heng et al. 2008)
and continuous flow membrane filtration under pressure (Magenheim et al. 1993; Helle et al. 2010). Re-
cently, efforts have been made to modify compendial methods with dialysis membranes (USP apparatus
IV (Bhardwaj and Burgess 2010) and USP apparatus I (Abdel-Mottaleb and Lamprecht 2011)). For stud-
ies on sustained release nanoparticulate formulations with an undissolvable matrix membrane diffusion
techniques are eligible. However, results are heavily distorted for rapidly dissolving nanocrystals due to
comparatively slow membrane diffusion kinetics of drug molecules. Also a microdialysis system was
evaluated not suitable to measure dissolution of nanocrystals, since the surfactants and micelles com-
monly employed in dissolution media for poorly water soluble drugs cause problems (Junemann and
Dressman 2012).
(c) In situ analytical techniques, which avoid the need to separate dissolved API, are certainly the most
promising approach to assess nanocrystal dissolution. Ideally, they are designed as on-line and real-time
methods with high temporal resolution and have a noninvasive character. Being implemented in dissolu-
tion testing of conventional solid dosage forms it was an obvious step to use UV/VIS fiber optic probes
(Aldridge et al. 1995; Chen and Brown 1994; Tsinman et al. 2009; Alonzo et al. 2010; Galli 2006). How-
ever, recent research disproves the use of this technique for nanosized material due to the light absorption
by nanoparticles (Van Eerdenbrugh et al. 2011). Moreover electrochemical analytics, like polarography,
potentiometry and voltammetry, have been suggested, but are limited to electroactive APIs (Charalam-
popoulos et al. 2003; Rosenblatt et al. 2007; Mora et al. 2009; Juenemann et al. 2011a). Junemann and
Dressman (2012) proposed to use the ultrasonic resonator technology, which measures the sound veloc-
ity in liquid samples, which is dependent on the solute concentration. This technique was too slow and
not sensitive enough to detect fenofibrate in a saturated FaSSIF solution. Solution calorimetry has been
applied to measure nanocrystal dissolution (Kayaert et al. 2010). Calorimetry detects many phenomena
associated with any kind of molecular interaction and it is challenging to extract the net proportion of
heat change resulting from particle dissolution. Nevertheless a sound method development could provide
a platform for the measurement of nanoparticle dissolution by calorimetric methods in future. Finally,
a turbidimetric approach to assess small particle dissolution was introduced by Tucker (2002) and was
followed up by Crisp et al. (2007) and Chaubal and Popescu (2008). The use of the light scattering prop-
erties of particles dispersed in liquid to monitor dissolution generated promising results and encourages
further research.
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1.2.2 Permeation
The absorption of drug molecules across the intestinal membrane can basically follow two different paths.
Either the drug permeates through the cell crossing the apical membrane, the cytosol and the basolateral
membrane (transcellular route) or the drug transits through the water filled pores between epithelial
cells thereby crossing the tight junctions (paracellular route). On both routes passive diffusion along a
concentration gradient is the driving force. The physicochemical properties of a drug molecule determine
the preferred pathway and the rate of permeation, the permeability. The molecules aqueous solubility,
its lipophilicity, molecule size, polarity and ionizability play a role. Small, hydrophilic molecules, for
instance, prefer the paracellular route (Karlsson et al. 1999). Lipophilic molecules partition into the cell
membrane more easily and passage transcellularly. Passive transcellular permeability shows a predicted
maximum for a octanol/water partition coefficient (log P) of 2 and decreases if log P values of 4 are
exceeded (Artursson et al. 2001). Passive transcellular permeability is the main mechanism of absorption
for many lipophilic compounds.
In addition to passive diffusive processes carriers can be involved in the transcellular pathway, if the drug
molecule is substrate of a specific transporter localized in the cell membrane. Carrier-mediated uptake
occurs via active transporters or passive transporters (facilitated diffusion) (Buckley et al. 2012; Balimane
et al. 2006). Eﬄux transporters play a more important role in drug molecule permeation across epithelial
barriers, since pharmaceuticals can be recognized as xenobiotics, the exposure to which the organism
tries to minimize. The eﬄux transporters transport the substrates against a concentration gradient and
adenosine triphosphate (ATP) hydrolysis supplies the energy for this active transport. P-glycoprotein (P-
gp) or the multidrug resistance-associated protein 2 (MRP-2) are only two prominent examples (Fricker
and Miller 2002). Finally endo- or transcytosis are possible transport mechanisms in which the drug does
not pass the membrane but is entrapped and transported in vesicles formed by invagination of the plasma
membrane.
In vitro permeation testing
Various methods are used as model systems for intestinal epithelial permeability and they can be clas-
sified into artificial membrane and cell culture systems. Buckley et al. (2012); Balimane et al. (2006);
Hidalgo (2001); Braun et al. (2000) published excellent reviews, which will guide the reader through the
variety of models and protocols, give an industrial perspective on permeability assessment, and describe
current developments in permeability testing of poorly water soluble drugs.
The human colon carcinoma cell line Caco-2 plays the most important role in cell culture-based in vitro
permeability testing. It displays many characteristics of the in vivo epithelial permeation barrier: Tight
junctions, microvilli, metabolizing enzymes, and a wide range of drug transporters. As main differences
to the in vivo situation were identified: the lack of a mucus layer adjacent to the cell surface, and a vari-
able and in general lower expression level of transporters and enzymes (Ohura et al. 2010). Compared to
artificial systems the work with biological systems is time consuming and costly. Their higher inherent
variability adds effort and limits comparability. However, biological systems are more predictive for the
in vivo situation. Figure 1.3 shows a schematic representation of a Caco-2 permeability assay.
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Figure 1.3: In vitro drug permeability assay. A cell monolyer (e.g. Caco-2 cells) grown on a permeable
filter support forms the barrier between apical and basolateral compartment. Reprinted by permission
from Macmillan Publishers Ltd: Nature Protocols (Hubatsch et al. 2007), copyright (2007) by Nature
Publishing Group.
The permeability of drugs has been extensively studied by in vitro assays with Caco-2 monolayers (Braun
et al. 2000). In general drugs are applied as solutions to the apical side. As transport media buffered saline
solutions, supplemented with glucose are applied. Most often Hank´s balanced salt solution (HBSS) and
Krebs bicarbonate Ringer solution (KBR) are used and often a pH gradient with pH 6.5 apically and pH
7.4 basolaterally mimicking phyiological conditions in the intestine is established (Braun et al. 2000;
Ingels and Augustijns 2003; Buckley et al. 2012).
Attempts have been made to modify the experimental setup of permeability assays to overcome some
of the hurdles associated with the permeability testing of poorly soluble drugs. As problems insufficient
concentrations in the donor and receiver compartment, adsorption of API to the apparatus surfaces and
accumulation in the permeation barrier have been identified. Consequences can be poor API recovery,
non-sink conditions and analytical challenges (Buckley et al. 2012).
As an alternative to the standard horizontal setup (Fig. 1.3) a side-by-side diffusion chamber system with
vertical orientation of the Caco-2 monolayer has been proposed (Hidalgo et al. 1991; Karlsson and Ar-
tursson 1992; Rubas et al. 1996; Yu and Sinko 1997; Braun et al. 2000). In ex-vivo transport experiments
with excised tissues the vertical setup is widespread and side-by-side ussing chambers are used, which
are similar to the used side-by-side diffusion chambers (Tsutsumi et al. 2003). The transport buffer is
circulated by a gas-lift system and flows in parallel to the surface of the cell monolayer (Hidalgo et al.
1991). Improved hydrodynamics have been identified as a main advantage of this system. A reduction
of the unstirred water layer (UWL) adjacent to the monolayer was achieved, which is close to physio-
logical conditions in humans (Karlsson and Artursson 1992). The UWL forms a significant resistance
to the permeation of highly permeable/lipohilic drugs, many of which are poorly soluble. Consequently
control and minimization of the UWL in permeability assays can result in more meaningful permeability
estimates of lipophilic compounds (Tsutsumi et al. 2003; Buckley et al. 2012).
Another more popular strategy to cope with the challenges associated with permeability testing of poorly
soluble drugs is the modification of transport media. The addition of cosolvents and/or solubilizers has
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been extensively studied, since higher dissolved concentrations can be achieved and the wettability of
APIs can be improved. The cosolvent dimethylsulfoxide (DMSO) at concentrations of ≤ 1 % is used in
standard screening procedures (Hidalgo 2001; Ingels and Augustijns 2003; Balimane et al. 2006). Within
this development a focus was set on biorelevant amphiphilic molecules like bile salts and phospholipids.
In addition to their solubilizing properties they mimic phyiological conditions and an improved in vitro-
in vivo correlation is expected. The use of biorelevant media for transport studies goes in parallel with
their use in dissoluion studies. Phosphatidylcholine (PC) and sodium taurocholate (NaTC) are most fre-
quently used, since they are the most abundant phospholipid/bile salt in human bile secretions. 3 mM
lecithin and 0.75 mM NaTC are often chosen to mimick the fasted condition. These concentrations are
equally used in the fasted state simulated intestinal fluid (FaSSIF) for dissolution studies (Galia et al.
1998; Kleberg et al. 2010). On the basolateral side a media supplementation with bovine serum albumin
(BSA) 1− 4.5 % was successfully applied to mimick in vivo conditions and to enhance the API recovery
(Saha and Kou 2002; Kataoka et al. 2003; Fossati et al. 2008).
A good compatibility of biorelevent media with Caco-2 cells was demonstrated, with respect to mono-
layer integrity and cell viability (Ingels et al. 2002, 2004; Patel et al. 2006; Fossati et al. 2008). Different
effects on the permeability compared to standard media have been described. Permeabilities were in-
creased by 60%, decreased by 75% or remained unaffected (Kleberg et al. 2010). In studies with a broad
range of compounds (BCS I-IV) the overall correlation of in vitro permeability to in vivo fraction ab-
sorbed in humans was found to be very similar when comparing standard and biorelevant media. Impact
was shown on the permeability of poorly water soluble drugs and the recovery of lipophilic compounds
was improved. However, the inhibitory effect of NaTC on P-gp eﬄux transporters has to be carefully
considered (Ingels et al. 2004; Fossati et al. 2008).
Only few mechanistic studies on the effect of biorelevant media on permeability are available. Micellar
encapsulation, modulation of membrane fluidity and modulation of activity of membrane transporters
have been suggested to give contributions. It is thought that only free drug molecules in solution are
absorbable. Colloids might function as cargos delivering encapsulated drug molecules across the mucus
layer and unstirred water layer towards the enterocytes by mechanism of facilitated diffusion. On the
other hand colloids can function as depots for poorly water soluble drugs. In the case of a low partition
coefficient of drug from the colloid into the solution the concentration of free drug available for absorp-
tion can be reduced (Brouwers et al. 2006; Yano et al. 2010; Kleberg et al. 2010).
In parallel to the modification of transport media, the application of permeability assays has been ex-
tended to study the effect of pharmaceutical excipients on drug permeation through solubilization or
modulation of tight junctions (Takahashi et al. 2002; Thanou et al. 2001). Beyond that, effects of drug
delivery systems incorporating poorly water soluble drugs on drug permeability are increasingly stud-
ied (Linn et al. 2012; Buckley et al. 2012). Permeability studies on formulations like self emulsifying
drug delivery systems (SEDDS) (Buyukozturk et al. 2010; Kataoka et al. 2012), liposomes (Parmentier
et al. 2010), melt-extruded solid dispersions (Linn et al. 2012), cyclodextrines (Dahan et al. 2010) and
mesoporous silica (Kaukonen et al. 2007; Mellaerts et al. 2008) have been published. Buch et al. (2009)
performed permeability studies with fenofibrate formulated as a tablet based on a melt-extrudate and a
tablet formulation based on a nanosuspension.
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Figure 1.4: Advanced Compartmental Absorption and Transit (ACAT) model compartments (EHC: en-
terohepatic circulation, GB: gall bladder). Reproduced with permissions from Simulations Plus, Inc.
(GastroPlusTM 7.0 product manual).
1.2.3 Pharmacokinetic modeling & simulation
A mechanistic approach to mathematically model the oral absorption was developed based on the BCS
and the physiology of the gastrointestinal tract. The model is known as the Compartmental Absorp-
tion and Transit (CAT) model (Yu et al. 1996a,b) and was further refined to form the Advanced CAT
(ACAT) model. More physiochemical and physiological parameters as well as absorption in the stomach
and colon are considered in the ACAT model. It describes the release, dissolution, luminal degradation,
metabolism, and absorption of a drug as it transits through the GI tract. Nine GI compartments (stomach,
seven segments of the small intestine, colon) and six states of drug component (unreleased, undissolved,
dissolved, degraded, metabolized, absorbed) are distinguished (Fig. 1.4). The ACAT model was devel-
oped by Simulations Plus, Inc. and is available under the name GastroPlusTM. Detailed model descrip-
tions and case studies using the ACAT model in pharmaceutical research and development are available
from Huang et al. (2009); Kesisoglou and Wu (2008); Mathias and Crison (2012), the GastroPlusTM
manual and others.
GastroPlusTM offers the opportunity to adjust the saturation solubility of nanoparticles by the so called
nanofactor effect. It was introduced to adjust the model to better simulate PK profiles of nanocrystal for-
mulations. A need to modify the model for nano formulations was identified, since it was observed that
faster dissolution and/or enhanced solubility alone were not sufficient to describe higher bioavailabili-
ties. The nanofactor effect is based on the hypothesis that a local supersaturation at the apical membrane
could occur when nano-sized particles are trapped between apical microvilli. The local supersaturation is
given by the nanofactor effect, which specifies the extent by which drug can dissolve from different sized
particles above the solubility limit. It is an empirical equation and requires the input of a user-defined,
compound specific parameter, the nanofactor. The default equation with the default nanofactor (0.5) was
calibrated to explain aprepitant PK profiles with particle sizes of 120 nm up to 5.5µm (Wu et al. (2004),
GastroPlusTM manual).
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(a) Rayleigh vs Mie scattering (b) Rayleigh vs Mie scattering: Zoom
Figure 1.5: Relative scattering intensities vs particle diameter according to Rayleigh and Mie theory
of light scattering. Calculated with MiePlot 4.2.03 (http://www.philiplaven.com/mieplot.htm). Input
values: wavelength λ0 = 633 nm, unpolarized light, refractive index of particle npart = 1.51, imaginary
refractive index of particle npart,im = 0, refractive index of medium nmed = 1.33, different detection
angles θ.
1.3 Light Scattering
The light scattering properties of a cloud of particles depend on particle size and number. The correlation
between scattering intensity and particle number is linear for diluted samples, in which each particle
scatters light independently without being influenced by proximate particles (van de Hulst 1957; Elsayed
and Cevc 2011).
The dependence of scattering properties on particle size is more complex. Depending on the size range
different theories describe the correlation between scattering intensity and particle size or detection angle.
The Rayleigh theory describes the light scattering by spherical homogeneous particles smaller than the
wavelength of incident light. In the case of an unpolarized light beam the scattering intensity I of light
scattered by a single particle is given by
I =
8pi4a6n6medI0
r2λ40
∣∣∣∣∣∣m2 − 1m2 + 2
∣∣∣∣∣∣2 (1 + cos2θ) (1.6)
where I0 is the intensity of incident monochromatic light with the wavelength λ0, a is the radius,
nmed is the refractive index of the medium surrounding the particle, r is the observation distance, m is
the relative refractive index of the bulk particle material (m = npart/nmed with npart being the refractive
index of the particle), and θ is the angle between the detection direction and the forward direction of the
incident light beam (Yguerabide and Yguerabide 1998).
Strictly spoken the Rayleigh theory applies to particles for which the radius is a  λ0/(2pinmed |m|), which
is approximately a  λ0/10. Equation 1.6 denotes that the scattered light intensity increases with the
sixth power of the particle radius. Figure 1.5 shows the scattering intensity vs particle size graphs for two
different detection angles θ. No differences can be observed between the detection angels 0◦ and 173◦.
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As an approximation isotropic light scattering into all directions can be assumed for small particles.
The Mie theory describes the light scattering by spherical homogeneous particles of any size. Figure 1.5
illustrates that for an increasing particle size the scattering intensity does not continuously increase, but
varies around a mean value with maxima and minima. More light is scattered into the forward direction
(θ = 0◦) than into the backward direction (θ = 173◦) (Yguerabide and Yguerabide 1998).
1.4 Aim
The aim of this thesis was a biopharmaceutical characterization of oral nanoscopic formulations. As a
nanoscopic formulation crystalline nanosuspensions – also referred to as nanocrystals – were selected,
since the nanocrystal technology has proved to be one of the most promising and successful strategies
for a bioavailability enhancement of poorly water soluble drugs. The biopharmaceutical characterization
conducted in this study comprises solubility, dissolution, permeation and in vivo pharmacokinetic stud-
ies. Special emphasis was put on a quantification of the effects of particle size reduction on solubility,
dissolution, permeation and bioavailability. The intention was to evaluate, whether an in vitro-in vivo
correlation can be established.
The goals of this thesis were:
• Manufacturing and characterization of nanosuspensions and microsuspensions with various parti-
cle sizes and narrow particle size distributions.
• Determination of the solubility and dissolution kinetics of nanocrystals. Solubility and dissolution
testing on nanocrystal formulations is challenging and reliable methods are rare. Especially for
dissolution testing the pharmaceutical industries identified a need to evaluate and establish new
techniques, which are in vivo predictive and/or can serve as quality control tools. The objective
of this study was to develop an in situ noninvasive analytical method to measure dissolution and
solubility. Different techniques were evaluated and the most promising one was a light scattering
technique. A method based on the measurement of light scattering intensities for the determination
of solid/dissolved fractions was tested, developed and applied to different samples.
• Evaluation of the best suitable experimental setup to measure drug substance permeability across
Caco-2 monolayers, when nanocrystal formulations are employed.
• Design and realization of an in vivo pharmacokinetic study in rats.
• Analysis of particle size, solubility, dissolution, permeation and pharmacokinetic data with the
focus on in vitro-in vivo relations.
• Testing of the predictivity of in silico modeling to simulate in vivo absorption and pharmacokinet-
ics.
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2
Materials and Methods
2.1 Materials
2.1.1 Model compounds
Fenofibrate (FF) and the Merck Serono compound AS (AS) were used as poorly water soluble model
compounds. Table 2.1 lists their physicochemical properties. The chemical structures of fenofibrate and
its metabolite fenofibric acid (FFA) are given in Figure 2.1.
Fenofibrate is the isopropyl ester prodrug of its active metabolite fenofibric acid (2-[4-(4-chloro-benzoyl)
phenoxy]-2-methylpropanoic acid). Fenofibrate is a well known poorly water soluble model compound
with a high permeability and is classified as a BCS II drug (Granero et al. 2005). Fibric acid derivatives
(fibrates) are a class of compounds which play an important role in the management of hypercholes-
terolaemia, mixed dyslipidaemia, hypertriglyceridaemia and diabetic dyslipidemia. The lipid-modifying
effects of fenofibrate are mostly mediated by its ability to activate peroxisome proliferator activated re-
ceptor α receptor (Steinhilber et al. 2007). After oral administration fenofibrate is rapidly converted
Figure 2.1: Chemical structures of fenofibrate (a) and its active metabolite fenofibric acid (b)
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Table 2.1: Model compounds.
Fenofibrate Fenofibric acid Compound AS
Molecular formula C20H21ClO4 C17H15ClO4
Molecular weight [g/mol] 360.8 318.8
Physiocochemical properties
Solubility in water [µg/ml] < 0.3 1 70 2 < 10 5
log P 5.24 3 3.99 2 2.17 4
pKa - 3.1 2 6.2 4
Melting point Tm [◦C] 80 − 81 3 179 − 183 2 210 4
Density [g/cm3] 1.18 ± 0.06 5 - 1.42 ± 0.10 5
logP: octanol-water partition coefficient.
1 Granero et al. (2005).
2 Linn et al. (2012).
3 Albinus (1993).
4 Merck internal data.
5 predicted by I-lab 2.0 software, ACD/labs, Toronto, Canada (ilab.acdlabs.com).
through hydrolysis of its ester bond to fenofibric acid. Hydrolysis is catalyzed by both tissue and plasma
esterases and begins concomitantly with absorption. Only fenofibric acid and no unchanged fenofibrate
can be detected in the blood after an oral dose (Keating and Croom 2007; Chapman 1987; Yun et al.
2006; Buch 2010).
The Merck Serono compound AS (AS) was synthesized in the laboratories of Merck Serono. It is a
phosphoinositide 3-kinase-δ inhibitor intended for the treatment of rheumatoid arthritis (Rommel et al.
2007). It is no longer part of the Merck Serono development pipeline. Since it is, like fenofibrate, a
poorly water soluble and highly permeable compound, it was selected for this study. The same stabi-
lizers were applicable for the production of compound AS and fenofibrate micro- and nanosuspensions
which offered a good comparability of the formulations.
2.1.2 Chemicals and reagents
Table 2.2 provides a list of various chemicals, reagents and drug products used in this work. All other
chemicals were purchased from the usual commercial sources in highest available quality. Water was of
Milli Q grade with 0.055 µS/cm, 5ppb TOC (Merck Millipore, Billerica, MA, USA).
2.1.3 Instruments and equipment
Tables 2.3 and 2.4 provide a list of the most important instruments used in this work. All other materials
were standard laboratory equipment and were purchased from the usual commercial sources.
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2.2 Manufacturing of micro- and nanosuspensions
All formulations used in this study were aqueous suspensions of an API stabilized by HPMC (steric
stabilizer) and DOSS (electrostatic stabilizer). They were composed of API / HPMC / DOSS at the ratio
of 20 / 2.5 / 0.1 by total suspension weight, which corresponds to a API concentration of 200 mg/ml. The
actual API concentration was determined for each formulation after manufacturing. Micro- and nanosus-
pensions were prepared by wet media milling. Prior to milling a slurry was prepared by dispersing the
API in the aqueous stabilizer solution and homogenization by magnetic stirring. This slurry was used as
a coarse suspension and was named raw nanosuspension (raw NS).
Two different kinds of milling equipment were used to enable the production of suspensions with
different particle sizes. A high energy process was based on an agitator ball mill with yttrium-
stabilized zirconium oxide beads (0.2 − 0.3 mm). By variation of the process parameters milling speed
(2000 / 3000 / 4000 rpm), bead fill level (50 / 70 %) and process duration (1 − 120 min) distinct particle
sizes could be generated. A low energy process was designed using a ball milling setup with zirconium
oxide balls (5 mm) agitated in a 12 ml zirconium oxide grinding bowl by magnetic stirring. With the low
energy process and with process durations of only 1 min suspensions of wide particle size distributions
were obtained and further steps were performed to create suspensions of defined size with narrow size
distribution. The post milling processes covered sedimentation, centrifugation and isolation of different
supernatant/sediment layers. For example, microparticles were separated off by sedimentation and sam-
pling of the topmost supernatant layer. On the contrary for the production of bigger sized suspensions
the supernated was discarded and the sediment was redispersed in water. The manufacturing details for
all suspensions are summarized in Table 2.5. All formulations were stored at 4 − 8◦C.
2.3 Physical state characterization
2.3.1 Differential scanning calorimetry
By differential scanning calorimetry (DSC) the physical state of drug substances and formulations was
characterized. DSC measurements were conducted with a DSC821e instrument (Tab. 2.4). 10± 1 mg of
drug substances were weighted into 100 µl aluminum pans and the pans were sealed with a perforated lid.
In the case of micro- and nanosuspensions the weighted crucibles were filled with approximately 100 µl
of suspension and the water was allowed to completely evaporate at room temperature (approximately
72 h). Depending on the suspension concentration this process was repeated to yield a total amount of
solids of 10± 1 mg. Thermograms showing the heat flux versus temperature with endothermic reactions
displayed in positive direction were recorded with following method: Heating from 25 − 250◦C at a rate
of 10 K/min. From the thermograms the enthalpies of transition ∆H [J/g] were calculated via peak inte-
gration with StarSoftware (Mettler-Toledo, Greifensee, Switzerland). For each sample three repetitions
were made.
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Table 2.5: Manufacturing of suspensions.
Formulation Milling Batch size Bead fill level Speed Milling time Post milling
equipment [ml] [rpm] processing
Fenofibrate suspensions
NS 120nm DM 100 70 % 4000 120 min
NS 140nm DM 100 50 % 2000 120 min
NS 160nm DM 100 50 % 2000 50 min
NS 180nm DM 100 70 % 4000 1 min 1
NS 270nm DM 100 70 % 4000 1 min 1
NS 650nm DM 100 50 % 2000 15 min
NS 800nm LE 4 10 pcs 250 18 h 2
NS 1070nm LE 4 10 pcs 250 17 h 2
MS 7.9µm LE 4 10 pcs 250 3.5 h 3
Compound AS suspensions
NS 100nm DM 100 70 % 2000 40 min
NS 130nm LE 4 10 pcs 500 4 h 4
NS 150nm LE 4 10 pcs 500 5 h 4
NS 860nm LE 4 10 pcs 250 26 h 5
NS 1020nm LE 4 10 pcs 250 24 h 5
NS 1320nm LE 4 10 pcs 50 5 h 5
MS 3.4µm LE 4 10 pcs 250 22 h 6
MS 6.8µm LE 4 10 pcs 250 3 h
DM: agitator ball mill Dyno R©Mill ResearchLab. LE: low energy ball milling by magnetic stirring. pcs: pieces.
1 4 weeks sedimentation - sampling of supernatant layers
2 72 h sedimentation - sampling of supernatant layers
3 72 h sedimentation - discard of supernatant layers
4 3-5 days sedimentation - supernatant centrifugation - supernatant sampling
5 3-5 days sedimentation - supernatant centrifugation - sediment redispersion
6 72 h sedimentation - sediment redispersion
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2.4 Light scattering measurements
A Zetasizer instrument with Zetasizer software 6.20 (Tab. 2.3) was used for various purposes. The in-
strument and software are designed to perform dynamic light scattering (DLS) measurements for the
determination of particle sizes (section 2.5.1). For this purpose light scattering intensity fluctuations are
recorded and analyzed (Brittain 2003). In addition the instrument was used to measure absolute light
scattering intensities, which can be read out as mean count rate in kilo counts per second (kcps). The
mean count rate gives the arithmetic mean of the scattering signal (count rate) detected during a mea-
surement run. The number and duration of measurement runs can be varied in the measurement settings.
The Zetasizer instrument was equipped with a He-Ne laser (wavelength 633 nm, 4.0 mW) and an
avalanche photodiode served as a detector at a detection angle of 173◦ (backscatter mode). In the
measurement settings the attenuator and the measurement position can be varied. Since both have an
influence on the intensity of scattered light it is crucial to keep them constant, when it is intended to
compare absolute scattering intensities of different measurements. The incident laser light is varied by
the attenuator, which can be set from 0 (total laser block) to 11 (full laser power). In this study a fixed
attenuator of 10 (30 % of laser light enters the sample cuvette, data provided by Malvern) was used for all
determinations of absolute light scattering intensities. The measurement position was fixed at 4.65 mm
(distance from cuvette wall) to ensure a constant scattering volume. The scattering volume is the area
of the laser beam crossing the detection window and has a volume in the order of magnitude of 0.01 µl
(data supplied by Malvern). Both, attenuator and position settings, were chosen to give scattering inten-
sity values in the range of 100 − 2000 kcps. All measurements were performed at 25 ◦C in disposable
semi-micro polystyrene cuvettes with lids (Tab. 2.3).
2.4.1 Validation
It was validated that the laser and detector of the Zetasizer instrument function in a constant and lin-
ear mode for the considered scattering intensities, since the instrument is calibrated for measurement
and analysis of intensity fluctuations, but not for recording absolute intensity data. For that purpose the
correlation between particle concentration and scattering intensity of spherical polystyrene nanoparti-
cles (NanosphereTM Size Standards 3150A, Z average 147± 3 nm, Tab. 2.3) was evaluated. The parti-
cle suspension with a concentration of 1% solids (data provided by Thermo Scientific) was diluted in
0.06% sodium chloride solution according to the dilution protocol for calibration (protocol provided by
Malvern). Dilutions of 0.01−0.22∗10−3 % solids were prepared and immediately the absolute scattering
intensities were determined (Three measurements with 10 runs at 10 s on three independently prepared
samples).
Furthermore the correlation of scattering intensity and particle concentration was explored for the FF
suspension NS 1070nm. Seven different dilutions in water were prepared with FF concentrations rang-
ing from 0−5.5 µg/ml. The solubility was exceeded at least twofold in the prepared samples and stability
of particle size throughout the measurement was assured. (Three measurements with 10 runs at 10 s on
three independently prepared samples).
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2.5 Determination of particle size and morphology
2.5.1 Dynamic light scattering
Dynamic light scattering (DLS) measurements were conducted for the determination of submicron par-
ticle sizes using a Zetasizer instrument. Nanosuspensions were diluted with water to concentrations of
typically 20−200 µg/ml. At these concentrations the drug substance solubility is exceeded by at least fac-
tor twenty, which prevents particle dissolution and ensures stable particle size. The effect of nanosuspen-
sion ingredients on the dispersion medium viscosity could be neglected due to the high dilutions (HPMC
concentration < 0.0025 %). Threefold size measurements at position 4.65 mm with automated attenuator
settings at 25 ◦C were performed. Micelle size in the dissolution media was determined likewise. Particle
size is reported as intensity weighted mean hydrodynamic size (Z average) and the polydispersity index
(PDI) provides a measure of distribution width.
2.5.2 Static light scattering
Static light scattering (SLS) measurements were performed using a Horiba LA-950 instrument for the
determination of particle sizes. The concentration of nanosuspensions used was adjusted to meet the
optimum condition of 80 - 90 % transmission for the red laser and a 70 - 90 % transmission for the blue
laser. In the software settings the refractive indices of FF and AS were set to 1.51 and 1.60 respectively.
The refractive indices of APIs were determined by refractive index measurements of API solutions in
ethanol and extrapolation to 0 % solvent (Saveyn et al. 2002).
Size distributions measured by SLS are reported on a volume fraction basis calculated by using 15 itera-
tions. A minimum of three repetitions was performed for each size determination.
2.5.3 Scanning electron microscopy
Scanning electron microscope (SEM) images were taken to gain insight into the morphology of suspen-
sion particles. A few microliters of suspension were put onto a glass specimen holder and were dried at
room temperature. Subsequently an ultrathin coating of the specimen was applied by depositing 10 nm
of platinum on the sample by low-vacuum sputter coating. SEM images were taken with a LEO 1530
Gemini instrument (Tab. 2.3). The instrument was equipped with a field emission gun, which was used
at acceleration voltage 5 kV, and detection was conducted with an inlens detector.
2.6 Concentration determination
2.6.1 Fluorescence spectroscopy
Fluorometric quantification of the fluorescent dye Lucifer Yellow was conducted with a Fluoroscan As-
cent microplate reader in 96-well plates (Tab. 2.4). Extinction and emission wavelengths were 485 nm
and 538 nm. A calibration with a minimum of six data points covering the measurement range was re-
peated with every series of fluorescence measurements. A calibration was accepted as valid, if it resulted
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Table 2.6: Methods for high pressure liquid chromatography (HPLC).
Fenofibrate and fenofibric acid1 Compound AS
Mobile phase
Eluent A H2O/AcN: 95/5 + 0.01% TFA H2O/AcN: 95/5 + 0.1% TFA
Eluent B H2O/AcN: 5/95 + 0.01% TFA H2O/AcN: 5/95 + 0.1% TFA
Extraction medium H2O/AcN: 20/80 H2O/AcN: 20/80
Column Zorbax Eclipse Plus C18 4.6 x
50mm 3.5µm
Zorbax Eclipse Plus C18 2.1 x
50mm 3.5µm
Column temperature 30 ◦C 50 ◦C
Flow 2 ml/min 1.8 ml/min
Gradient 0 min A/B 100/0 0 min A/B 100/0
3 min A/B 80/20 3 min A/B 75/25
6.8 min A/B 30/70 6 min A/B 70/30
8.3 min A/B 0/100 10 min A/B 20/80
11 min A/B 0/100 10.1 min A/B 0/100
12 min A/B 100/0 12 min A/B 0/100
12.1 min A/B 100/0
14 min A/B 100/0
Injection volume 20 µl 10 µl
Sample temperature 20 ◦C 10 ◦C
Detection wavelength 288 nm1 268 nm
1 Ketoconazole and griseofulvin were determined with the same method, however, with other detection wavelengths:
210 nm (KC) and 293 nm (GF).
in coefficients of determination R2 > 0.995.
2.6.2 High pressure liquid chromatography
Fenofibrate, fenofibric acid, compound AS, ketoconazole (KC) and griseofulvin (GF) concentrations
were determined by high performance liquid chromatography (HPLC). Two different HPLC systems
(Merck Hitachi LaChrom and Dionex 3000, Tab. 2.3) were used and the detailed methods can be found
in Table 2.6. All samples were diluted in HPLC vials with the extraction medium 1:1. Three independant
dilutions of each sample were prepared and two injections were performed from each vial. A complete
calibration of the method was repeated every three months and control standards were run with each
sequence. Calibration standards were prepared in extraction medium at concentrations of 1− 100 µg/ml.
2.6.3 Plasma extraction
To determine concentrations of fenofibric acid in rat plasma samples it was necessary to extract the API
from the plasma by a protein precipitation protocol. Plasma samples were thawed at room tempera-
ture, homogenized via vortexing, and centrifuged to separate off the cryoprecipitate. 100 µl of plasma
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were then transfered to a 1.5 ml micro tube, acidified with 20 µl of 1 M hydrochloric acid, and vortexed.
The protein precipitation step was carried out by adding 380 µl of ice cold acetonitrile, vortexing and
subsequent storage of samples for 10 min at room temperature. Via centrifugation the precipitate was
separated off and the supernatant was quantitatively transfered to a clean tube. Under vacuum the sam-
ples were evaporated to dryness (approximately 20 h). The residue was reconstituted in 200 µl mobile
phase eluent B (H2O / AcN: 5 / 95 + 0.01 % TFA). Therefore the sealed tubes were put into a ultrasonic
bath for 10 min. In most samples a small undissolvable fraction remained and was centrifuged off. The
clear supernatant was transfered into a HPLC vial with micro volume insert (250 µl, pulled point glass
inserts) and HPLC analysis was performed using the standard protocol for fenofibric acid quantification
(Tab. 2.6). All centrifugation steps were carried out at 15700 g for 5 − 10 min.
2.7 Solubility
2.7.1 Drug substance solubility
An excess amount of API (10 mg/ml) was dispersed in the test medium and stirred for 24 h at 25 ± 1◦C.
To separate off undissolved material samples were centrifuged at 16060 g for 30 min and subsequently
the supernatant was filtered (Whatman Anotop 10 0.1 µm). Control DLS measurements were performed
on the filtrates and absence of undissolved material was assumed if no particles apart from polysor-
bate micelles could be detected. The concentration of dissolved drug was quantified by HPLC. Three
independent experimental series with triplicates were performed.
2.7.2 Nanosuspension solubility by light scattering method
To determine the solubility of nanosuspensions an approach of monitoring the presence of solid nanopar-
ticles by light scattering (instead of determining concentrations of dissolved material) was introduced by
Lindfors et al. (2006) and taken up by Van Eerdenbrugh et al. (2010). In the presented study this method
was modified and a Zetasizer instrument was used to measure the scattering intensity.
At the time zero nanosuspension dilutions of 0−14 µg/ml (FF) and 0−9.5 µg/ml (AS) in the test medium
were prepared and stored in sealed cuvettes at 25±1◦C. At distinct time points the samples were homog-
enized via shaking and absolute scattering intensities were measured (section 2.4, settings: one measure-
ment with 8 runs at 8 s). The resulting data were plotted in a scattering intensity vs concentration graph
and two linear segments could be identified: The first one represents completely dissolved concentra-
tions with scattering intensities equal to blank medium and the second one represents partially dissolved
concentrations with a slope corresponding to an increasing solid fraction. To a minimum of seven data
points of each branch a linear function was fitted. Their intersection point was calculated and interpreted
as the nanosuspension solubility. For all dilutions the concentration of the nanosuspension excipient
DOSS was below the critical micelle concentration of 1.2 mg/ml (Chatterjee et al. 2001) and hence it
was avoided that solubilization influences solubility. Each experiment was performed in triplicate.
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Table 2.7: Dissolution media.
Simulated gastric fluid supplemented with 0.1% Tween 80 (SGF + Tween)
NaCl 2.00 g 34.2 mM
HCl 1N 80 ml
Tween 80 0.94 ml 0.76 mM
Milli Q water ad 1000 ml
pH adjusted to 1.2± 0.05
Fasted state simulated intestinal fluid (FaSSIF)
NaCl 6.19 g 106 mM
NaOH 0.42 g 34.2 mM
NaH2PO4 3.44 g 28.7 mM
sodium taurocholate
∗
3.00 mM
lecithin
∗
0.75 mM
Milli Q water ad 1000 ml
pH adjusted to 6.5± 0.05
∗
contained in 2.24 g SIF powder
2.8 Dissolution
2.8.1 Dissolution media
Two kinds of dissolution media were used: Simulated gastric fluid (SGF) without pepsin according to
United States Pharmacopeia (USP34-NF29 S1) supplemented with 0.1% (w/V) polysorbate 80 (Tween R©
80) and fasted state simulated intestinal fluid (FaSSIF). The use of the compendial medium SGF is
widespread and a supplementation with surfactants is often done in dissolution testing of poorly water
soluble drugs (Lee et al. 2008). The use of biorelevant media like FaSSIF has emerged in the last decade
and it has nowadays developed to a standard medium in pharmaceutical dissolutin testing, especially if
an in vitro-in vivo correlation is intented (Galia et al. 1998; Lee et al. 2008). FaSSIF was prepared with
SIF powder (Tab. 2.2) according the protocol provided by Phares. The compositions of dissolution media
are given in Table 2.7. SGF + Tween was stored at 4−8◦C and used within seven days. FaSSIF prepared
from SIF powder is stable for two days at room temperature (data provided by Phares). The refractive
indices of dissolution media were determined with a digital refractometer (Tab. 2.4).
2.8.2 Conventional method: Sampling and separation
Conventional dissolution tests were performed with a USP II paddle apparatus at 25 ± 1◦C at 100 rpm
rotation speed and a medium volume of 500 ml. After 2.5 min, 5 min, 10 min, 15 min, 20 min, 30 min,
45 min, 60 min, 90 min and 120 min 1 ml samples were withdrawn and filtered (Whatman Anotop 10
0.02 µm). The first 0.5 ml of filtrate was discarded. The filtrate was analyzed for undissolved material
by a DLS measurement. Absence of drug crystals was assumed if no particles apart from polysorbate 80
micelles could be detected. Shorter sampling intervals (0.3, 0.7, 1.0, 1.3, 1.7, 2.0, 2.3, 2.7, 5.0 min) were
chosen for the dissolution experiment with a nanosuspension.
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Concentrations of the filtrates were determined by HPLC and represent the dissolved concentration. The
undissolved fraction was calculated by subtraction of the dissolved concentration from the total drug
concentration. The fraction dissolved was calculated as percentage of dissolved concentration of total
API concentration.
2.8.3 Dialysis method: Continuous separation
The conventional sampling and separation experiment was modified by using a dialysis setup. A nanosus-
pension was injected into a dialysis cassette floating in the dissolution medium in a paddle apparatus
dissolution vessel. The idea was that dissolved API will diffuse across the dialysis membrane whereas
nanoparticles will be retained in the dialysis cassette. Slide-A-Lyzer dialysis cassettes with a molecular
weight cut off of 10kD were used and filled with 3 ml of prediluted formulations (207 µg/ml). A fenofi-
brate nanosuspension (NS 120nm) was compared to a coarse suspension (raw NS, section 2.2). The
dissolution medium was SGF + Tween. The dissolution vessels were filled with 900 ml and the rotation
speed was 100 rpm. The experiment was performed at 37 ◦C. 100 µl samples were withdrawn through
the injection ports of the dialysis cassettes (donor compartment) with a Hamilton microsyringe.
Concentrations of fenofibrate in the donor samples were determined by HPLC. The concentrations in
the receiver compartment were calculated by subtracting the donor concentrations from the total API
concentration.
2.8.4 Noninvasive analytical techniques
The feasibility of noninvasive analytical techniques for the purpose of nanocrystal dissolution monitoring
was evaluated. The focus was set on a noninvasive light scattering technique which will be described in
a separate section (section 2.9).
Nuclear magnetic resonance spectroscopy and Raman spectroscopy
The idea to use spectroscopic techniques was to follow the transition of physical state of an API molecule
during dissolution. The API concentrations employed in nanocrystal dissolution experiments are in the
lower µg/ml range, due to poor solubility of APIs. Consequently the sensitivity of the analytical tech-
nique to detect and quantify the API was the critical point about the applicability of spectroscopic tech-
niques. Since nanocrystal dissolution experiments were conducted at concentrations below the saturation
solubility, a saturated solution displayed the maximal relevant API concentration. The sensitivity of spec-
troscopic techniques was evaluated by measurement of a saturated API solution. Saturated solution of
fenofibrate in SGF + Tween were prepared like described in section 2.7.1.
For the evaluation of nuclear magnetic resonance spectroscopy (NMR), the medium was prepared with
DCl and D2O. NMR measurements with respect to 1H nuclei (Proton NMR) were performed with a
Oxford NMR instrument (Tab. 2.4). Raman spectra of a saturated solution were recorded with a Raman
microscope at a laser wavelength of 532 nm (Tab. 2.4).
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Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) is a technique combining laser light scattering microscopy with a
charge-coupled device (CCD) camera which enables the visualization and recording of nanoparticles in
solution. Individual particles can be tracked by the software. Their particle size is calculated from the
particle movement by applying the Stokes-Einstein equation (Filipe et al. 2010). The size and scattering
intensity of particles can be determined simultaneously on a particle-by-particle basis. In addition the
particles are counted.
Feasibility studies were carried out with a fenofibrate nanosuspension NS 140nm, which was diluted with
SGF + Tween to concentrations of 5−20 µg/ml. Immediately after dilution a NTA video was recorded and
sequentially analyzed in steps of 15 − 60 s to follow the process of particle dissolution. Measurements
were performed with a NanoSight LM20 instrument and analyzed with NTA 2.0 Analytical Software
(Tab. 2.4).
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) is a thermodynamic method and measures the heat released or
absorbed during various interactions or reactions. Calorimetric effects are associated with particle dis-
solution and it was evaluated, if this effect was measurable for nanocrystal dissolution with a VP-ITC
instrument (Tab. 2.4). The sample cell was filled with 1.4 ml of SGF + Tween and the system tempera-
ture was set to 25◦C. The fenofibrate nanosuspension NS 140nm was diluted with SGF + Tween (1:1000)
and was stepwise injected into the sample cell with an injection speed of 0.5 ml/s. As a negative control
sample an aqueous solution of the nanosuspension stabilizers HPMC and DOSS was prepared at equal
concentrations as in the nanosuspension (2.5 % HPMC, 0.1 % DOSS). This solution was likewise diluted
and injected into the sample cell.
2.9 Dissolution by light scattering
Nanocrystal dissolution was followed by monitoring changes of light scattering intensity with a Zetasizer
instrument (section 2.4). The method will be described in the following and Figure 2.2 provides an
overview of experimental setup and data evaluation method.
2.9.1 Experimental setup
The dissolution experiments were conducted at concentrations below the nanosuspension solubility after
24 h (S NS 24h) and nanosuspensions were diluted with the test medium in two steps. In the predilution step
1−10 µl of nanosuspension were added to 5−10 ml of medium under magnetic stirring to a concentration
8 − 10 fold above the solubility S NS 24h. Within 30 s the final dilution step was performed directly in the
cuvette by adding 20 − 100 µl of prediluted nanosuspension to a total volume of 1 ml and this time was
defined as zero. Gentle mixing was performed by four 180◦-turnings of the cuvette taking care of no air
bubbles to occur. A series of measurements was started subsequent to placing the cuvette in the sample
cell. Measurement parameters were: 2 runs at 2 s, measurement position 4.65 mm, attenuator 10 and
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Figure 2.2: Nanocrystal dissolution by light scattering: Schematic representation of experimental setup
(upper panel), resulting dissolution graph and data evaluation method (lower panel). C is the concentra-
tion and CS is the saturation solubility. f (t) is the scattering intensity, t is the time after dilution and M,
c and y0 are the unknown function parameters. DT is the dissolution time.
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25◦C. Before each dissolution experiment a blank medium measurement was conducted in the identical
cuvette already containing the respective volume of medium for the final dilution step. The final result is
reported as ∆ Mean Count Rate, which is the mean count rate of each dissolution measurement reduced
by the mean count rate of the blank measurement.
2.9.2 Method development
In light scattering dissolution experiments a decreasing scattering intensity signal was observed, which
might not only be due to particle dissolution but also due to particle adsorption onto cuvette walls. The
extent of API adsorption, the influence of cuvette material and fluid flow were evaluated.
Adsorption
To evaluate the extent of adsorption API recovery studies were performed. The fenofibrate nanosus-
pension NS 120nm was used as a model formulation. It was dispersed in two different media (SGF +
Tween and FaSSIF) at two concentration levels (5 µg/ml and 10 µg/ml) in two different cuvette types
(polystyrene disposable cuvettes (PS) and quartz glass cuvettes (QS), Tab. 2.3). After 1, 5 and 10 min
samples were withdrawn and subjected to HPLC concentration determination.
Cuvettes
To evaluate the effect of cuvette material dissolution experiments with NS 120nm at a concentration
of 5.5 µg/ml in SGF + Tween or FaSSIF were performed in three different cuvette types: polystyrene
disposable (PS), quartz glass (QS) and optical glass (OS) cuvettes (Tab. 2.3). PS and QS cuvettes were
used in two different conditions: (1) after thorough cleaning and drying and (2) reuse after a dissolution
experiment (the cuvette was emptied after the first experiment and reused as is for a second identical
experiment). The idea of the reuse experiments was to evaluate possible adsorption effects. If adsorption
of particles or API onto cuvette walls influenced dissolution relevantly, it would be expected that an
influence on dissolution profiles in reused cuvettes would be seen, since cuvette wall surfaces would
already be coated during the first experiment.
Fluid flow
To evaluate whether the mixing step of the dissolution experiments and the resulting fluid flow in the
sample effects the measured light scattering signal, a rested sample was compared to a just mixed sample.
For that purpose spherical polystyrene nanoparticles (NanosphereTM Size Standards 3150A, Z average
147±3 nm, Tab. 2.3) were dispersed in SGF + Tween at a concentration of 0.5 ∗ 10−3 % solids. For
the mixed sample the time flow and mixing procedure of a dissolution experiment was followed. For
the rested sample a resting step of 10 min was included between mixing and starting the measurement.
A series of 15 measurements was performed with the parameters: measurement position 4.65 mm and
attenuator 6, 10 runs at 10 s.
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2.9.3 Data evaluation
Exponential models were chosen to describe the dissolution curves in an empirical and pragmatic way
and to enable the calculation of characteristic data points to improve the comparability of different disso-
lution profiles. Selection of functions for data fitting was governed by the intention of introducing only a
low level of complexity. Exponential (Eq. 2.1) and biexponential (Eq. 2.2) functions have been described
to model dissolution data previously (Costa and Sousa Lobo 2001; Langguth et al. 2004; Laakso et al.
1984). Especially biexponential models have been successfully fitted to dissolution profiles of micron
and submicron particle size distributions (Tsinman et al. 2009; Galli 2006; Tinke et al. 2005; Tay et al.
2011). In this study simple exponential function fitting was not sufficient in all cases so that biexponential
function fitting was applied for all tests.
f (t) = Me−t/c + y0 (2.1)
f (t) = M1e−t/c1 + M2e−t/c2 + y0 (2.2)
f (t) is the scattering intensity (∆ Mean Count Rate) in kcps, t is the time after dilution in minutes
and M, c and y0 are the unknown function parameters. To compare the goodness of fit for both models
not the coefficient of determination R2, but the adjusted coefficient of determination R2ad justed was used.
R2ad justed is more meaningful, when comparing models with different numbers of parameters (Costa and
Sousa Lobo 2001) and is calculated as
R2ad justed = 1 −
(n − 1)
(n − p) (1 − R
2) (2.3)
where n is the number of dissolution data points and p is the number of parameters in the model.
The fitted functions were further analyzed by calculating the time, when only 1% of the initial scattering
intensity (fitted parameter M or M1 + M2) remains. This time is defined as the total dissolution time
DT . For exponential and biexponential functions DT was calculated according to Eq. 2.4 and Eq. 2.5
respectively.
f (DT ) = 0.01M (2.4)
f (DT ) = 0.01(M1 + M2) (2.5)
By applying these equations the function offset y0 was neglected. This was possible, since y0 was
very small compared to M or M1 + M2, respectively (< 10 kcps). The function fitting and determination
of DT was performed for each repetition of a dissolution experiment. Subsequently arithmetic means
and standard deviations of DT were calculated.
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2.9.4 Application to a market drug product
EMEND R© 80 mg capsule (Tab. 2.2) is a market product of the API aprepitant based on nanocrystals. The
feasibility of the light scattering dissolution method to monitor dissolution of aprepitant nanocrystals
released from EMEND R© was tested. Since the formulation contains undissolvable excipients which
disturb light scattering measurements, a filtration step was added to the dissolution protocol.
The total number of pellets contained in a single EMEND R© capsule and individual pellet weight was
determined. This allowed the calculation of API content of single pellets. Pellets were then dispersed in
SGF + Tween by magnetic stirring. By this process nanocrsystals were released from the pellets and their
dissolution was prevented by choice of a concentration above the aprepitant solubility. In the predilution
step (Fig. 2.2) undissolvable excipients were removed by filtration through a 0.45 µm filter (Spartan 30,
Whatman). The particle size of the filtrate was measured. The final dilution step and the light scattering
measurement were carried out according to the standard protocol (section 2.9.1). The experiment was
performed at 37◦C.
2.10 In vitro permeability studies
2.10.1 Cell culture
Caco-2 cells (DSMZ no. ACC 169) were supplied by Leibniz-Institut DSMZ - Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany. The cells were grown in cell
culture flasks in Dulbecco´s modified Eagle´s medium (DMEM) with supplements (Tab 2.8). The cells
were kept at 37 ◦C in an atmosphere with 5% CO2 and in equilibrium with distilled water. The medium
was changed every other day. The cells were subcultured at 80% confluency. Therefore the feeding
medium was removed, the cells were washed with HBSS−−, and TrypLETM Express was used to detach
the cells. Cells were used in the experiments at passage number 17 − 38.
For the permeability studies the Caco-2 cells were seeded on permeable filter supports (Tab. 2.4) at a
density of 65000 cells/cm2. No additional coating of the filter supports was required. The cells were
grown in feeding medium with 1.5 ml on the basolateral and 0.5 ml on the apical side. Every other
day the medium was exchanged by performing the following steps: removing apical medium, removing
basolateral medium, adding basolateral medium, adding apical medium. After 21 ± 7 days the cells
formed a confluent monolayer (verified microscopically) and were ready to be used in permeability
experiments.
2.10.2 Transport media for permeability studies
Hank´s balances salt solution (Hanks and Wallace 1949) supplemented with bivalent cations of magne-
sium and calcium (HBSS++) was used as transport medium. The pH was adjusted to 6.5 ± 0.05 for the
apical medium and to 7.4 ± 0.05 for the basolateral medium. HBSS++ was prepared on the basis of pre-
mixed salts (Tab. 2.2). In the apical compartment as alternative medium transport-FaSSIF (tFaSSIF) was
used, which was composed of HBSS++ with addition of sodium taurocholate and lecithin. SIF powder
was used for preparation (Tab. 2.2). Table 2.9 provides the compositions of all transport media.
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Table 2.8: Cell culture media and buffers
Feeding media: Dulbecco´s modified Eagle´s medium (DMEM) with supplements
fetal bovine serum 10 % (V/V)
Na-pyruvat 100 mM 1 % (V/V)
non-essential amino acids 100x 1 % (V/V)
l-glutamin 200 mM 1 % (V/V)
pencicillin 100 U
streptomycin 100 µg/ml
ciprofloxacin 20 µg/ml
Hanks´ balanced salt solution (HBSS−−)
KCl 0.4 g 5.37 mM
KH2PO4 0.4 g 0.44 mM
NaCl 8.0 g 137 mM
Na2HPO4 0.048 g 3.38 mM
NaHCO3 0.35 g 4.16 mM
Milli Q water ad 1000 ml
Table 2.9: Transport media.
Hanks´ balanced salt solution (HBSS++)
KCl 0.4 g 5.37 mM
KH2PO4 0.4 g 0.44 mM
NaCl 8.0 g 137 mM
Na2HPO4 0.048 g 3.38 mM
NaHCO3 0.35 g 4.16 mM
CaCl2*2H2O 0.185 g 1.26 mM
MgSO4*7H2O 0.1 g 0.41 mM
MgCl2*6H2O 0.1 g 0.49 mM
D-Glucose 3.5 g 19.4 mM
HEPES 2.38 g 10.0 mM
Milli Q water ad 1000 ml
pH (apical medium) adjusted to 6.5 ± 0.05
pH (basolateral medium) adjusted to 7.4 ± 0.05
Transport-FaSSIF (tFaSSIF)
HBSS++ pH 6.5 1000 ml
sodium taurocholate
∗
3.00 mM
lecithin
∗
0.75 mM
∗
contained in 2.24 g SIF powder
34 Materials and Methods
2.10.3 Monolayer characterization and validation of transport study protocol
The transepithelial electrical resistance (T EER) of monolayers was monitored prior to and during trans-
port studies. It was measured in transport media at 37 ◦C. To obtain the resistance of the cell monolayer
itself the background resistance of the filter and medium needs to be subtracted. The background re-
sistance was determined by T EER measurements of empty filters under the same conditions as during
transport experiments. Background values of 164 Ωcm2 (measured in cell culture plate) and 125 Ωcm2
(measured in side-by-side diffusion chambers) were determined. By multiplying with the filter surface
area [cm2] the monolayer resistances [Ω] were converted to the resistance of unit area [Ωcm2] (Tavelin
et al. 2002). Monolayers with T EER > 250 Ωcm2 were used for transport studies.
Experiments with the solutions of the paracellular marker Lucifer Yellow (0.5 mmol/l) and suspensions
of the BCS II drugs ketoconazole and griseofulvin (0.5 mmol/l) were performed to validate the perme-
ability assays. The experimental protocols were the same as will be described in the following.
2.10.4 Horizontal permeability assay
In the horizontal permeabilty assay the cell monolayer, grown on a permeable filter support, was po-
sitioned horizontally, which is the standard experimental setup for permeability experiments. As filter
supports Transwell R© inserts were used (polyester membrane, 0.4 µm pore size, 4∗106 pores/cm2, 1.1 cm2
growth area, Tab. 2.4). The permeability assays were performed in a cellZscope R© instrument, which of-
fered automated monitoring of the transepithelial electrical resistance (T EER) and the cell capacitance
(CCl) by measuring the frequency-dependent impedance of the cell layer. A background correction of
measured T EER values is not necessary with the cellZscope R© device and conversion to the resistance of
unit area is done automatically by the software. Wegener et al. (2004) described the cellZscope R© device
and the theoretical background of impedance measurements.
24 h prior to the experiment the cells were put on serum-free feeding medium. All transport media and
the cellZscope R© instrument were prewarmed to 37 ◦C. Prior to the experiment the cells were washed
twice with transport medium. Subsequently the filter inserts were transfered from the cell culture plate
into the cellZscope R© instrument and the cell monolayers were allowed to equilibrate for 2 h. During
the equilibration and the experiment the instrument was located in a climate chamber at 37 ◦C and was
subjected to gentle horizontal shaking (150 rpm). 1 ml of transport medium with pH 7.4 was used on the
basolateral side and 0.5 ml of transport medium with pH 6.5 was used on the apical side.
Meanwhile predilutions of the formulations or solutions to be used in the transport experiment were pre-
pared in apical medium. The concentrations were adjusted so that addition of 200 µl of predilution into
500 µl of apical medium resulted in the concentration desired for the transport experiment. All trans-
port assays were performed in apical to basolateral (A to B) direction. Fenofibrate concentrations of
181 µg/ml (0.5 mmol/l) were used. This concentration is in accordance with Kataoka et al. (2006), who
suggested to use 1% of the clinical dose in about 1/100 of the physiological volume of the human GI
tract (1.45 mg FF in 8 ml). Compound AS was applied in equimolar dose.
The transport experiment was started by addition of 200 µl of prediluted formulation or solution into the
apical compartment. Mixing was performed by gentle up- and down pipetting. Directly after addition
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(a) Vertical diffusion chamber system. (b) SnapwellTM side-by-side diffusion
chambers.
Figure 2.3: The vertical diffusion chamber system. Reprint from Warner’s Guide to Ussing Chamber
Systems; Warner Instruments, LLC, Hamden, CT, USA with kind permission.
and at the end of the experiment a apical sample of 100 µl was withdrawn. Basolateral sampling was
performed after 30, 60, 90 and 120 min. The sample size was 200 µl and was replaced by fresh transport
medium. Samples were stored at -20 ◦C until concentration determination by HPLC.
2.10.5 Vertical permeability assay
In the vertical permeability assay the cell monolayer was positioned vertically in side-by-side diffu-
sion chambers (Tab. 2.4 and Fig. 2.3). Cells were grown on SnapwellTM inserts (polyester membrane,
0.4 µm pore size, 4∗106 pores/cm2, 1.1 cm2 growth area) and the filter supports were mounted in vertical
SnapwellTM diffusion chambers. A heater block, designed to hold six diffusion chambers, provided a
regulation of temperature by use of an external circulating water bath. A gas manifold distributed car-
bogen gas to the chambers and media circulation was generated by a gas-lift process. A gas flow meter
(rotameter) was used to control the gas flow rate (80−100 ml/min) into the gas manifold and via the flow
valves the flow into each chamber was fine tuned (4 − 6 bubbles/s).
The transport experiments were carried out at 37 ◦C. After mounting the filter supports in the diffusion
chambers the apical and basolateral chambers were filled with 6 ml of prewarmed transport media. All
steps of cell washing, equilibration, preparation of prediluted formulations and sampling were carried out
like described for the horizontal permeability assay. Transepithelial electrical resistances were measured
at distinct time points with a so-called ‘chopstick’ device (Millicell R©-ERS).
2.10.6 Data evaluation
The determined mass of substrate [µg] appearing in the receiver compartment (corrected for dilutions
due to sampling and medium replacement) was plotted against sampling time [s]. Curve fitting using
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standard linear regression parameters (coefficient of determination R2 > 0.90) was used to give the rate
of drug transport dQ/dt [µg/s]. The apparent permeation coefficient Papp was calculated according to
the following equation (Balimane and Chong 2008):
Papp[cm/s] =
dQ
dt
1
C0A
(2.6)
C0 is the initial apical drug concentration [µg/ml] and A is the surface area of the filter [cm2].
The recovery of API from transport experiments was calculated by taking into account the amount of API
in the apical compartment QA120min and in the basolateral compartment QB120min (corrected for dilutions
due to sampling and medium replacement) and relating it to the total initial API amount in the apical
compartment QA0min = C0VA, with VA being the volume of apical medium.
Recovery[%] =
QA120min + QB120min
QA0min
∗ 100% (2.7)
In the case of fenofibrate its metabolite fenofibric acid occured in donor and receiver compartments
during transport studies. For the calculation of API recovery the total amounts of FF and FFA were taken
into account.
2.11 In vivo pharmacokinetics
2.11.1 Study setup
Pharmacokinetical (PK) studies on rats were performed for orally (p.o.) administered suspensions of FF
and AS with varying particle sizes and for intravenously (i.v.) administered API solutions.
Healty, male Wistar rats with approximately 250 g weight (Charles River, Sulzfeld, Germany) were
housed in cages for a minimum of three days prior to administration. Holding and study areas had auto-
matic control of light cycles (12 h light / 12 h dark), temperature (23±1◦C) and humidity (60±10%). Tap
water and food (Tab. 2.4) were offered ad libitum. Food was removed at least 10 h prior to administration
and replaced 3 h after dosing. The animals were uniquely identified by ear marks. Prior to administration
animals were weighted and body weights of 200 − 290 g were registerd.
The intravenous formulations were injected into the tail vein and oral formulations were administered
by gastric gavage. Details about the formulations and administration are given below and in Table 2.10.
The exact administration volume was adjusted according to the individual animal weight to ensure dose
consistency. The dose of fenofibrate was 2.1 mg/kg in accordance with the clinical dose (145 mg for a
70 kg adult) (Buch et al. 2009; Zhu et al. 2010). The dose of compound AS was selected to be equimolar
to the fenofibrate dose.
Each study group consisted of six animals and received one of the formulations. Two subgroups with
three animals were formed and at four time points blood samples were taken from each animal. The sam-
pling times after administration were: 10 min, 1 h, 3 h and 8 h for group A and 30 min, 2 h, 5 h, 25 h for
group B. Data of subgroups were pooled to yield PK profiles with eight data points for each formulation.
Blood samples of 200 µl were collected from the tail vein in Li-Heparin coated blood collection tubes
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Table 2.10: Summary of in vivo pharmacokinetic experiments.
Formulation administration route administration volume dose dose
[µl / 250 g body weight] [mg/kg] [mmol/kg]
Fenofibrate
FFA solution intravenous 250 2.1 0.006
NS 140nm oral 900 2.1 0.006
NS 270nm oral 900 2.1 0.006
NS 1070nm oral 900 2.1 0.006
MS 7.9µm oral 900 2.1 0.006
Compound AS
AS solution intravenous 500 1.0 0.002
NS 100nm oral 800 2.7 0.006
NS 150nm oral 800 2.7 0.006
NS 860nm oral 800 2.7 0.006
NS 1320nm oral 800 2.7 0.006
MS 6.8µm oral 800 2.7 0.006
Microvette R© 200, (Tab. 2.4). Via centrifugation the blood cells were separated off to gain the blood
plasma. Plasma samples were stored at -20◦C and analyzed within 21 days (section 2.6). After the last
sampling time the rats were sacrificed by CO2 - asphyxia.
2.11.2 Intravenous formulations
The objective of i.v. formulation development was to yield clear solutions with a sufficiently high API
concentration to achieve an administration volume of maximal 500 µl. For that purpose various com-
positions of solubilizers and cosolvents in phosphate buffered saline (PBS, Table 2.11) were screened
with the intention of keeping the percentage of additives low. The formulations which resulted in stable
particle free solutions were chosen as i.v. formulations. Visual inspection was performed to control for
absence of particles.
Fenofibric acid was selected for i.v. administration instead of fenofibrate, since very high percentages
of additives were necessary to generate a solution of fenofibrate with the desired concentration. In vivo
a very rapid and complete metabolization of fenofibrate takes place during oral absorption and only
fenofibric acid can be found in the blood compartment. This offers the possibility of comparing intra-
venous fenofibric acid administration to oral fenofibrate administration (Zhu et al. 2010). Solutions of
fenofibric acid (2 mg/ml) were obtained by adding fenofibric acid to a solution of 5 % macrogol-15-
hydroxystearate in PBS and stirring for 5 h. A filtration step (Anotop 10 syringe filter, 0.1 µm) was
performed to guarantee particle freeness.
The i.v. vehicle for AS consisted of 10 % macrogol-15-hydroxystearate and 5 % of ethanol in PBS. By
stirring of an excess amount of the API (1 mg/ml) for 20 h and susbsequent filtration (Anotop 10 syringe
filter, 0.1 µm) it was possible to obtain a solution of compound AS with 0.5 mg/ml.
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Table 2.11: PBS.
Dulbecco´s phosphate buffered saline (PBS)
KCl 0.2 g 2.68 mM
KH2PO4 0.2 g 1.47 mM
NaCl 8.0 g 137 mM
Na2HPO4 1.15 g 8.10 mM
Milli Q water ad 1000 ml
pH adjusted to 7.4± 0.05
2.11.3 Oral formulations
Micro- and nanosuspensions were orally administered. Their API concentration was adjusted to 0.6 −
0.8 mg/ml by dilution in Milli Q water to yield an administration volume of 800−900 µl for a rat of 250 g
weight. The diluted suspensions were stirred during withdrawal of the appropriate volumes into syringes
to guarantee administration of homogeneous suspensions and administration to animals was performed
immediately. The stability of particle size in the diluted suspensions was assured.
2.11.4 Data evaluation
Complete plasma concentration-time profiles for each formulation / study group were obtained by pool-
ing the data points of subgroups A and B. Plasma concentration-time profiles with eight data points from
a total number of six animals were obtained, in which each data point was taken from three animals.
The pharmacokinetic parameters Cmax and Tmax were directly taken from the plasma concentration-time
profiles. Cmax is the maximum observed plasma concentration and Tmax is the time at which Cmax is
observed. The area under the concentration-time curve AUC0→25h expresses the bioavailability F and
was calculated by integration of the concentration-time curve data points from 0 to 25 h.
The absolute bioavailability Fabs of an API is defined to be 100 % for i.v. administration of the API. The
absolute bioavailabilitiy of an orally administed suspension is calculated as:
Fabs =
AUCp.o. ∗ dosei.v.
AUCi.v. ∗ dosep.o. ∗ 100% (2.8)
The relative bioavailability Frel of the nanosuspensions (NS) was calculated with reference to the
AUC0→25h of the microsuspensions (MS):
Frel =
AUCNS
AUCMS
∗ 100% (2.9)
2.11.5 Pharmacokinetic modeling & simulation
The Advanced Compartmental Absorption and Transit (ACAT) Simulation Model was used to analyze
and to model the pharmacokinetics of micro- and nanoparticulate formulations. The ACAT model is
implemented in the GastroPlusTM software (version 8.0, Simulations Plus, Inc., Lancaster, CA, USA).
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2.12 Statistics
All values are presented as arithmetic means ± standard deviation if not otherwise stated. Statistical
significance was tested by the two-tailed Student´s t-test (Microsoft Excel software).
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3
Results and Discussion
3.1 Micro- and nanosuspensions
3.1.1 Particle size and morphology
Table 3.1 summarizes the results of SLS and DLS measurements and in Figure 3.1 the particle size
distributions are illustrated. Since all suspensions employed in this study have the same composition
(API / HPMC / DOSS / H2O = 20 / 2.5 / 0.1 / 77.4) the most distinctive feature was their particle size.
The SEM images of selected nanosuspensions displayed in Figure 3.2 provide information about the par-
ticle morphology. It can be seen that harsher milling conditions applied to FF NS 140nm and AS NS
100nm lead to smoother particles with a shape closer to ideal sphericity (see section 2.2 for manufac-
turing details). The formulation AS NS 860nm, which was produced by a low energy process, does not
only comprise bigger particles with a wider particle size distribution, but also more irregularly shaped
particles with sharp edges.
3.1.2 Suspension production process
The agitator ball milling process is very efficient in terms of particle size reduction. Figure 3.3(a) gives
an example of how compound AS particle size developed during the milling process. It can be seen that
within only a few minutes nanoparticles were generated. However, particle size distributions at short
process times were wide and bimodal . After 10 min only a very small fraction of micron sized par-
ticles remained and in the continuation of the process this fraction disappeared, while the percentage
of small particles increased. However, an only marginal further decrease of the minimum particle size
was observed for longer milling times. The fenofibrate particle size reduction by agitation ball milling
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(a) Fenofibrate suspensions. (b) Compound AS suspensions.
Figure 3.1: Particle size distributions of FF and AS micro- and nanosuspensions measured by SLS.
Table 3.1: Particle size of of FF and AS micro- and nanosuspensions.
Formulation SLS diameter DLS diameter
[nm] Mean D10 D50 D90 Z-Average PDI
Fenofibrate
NS 120nm 123± 4 72± 1 113± 3 188± 7 219± 2 0.204± 0.005
NS 140nm 138± 2 79± 1 130± 2 210± 4 215± 4 0.184± 0.013
NS 160nm 156± 12 80± 2 138± 5 237± 13 280± 5 0.189± 0.024
NS 180nm 184± 5 92± 2 168± 5 293± 9 296± 3 0.183± 0.021
NS 270nm 266± 3 97± 1 193± 3 501± 10 381± 10 0.265± 0.041
NS 650nm 645± 79 142± 29 365± 89 1491± 100 618± 25 0.207± 0.036
NS 800nm 797± 109 155± 64 647± 214 1630± 53 714± 79 0.566± 0.444
NS 1070nm 1068± 44 247± 40 918± 42 2099± 73
MS 7.9µm 7900± 1780 3357± 202 6118± 318 10979± 919
Compound AS
NS 100nm 98± 1 61± 1 91± 1 144± 3 215 ± 8 0.183 ± 0.017
NS 130nm 126± 2 68± 0 116± 2 196± 4 261 ± 5 0.127 ± 0.018
NS 150nm 145± 8 69± 0 124± 3 232± 18 270 ± 5 0.128 ± 0.025
NS 860nm 855± 52 475± 71 811± 34 1275± 74 588 ± 78 0.161 ± 0.089
NS 1320nm 1321± 80 700± 47 1164± 54 2142± 150
MS 3.4µm 3432± 102 1649± 95 3207± 117 5513± 125
MS 6.8µm 6827± 840 1162± 188 4295± 421 11728± 1400
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(a) Fenofibrate: NS 140nm (b) Compound AS: NS 100nm (c) Compound AS: NS 860nm
Figure 3.2: Scanning electron microscopy micrographs of different nanosuspensions.
proceeded in a very similar way (data not shown).
The agitator ball milling process was very well suitable for the production a nanosuspensions with a very
small particle size. However, the milling conditions were to harsh to generate larger sized suspensions.
Therefore a low energy ball milling process was developed. With this process the particle size reduction
was much slower and easier to control. However, it followed a similar scheme than the agitator ball
milling with the generation of bimodal size distributions. The implementation of post milling process
steps helped to gain suspensions with monomodal size distribution out of bimodal milling products. Fig-
ure 3.3(b) gives an example.
The development of particle size during the milling process and the SEM images (Fig. 3.2) give indica-
tions on the mechanism of particle size reduction for the applied systems. Rather crystal breaking than
crystal friction can be assumed to be the main mechanism, since friction would lead to a more continuous
size reduction. The particle shape of NS 860nm suggests that particles have been formed by breaking or
splitting of bigger sized API crystals. Since the smaller suspensions have a smoother surface and a more
roundish shape, friction seems to become more important for the shaping of small API crystal fragments.
3.1.3 Physical state
To investigate the physical state of the APIs in nanosuspensions a DSC analysis was performed for
selected formulations of fenofibrate and compound AS. Thermograms are exemplarily shown for com-
pound AS in Figure 3.4. Endothermic peaks indicate melting of API crystals and no other thermic events
were observed. By peak integration the enthalpies of fusion were determined to be 129 ± 5 J/g for com-
pound AS and 149 ± 6 J/g for fenofibrate (data not shown). Melting points were determined to be 213◦C
for compound AS and 83◦C for fenofibrate. Both are in good accordance with previously reported data
(Tab. 2.1). Relative enthalpies of fusion (API in suspensions / pure API) were calculated to be 80−100 %,
indicating that no relevant transformation of physical state appeared during milling (Fig. 3.5). All sus-
pensions contained crystalline API. A slight decrease in melting temperature with decreasing particle
size can be observed and has been reported and discussed previously.
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(a) NS 100nm: Production process (b) NS 150nm and NS 1320nm: Production process
Figure 3.3: Examples for compound AS suspension production. Particle size distributions of final prod-
ucts and precursors measured by SLS. (a) Production of NS 100nm by agitator ball milling and in-process
controls at different milling time points. (b) Production of NS 150nm and NS 1320nm by low energy
ball milling and two post milling process steps. (1) Milling product of low energy process at 500 rpm
and 5 h milling time (dashed black line). (2) Supernatant of the milling product taken after 5 days of
sedimentation (black line). (3) 1.5 ml of the supernatant were centrifuged (4000 g, 10 min). Sampling of
the uppermost 0.8 ml of supernatant resulted in NS 150nm (purple line). The middle supernatant layer
0.2 ml was discarded. The lowermost 0.5 ml were redispersed in 1 ml of water and this resulted in NS
1320nm (green line).
Figure 3.4: DSC thermograms of compound AS drug substance and selected AS formulations. Thermo-
grams show the heat flux versus temperature with endothermic reactions displayed in positive direction
(n = 3).
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(a) Fenofibrate (b) Compound AS
Figure 3.5: Relative enthalpies of fusion (API in suspensions / pure API) (columns) and melting points
(lines) of APIs and selected formulations determined by differential scanning calorimetry.
3.1.4 Stability
Formulations were stable for a minimum of four weeks at 4 − 8◦C in terms of particle size and physical
state (data not shown). For bigger sized nanosuspensions and microsuspensions particle sedimentation
occurred. However, the particles were completely redispersable by stirring or vortex mixing.
3.2 Dissolution media
Simulated gastric fluid supplemented with 0.1% of Tween R© 80 (SGF + Tween) was mainly used as dis-
solution medium. It was characterized by DLS measurements on eight batches. The size of polysorbate
80 (Tween R© 80) micelles was 10.6 ± 0.9 nm with a polydispersity index of 0.112 ± 0.040. Blank medium
measurements for dissolution experiments gave scattering intensities of 82 ± 5 kcps at attenuator setting
10. The refractive index was determined to be 1.334 (n = 3) and hence did not relevantly deviate from
the refractive index of water (1.333). That the viscosity of SGF + Tween does not change sigificantly
compared to the viscosity of water was reported elswhere (Lange 2009). Stability of SGF + Tween at
4 − 8◦C was demonstrated for seven days in terms of micelle size, absolute scattering intensity and pH
(data not shown).
Fasted-state simulated intestinal fluid (FaSSIF) was evaluated as an alternative dissolution medium. It
was characterized by DLS measurements on seven batches. The size of micelles was 43.6 ± 8.2 nm with
a polydispersity index of 0.027 ± 0.011. Blank medium measurements for dissolution experiments gave
scattering intensities of 196 ± 91 kcps at attenuator setting 7.
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(a) Polystyrene nanoparticles. (b) FF NS 1070nm.
Figure 3.6: Correlation of particle concentration and scattering intensity. Scattering intensities were
measured with a Zetasizer instrument and are expressed as mean count rate.
3.3 Light scattering measurements
3.3.1 Validation
Figure 3.6 shows the results of the light scattering intensity validation experiments. For the spherical
polystyrene nanoparticles a linear correlation between particle concentration and scattering intensity
prevailed in the range of 100-2000 kcps (R2 = 0.997). This linear correlation is in accordance with
theory (van de Hulst 1957; Elsayed and Cevc 2011) and consequently this experiment served as a proof
for linear functionality of the laser and detector for the considered instrument settings and measured
scattering intensities. For higher particle concentrations and therefore higher scattering intensities a
deviation from linearity was observed. In the second experiment the investigation of dependence of
scattering intensity on concentration was extended to the suspension NS 1070nm. In contrast to the
NanosphereTM Size Standard this system is polydisperse with particles in the nano- to micrometer range
and particle shape deviates from ideal sphericity. Nevertheless a linear correlation of scattering intensity
and particle concentration was observed (R2 = 0.998).
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3.4 Solubility
Parts of this section are published in Anhalt et al. (2012)
The solubilities of drug substances and nanosuspensions in different media were determined. The
conventional setup applied for drug substance solubility measurement is a separation based technique:
API is dispersed and after an equilibration time the solid material is separated to quantify the concentra-
tion of dissolved API. For the nanosuspensions not a separation based technique, but a light scattering
approach was evaluated to determine solubilities.
3.4.1 Drug substances
Table 3.2 summarizes the solubilities of APIs. The solubility of fenofibrate was determined in SGF
supplemented with Tween R© 80 at various concentrations. A linear correlation of the Tween R© 80 con-
centration and solubility was demonstrated (R2 = 0.995):
solubility [µg/ml] = 83.90 [µg/ml/%] × concentration Tween R© 80 [%] + 0.16 [µg/ml]
Table 3.2: Solubility of APIs in different media after 24 h of equilibration at 25◦C.
Medium API solubility [µg/ml]
Fenofibrate Compound AS
H2O 0.10 ± 0.07
SGF 0.12 ± 0.08
SGF + 0.01%
∗
Tween 80 1.17 ± 0.30
SGF + 0.05% Tween 80 4.04 ± 0.19
SGF + 0.1% Tween 80 8.69 ± 0.78 11.92 ± 0.87
FaSSIF 11.26 ± 1.47 9.27 ± 1.42
∗ mass %
3.4.2 Nanosuspensions
The solubilities of nanosuspensions were determined in SGF + 0.1% Tween 80 by a light scattering
approach. Figures 3.7 and 3.8 present the scattering intensity vs concentration graphs. In Table 3.3 all
parameters of the curve analysis and resulting calculated solubilities are listed.
For the linear function fitting data points at concentrations c with 8.0 < c < 10.5 µg/ml (FF) and with
4.5 < c < 6.0 µg/ml (AS) were excluded. They are close to the solubility limit and have a high uncertainty
of data interpretation (Van Eerdenbrugh et al. 2010). For the horizontal branches, which correspond to
dissolved samples, coefficients of correlation are low. This can be explained by a low signal-to-noise
ratio for the measured scattering intensities of 75 − 90 kcps. Nevertheless low coefficients of correlation
do not alter the data analysis essentially, since the horizontal and ascending branches can be clearly
distinguished regarding slope and intercept.
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Figure 3.7: Solubility of fenofibrate nanosuspension NS 140nm determined by light scattering method
with variation of equilibration time. Measured scattering intensity vs total FF concentration (n = 3).
Evaluation of a suitable equilibration time
The fenofibrate formulation NS 140nm was used to evaluate the effect of equilibration time on the deter-
mination of nanosuspension solubility (Fig 3.7). The aim was to identify the time necessary to reach an
equilibrated system (stable dissolved and solid concentration over time) for the determination of equilib-
rium solubility.
The 0 h-graph shows the scattering data recorded 10 s after dilution and it exhibits a curved shape. How-
ever, for stable particles a linear increase of scattering intensity with increasing particle concentration
would be expected. The deviation from linearity indicates that particles are not stable and that the parti-
cle dissolution process has already started. After 2 h the two-branched shape becomes visible, in which
the horizontal branch corresponds to completely dissolved samples and the rising branch to partially dis-
solved samples. After 24 h the picture is the same with a shift to higher concentrations. After 96 h the
rising branch flattens and it is not possible to clearly identify a linear progression due to signal fluctua-
tions.
It was not possible to identify the time to reach a completely equilibrated system, in which the solubility
would correspond to saturation solubility. It seems that after 96 h the solubility further increased. How-
ever, data interpretation from the 96h-graph is subject to statistical shortcomings: The fluctuations of the
scattering signal can be explained by number fluctuations in the scattering volume. The term number
fluctuation describes the effect of a very low number of particles in the scattering volume, which results
in poor statistical validity of the measurement. Data interpretation of the 96h-graph is further challenged
by possible changes in particle size distribution and therefore light scattering properties of the system,
since not only dissolution, but also aggregation or Ostwald ripening might have been occurred. Further-
more, adsorption of API or particles onto the plastic cuvettes might be a potential source of error and
might be responsible for the shift of scattering graphs towards higher concentrations for longer equili-
bration times.
As a conclusion of the described results, the equilibration time of 24 h was selected for further experi-
ments, because on the one hand the particle dissolution process is in an advanced state and on the other
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(a) Fenofibrate (b) Compound AS
Figure 3.8: Solubility of FF and AS nanosuspensions determined by light scattering method with an
equilibration time of 24 h. Measured scattering intensity vs total concentration (n = 3).
hand data interpretation is still possible with adequate statistical quality. Following the definitions given
by Sugano et al. (2007) the measured solubilities (S NS ) are apparent solubilities, meaning that reasonable
long incubation times were chosen without the confirmation of stable dissolved and solid concentration
over time.
Solubility of fenofibrate nanosuspensions
Figure 3.8(a) and Table 3.3 present the solubilities (S NS ) determined for fenofibrate suspensions with
varying particle size.
For NS 140nm a significantly higher solubility was determined than for NS 270nm (9.86 ± 0.02 vs
8.70 ± 0.24 µg/ml). This finding is consistent with the Ostwald-Freundlich equation (Eq. 1.1) in terms
of an expected higher solubility for the smaller sized nanosuspension. However, the solubility of NS
1070nm was calculated to be 9.62 ± 0.50. µg/ml and hence higher than for the suspensions NS 270nm
with smaller particle size. This result can be interpreted as a lack of suitability of the scattering method
for NS 1070nm, which is due to the suspensions large particle size and therefore low particle number
density (number of particles per volume). At concentrations just above the solubility limit only few
undissolved particles remain, which are not detectable with the optical configuration of the ZetasizerTM.
This provokes the misleading interpretation of these samples as dissolved, where there might indeed be
particles left, and consequently leads to an overestimation of solubility. Another effect, which amplifies
the shortcomings of the scattering method for this suspension, is that smaller particles dissolve prefer-
entially and the size distribution is altered towards bigger particles, that are more difficult to be detected
(Van Eerdenbrugh et al. 2010). Furthermore, instabilities like aggregation and Ostwald ripening can also
lead to larger particles and thus increase the error. Even though samples are shaken up directly before
each measurement, settling of particles during the measurement might contribute to the high standard
deviations as well.
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Table 3.3: The solubilities of pure crystalline APIs and nanosuspensions in SGF + 0.1 % Tween at 25◦C.
The solubilities of APIs S API were determined by conventional method. The solubilities of nanosuspen-
sions S NS were determined by light scattering method and the results of the linear function fitting are
presented as well as the thereof derived solubilities.
Linear function fitting∗ Solubility
time Slope Intercept R2 absolute relative∗∗
[h] [kcps/µg/ml] [kcps] [µg/ml] [% S API]
Fenofibrate
NS 140nm 2
dissolved 0.9 82.9 0.752
9.57 ± 0.17 110.1 ± 9.1
undissolved 365.8 -3408.4 0.995
24
dissolved 1.0 77.5 0.910
9.86 ± 0.02 113.4 ± 9.0
undissolved 246.4 -2340.8 0.994
96
dissolved 1.1 88.7 0.683
10.38 ± 0.01 119.5 ± 9.0
undissolved 32.7 -239.7 0.751
NS 270nm 24
dissolved 1.0 76.2 0.661
8.70 ± 0.24 100.1 ± 9.4
undissolved 276.2 -2318.4 0.992
NS 1070nm 24
dissolved 0.4 78.3 0.392
9.62 ± 0.50 110.7 ± 10.4
undissolved 129.3 -1162.5 0.964
FF 24 8.69 ± 0.78 100.0 ± 12.7
Compound AS
NS 100nm 24
dissolved 1.0 85.8 0.464
5.78 ± 0.13 48.5 ± 7.7
undissolved 516.1 -2896.2 0.997
NS 150nm 24
dissolved 0.6 90.4 0.343
5.05 ± 0.21 42.3 ± 8.4
undissolved 590.0 -2884.8 0.994
NS 860nm 24
dissolved -0.1 98.4 0.002
4.59 ± 0.02 38.5 ± 7.3
undissolved 301.5 -1284.8 0.989
AS 24 11.92 ± 0.87 100.0 ± 10.4
∗ For FF linear functions were fitted to data points at concentrations c with c ≤ 8.0 µg/ml representing dissolved samples
and with c ≥ 10.5 µg/ml representing undissolved samples. For AS the respective concentrations were c ≤ 4.5 µg/ml and
c ≥ 6.0 µg/ml.
∗∗ Relative solubility values are calculated as S NS /S API ∗ 100%.
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Solubility of compound AS nanosuspensions
Figure 3.8(b) and Table 3.3 present the solubilities (S NS ) determined for compound AS suspensions with
varying particle size.
For NS 100nm a higher solubility was determined than for NS 150nm and for NS 860nm (5.78 ± 0.13
vs 5.05 ± 0.21 vs 4.59 ± 0.02 µg/ml). This finding is consistent with the Ostwald-Freundlich equation
(Eq. 1.1). The nanosuspension NS 860nm (SLS D90 = 1.3 µm) is better suitable for a solubility determi-
nation by the scattering method than the fenofibrate suspension NS 1070nm (SLS D90 = 2.1 µm), due
to its lower particle size and narrower size distribution. The potential sources of error in the solubility
determination, which are discussed above for FF NS 1070nm, are less likely to occur for NS 860nm.
However, one major difference for both APIs was observed. Lower solubilities of AS nanosuspensions
were determined than for the pure crystalline AS drug substance. On the contrary for fenofibrate the
opposite effect, which is consistent with the Ostwald-Freundlich theory, was observed.
The different methods used for nanosuspension and API solubility determination might be the reason.
The methodical differences are the mode of sample agitation and the concentration gradient of solid vs
dissolved API during the 24 h equilibration period. In the standard light scattering setup samples are
equilibrated in rested cuvettes. To evaluate the influence of sample agitation on solubility the nanosus-
pension NS 100nm was diluted to concentrations of 0−16 µg/ml and in accordance to the drug substance
solubility method samples were stirred during equilibration. Subsequently the sample was transferred to
a cuvette and the scattering intensity was determined. No major differences could be identified between
rested and stirred samples (Fig 3.9(a)).
To evaluate the effect of concentration gradient the nanosuspension solubility was determined according
to the drug substance solubility determination protocol: nanosuspension dilution, 24 h stirring, filtra-
tion (Whatman Anotop 10 0.02µm) and HPLC quantification of dissolved API. Figure 3.9(b) shows that
indeed an increasing fraction of dissolved API was seen when the total nanosuspension concentration
during equilibration was increased. It appears that for AS the concentration gradient and therefore so-
lution pressure is one determining parameter of the solubility measured after 24 h. This assumption is
supported by a comparison of API and nanosuspension solubilities determined by using a similar gra-
dient: For the determination of AS drug substance solubility a high excess of API (10000 µg/ml) was
used and the API solubility was 11.26±1.47 µg/ml. For the highest tested nanosuspension concentration
(2000 µg/ml) a similar value was determined: 12.77 µg/ml.
It can be concluded that a 1000 times higher concentration gradient in the protocol to measure the drug
substance solubility than in the protocol to measure the nanosuspension solubility could explain higher
solubilities determined for pure AS drug substance.
Nanosuspension solubility determination by the light scattering method: Discussion
The light scattering based determination of nanosuspension solubility proved to be a reproducible, sen-
sitive and experimentally convenient approach. The suitability of the Zetasizer R© instrument for this
application was demonstrated.
Limitations of the applied method became apparent for samples with mainly micron sized particles.
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(a) Stirring vs resting (b) Variation of concentration gradient
Figure 3.9: Methodical variations for the determination of AS nanosuspension solubility. (a) The stan-
dard setup with rested cuvettes during equilibration period was varied by applying agitation by magnetic
stirring. Scattering intensities were subsequently measured at attenuator 8 (n = 1). (b) Nanosuspension
solubility determination according to the drug substance solubility method (Stirring, filtration, quantifi-
cation of dissolved API) with varying concentration gradients (n = 1).
Their reduced particle number density and the sedimentation tendency of microparticles negatively af-
fect data quality. Additionally it was seen that the amount of excess API during equilibration, resulting
in differences in concentration gradient of solid vs dissolved API, can be a critical parameter.
Previously relative solubilities of 114.5 ± 2.1% for a itraconazole nanosuspension (Z average 220 ±
4 nm), 106.7 ± 1.0% for a phenytoin nanosuspension (Z average 406 ± 17 nm) and 97.0 ± 1.4% for a
naproxen nanosuspension (Z average 288 ± 4 nm) have been reported (Van Eerdenbrugh et al. 2010).
We determined relative solubilities of 113.4 ± 9.0% for NS 140nm (Z average 215 ± 4 nm) and of
100.1 ± 9.4% for NS 270nm (Z average 381 ± 10 nm). These results are in accordance with published
and theoretically predicted values ((Van Eerdenbrugh et al. 2010; Kesisoglou and Wu 2008) and hence
confirm the adequacy of the proposed method to determine nanocrystal solubility.
Unlike in previous publications (Van Eerdenbrugh et al. 2010; Lindfors et al. 2006) all dilutions were
prepared in one step and were not gradually increased by stepwise addition of suspensions to the cuvette.
This approach was chosen to be in close analogy to the standard procedure, in which an excess drug
amount is added at the beginning. Due to preferential dissolution of smaller size fractions and Ostwald
ripening, a one step dilution might lead to different size distributions and scattering properties among the
samples and could influence results. We demonstrated that this effect was not relevant for the determi-
nation of solubilities of the smaller sized suspensions. Linearity of the ascending branch and reasonable
results confirm the suitability of the presented method. However, a gradual increase of concentration
might improve the suitability of the method for the determination of bigger sizes suspensions (like for
example NS 1070nm).
The experimental error of the solubility determination by light scattering is small compared to the un-
certainty of the drug substance solubility determination (Tab. 3.3). Relative standard deviations of S NS
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for FF NS 140nm and 270nm are 0.3% and 2.8% compared to 9.0% for the drug substance solubility
S FF . Therefore, most of the variability in the calculated relative solubilities (S NS /S API) originates from
S FF . This highlights the potential of the proposed method to determine relevant solubility differences of
nanocrystal formulations with good precision.
3.4.3 Summary and conclusions
Solubilities of APIs and nanosuspensions in different media were determined. A light scattering
based determination of nanosuspension solubility proved to be a reproducible, sensitive and experi-
mentally convenient approach. The advantages over separation based techniques and the good agree-
ment of measured with estimated solubilities based on Ostwald-Freundlich equation were summarized
by Van Eerdenbrugh et al. (2010). It was seen that the applicability of the light scattering method for
particle suspensions with micron sized particles is limited and that the concentration gradient during
equilibration could influence results. Experiments on a greater number of APIs and formulations will
help to better characterize the strengths and limitations of the new method.
Previous investigators (Van Eerdenbrugh et al. 2010; Lindfors et al. 2006) focused on the solubility in-
crease by nanosuspensions but not on the kinetic nature of the dissolution process. From the findings of
the here presented experiment dealing with time variations (Fig. 3.7) the importance of the time factor
becomes obvious. The nanocrystal dissolution experiments presented in section 3.6 can be regarded as a
consistent continuation of the solubility experiments with a shift of the timescale from hours to minutes.
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3.5 Dissolution
Different techniques were evaluated to measure nanocrystal dissolution profiles. The results are summa-
rized in this section. The benchmark methods for dissolution testing are the compendial methods of the
pharmacopoeias, which follow the steps of dilution, sampling, separation and quantification. A compen-
dial dissolution setup with a USP II (paddle) apparatus and sample filtration was used in this study for
microparticle dissolution measurements. Furthermore its applicability for nanosuspensions was evalu-
ated. As an alternative to the sample filtration step in the compendial setup a separation by a dialysis
membrane was tested. Finally noninvasive in-situ analytical techniques were evaluated for their suitabil-
ity to measure nanocrystal dissolution. A light scattering method was the most promising approach and
the development and use of this novel setup will be presented in a separate section (section 3.6).
3.5.1 Conventional method: Sampling and separation
The dissolution profiles of selected suspensions of fenofibrate and compound AS were measured using
the conventional dissolution setup (Fig. 3.10). The dissolution of a FF nanosuspension was tested as
well (Fig. 3.11(a)). Even though sampling intervals as short as 20 s were applied only few data points
were collected during the short dissolution time (100 % of API were released after 2 min). In addition
high standard deviations were observed and make it difficult to discriminate between similar nanoscalic
formulations. Xia et al. (2010) and Quinn et al. (2012) used comparable methods to measure nanocrystal
dissolution and report very similar dissolution profiles with 100 % of API released after 5 min.
(a) Fenofibrate (b) Compound AS
Figure 3.10: Conventional dissolution of FF and AS suspensions in SGF + 0.1 % Tween 80. (a) FF
concentration 5.5 µg/ml. (b) AS concentration 2.7 µg/ml (n = 3).
3.5.2 Dialysis method: Continuous separation
The conventional sampling and separation experiment was modified by using a dialysis setup. A nanosus-
pension was injected into a dialysis cassette (donor) floating in the dissolution medium in a paddle
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(a) Conventional: Filtration (b) Conventional: Dialysis
Figure 3.11: Dissolution of fenofibrate formulations in SGF + 0.1 % Tween 80 with conventional fil-
tration and dialysis method. (a) Method: Paddle apparatus + sampling + filtration. FF concentration
5.5 µg/ml (n = 5). (b) Method: Paddle apparatus + dialysis membrane. NS 120nm vs coarse FF sus-
pension (raw NS). FF concentration 207 µg/ml in the donor compartment (n = 3). The apparent fraction
released is displayed, since the calculation of the fraction released is subject to various shortcomings as
explained in section 3.5.2.
apparatus dissolution vessel (receiver). The idea was to quantify the undissolved fraction (donor) by
withdrawal of samples from the donor compartment and to use this to calculate the dissolved fraction
(receiver). This method would lead to correct estimates of the fraction dissolved under the assumption
that the diffusion of dissolved API molecules across the dialysis membrane is fast and complete.
The fenofibrate nanosuspension NS 120nm and the coarse suspension raw NS were compared and the
results can be found in Figure 3.11(b). The dissolution curves suggest that almost no API is released from
NS 120nm whereas almost 60 % of API are released from the coarse suspension (raw NS) after 120 min.
However, results should be interpreted very carefully, since the used setup has several shortcomings.
Sampling from the donor compartment with a Hamilton syringe is difficult and especially for the sus-
pension with larger particles no homogenious particle dispersion can be guaranteed during sampling.
Consequently it is likely that erroneous concentrations are determinated from the donor compartment.
Furthermore adsorption of particles or API to the dialysis cassette is likely and was not quantified. That
almost no release from NS 120nm was seen could be attributed to an API membrane diffusion kinetics
being much slower than the dissolution kinetics of the nanocrystals. Furthermore an API concentration
manifold higher than the saturation concentration was used in the donor compartment. If a slow mem-
brane diffusion of drug molecules is assumed, the sink condition in the donor compartment is likely to
be violated.
Even though the experimental setup might be improved by applying a lower concentration in the donor
compartment or by sampling from the receiver compartment, the problems of slow membrane diffusion
kinetics and adsorption to the dialysis cassette would remain and heavily distort results. The dialysis
setup was not further evaluated in this study. Similar results were reported by Heng et al. (2008).
56 Results and Discussion
Figure 3.12: Raman spectra of dissolution medium SGF + 0.1 % Tween (red) and dissolution medium
saturated with fenofibrate (black/blue). 3150-3640 cm−1: O-H stretch band of water. 1150 cm−1: C16-
O3 stretching vibration, expected for fenofibrate but not detectable with the applied FF concentration
c = 8.7µg/ml.
3.5.3 Noninvasive analytical techniques
Different noninvasive analytical techniques were evaluated for their feasibility to measure the dissolution
of the fenofibrate nanosuspension NS 140nm in SGF + 0.1 % Tween 80.
Nuclear magnetic resonance spectroscopy and Raman spectroscopy
The idea to use spectroscopic techniques was to follow the transition of physical state of an API molecule
during dissolution. The sensitivity of the analytical technique was the critical point about the applicability
of spectroscopic techniques. Therefore it was tested if a fenofibrate signal from a saturated solution
in the dissolution medium (c = 8.7µg/ml) could be seen. However, under the applied conditions no
NMR or Raman spectroscopic signal of fenofibrate was detectable. The Raman spectra are presented in
Figure 3.12. For fenofibrate a band at 1150 cm−1 assigned to the C16-O3 stretching vibration would be
expected (Heinz et al. 2009). However, it was not visible in the saturated solution.
Pure medium and FF saturated medium produced identical NMR or Raman spectra. It was concluded
that the applied techniques are not suitable to measure fenofibrate release from nanocrystals due to their
too low sensitivity.
Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) is a technique combining laser light scattering microscopy with
a charge-coupled device camera. Individual particles can be tracked by the software and their particle
size is calculated from the particle movement. Filipe et al. (2010) used this technique to characterize
nanoparticles and highlights a high size resolution and sample visualization as the main advantages over
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(a) NS 140nm in dissolution medium. 20 µg/ml. (b) NS 140nm in dissolution medium. 10 µg/ml.
Figure 3.13: Nanoparticle tracking analysis. Screen shots of videos of fenofibrate nanocrystals in disso-
lution medium. Original images were modified by inverting black/white color (n = 1).
dynamic light scattering. Drawbacks are a more difficult device handling requiring some operational
skills and a high time-consumption.
At concentrations of 5 − 20 µg/ml fenofibrate nanocrystals were visible and trackable. However, the
characteristic particle number reduction during dissolution at concentrations c < 8.7µg/ml were not
detectable with NTA, due to a too low particle number in the samples. Figure 3.13 gives an idea of
the critically low particle numbers in these samples. In addition the filling and assembly of the sample
chamber was too slow to enable a dissolution monitoring directly after sample dilution. A defined sample
dilution directly in the assembled chamber was not possible. The applicability to a very narrow particle
concentration range and a strong dependence of results on the applied measurement and analysis settings
are inherent problems of the NTA technique. It was concluded that NTA is not suitable to measure
nanocrystal dissolution within the requirements and conditions of this study.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) is a thermodynamic method and measures the heat released or
absorbed during various interactions or reactions. It is the method of choice for characterizing thermo-
dynamics and stoichiometry of molecular interactions. In the pharmaceutical field it has been used to
analyze cyclodextrin-guest interactions or micellar-based systems. The interested reader will find more
examples reviewed by Bouchemal (2008). Calorimetric effects are also associated with particle dissolu-
tion and in this study it was evaluated whether ITC was capable of measuring this effect.
As a control experiment an aqueous stabilizer solution was injected into medium. No thermic reaction
caused for example by mixing was observed. The injection of a nanosuspension into medium resulted
in strong endothermic peaks (Fig 3.14). For subsequent injections the concentration gradient decreases
and in parallel the heat absorbed (area under the peak) decreases. This is a promising result and a
sound method development including thorough control measurements to account for phenomena like
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(a) Negative control: Injection of stabilizer solution. (b) Incremental injections of nanosuspension.
Figure 3.14: Isothermal titration calorimetry. (a) Negative control: Injection of 35 µl of a diluted sta-
bilizer solution into dissolution medium. (b) Injections of prediluted nanosuspension into dissolution
medium. Preinjection of 3 µl followed by incremental injections of 10 µl. Each 10 µl injection corre-
sponds to 2.4 µg FF and leads to incremental concentration increases of 1.7 µg/ml per injection (n = 1).
particle dilution/mixing, adsorption/desorption of surfactants/stabilizers to particles and micelle forma-
tion/reorganization could provide the basis to measure nanocrystal dissolution by ITC. However, in this
study the focus was set on another approach, the light scattering dissolution assessment. The technical
equipment was more simple and potentially offered a broader applicability than ITC.
3.5.4 Summary and conclusions
Conventional dissolution testing was successfully performed to measure fenofibrate and compound AS
microsuspension dissolution. However, the conventional setup was not suitable to measure nanocrystal
dissolution, neither with filtration nor with membrane diffusion applied for separation. Different non-
invasive in situ analytical techniques avoiding the critical separation step were evaluated. Within the
requirements and conditions of this study the spectroscopic methods and the nanoparticle tracking anal-
ysis were not suitable. The results of isothermal titration calorimetry applied to measure nanocrystal
dissolution were promising. However, this technique was not further evaluated in favor of a light scatter-
ing approach, which is described in the next section.
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3.6 Dissolution by light scattering
Parts of this section are published in Anhalt et al. (2012)
The measurement of nanocrystal dissolution by an approach of monitoring decreasing solid parti-
cle number and size based on light scattering allowed for a very fast data acquisition. The first data
point was recorded 25 s after dilution and the interval of subsequent data points was 10 s. The scattering
intensity, which is the primary measurement signal of each DLS measurement, was considered as
readout parameter. The standard data output of DLS measurements, the hydrodynamic particle diameter,
is derived from the intensity fluctuations by complex data analysis and exhibits a poor statistical quality
for the extremely short measurement time of 2 s applied within this work (Brittain 2003).
Below an overview of important steps and control experiments leading to the final experimental setup
will be presented (section 3.6.1). A comparative evaluation of the light scattering dissolution method
to the conventional dissolution method was carried out (section 3.6.2 and 3.6.5). Subsequently the
applicability of the new method will be demonstrated. For that purpose two sets of experiments were
carried out to investigate suitability, reproducibility and sensitivity. In a first step the particle size was
varied at a constant concentration; in a second step the concentration was varied keeping the particle
size constant. All experiments were performed with FF and with AS nanosuspensions (sections 3.6.3
and 3.6.4). All results are summarized in Tables 3.4 and 3.5.
3.6.1 Method development
The mixing step directly before a measurement and the resulting fluid flow in the cuvette did not alter
scattering intensity measurements (Fig. 3.15(a)).
The fenofibrate recovery from polystyrene and quartz glass cuvettes was determined in order to evaluate
whether particle adsorption onto the cuvette walls appears. Particle adsorption would be critical, since
adsorbed particles are not detected in scattering intensity measurements leading to incorrect estimates
of solid/dissolved particle fractions. SGF + 0.1 % Tween 80 or FaSSIF were used as media and the
fenofibrate nanosuspension NS 120nm was added at two concentration levels. Results are exemplarily
displayed for SGF + 0.1 % Tween 80 (Fig 3.15(b)). API recoveries of 85 − 90 % were determined under
all tested conditions. In addition it was tested whether the cuvette material influences the dissolution
profile and API recovery. No effect of cuvette material was observed (Fig. 3.15(b-d)). The use of a new
cuvette compared to a reused cuvette did not make a difference (Fig. 3.15(d)). However, a difference
would be expected in the case of relevant adsorption taking place, since the surfaces of used cuvettes
would already be coated.
Good API recoveries and a no influence of cuvette material or reuse on dissolution curves disprove the
assumption that particle adsorption might be responsible for the observed decreasing scattering profiles.
It can be concluded that measured profiles can truly be attributed to particle dissolution characterized
by a decreasing particle number and size. Disposable polystyrene cuvettes were selected for all further
experiments.
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(a) Fluid Flow (b) FF recovery from cuvettes
(c) Influence of cuvette material on dissolution profile (d) Influence of cuvette material on dissolution profile
Figure 3.15: Control tests during development of the light scattering dissolution setup. (a) Influence of
fluid flow on light scattering measurement. (b) FF recovery under different conditions. (c,d) Dissolution
of NS 120nm in SGF + 0.1 % Tween 80 under different conditions: (c) influence of cuvette material and
(d) cuvette reuse. Cuvette types: PS = polystyrene disposable (standard equipment), OS = optical glass,
QS = quarz glass (n = 3).
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(a) FF NS 1070nm. c = 5.5µg/ml (b) AS NS 860nm. c = 2.7µg/ml
Figure 3.16: The dissolution of FF NS 1070nm and AS NS 860nm in simulated gastric fluid supple-
mented with 0.1% polysorbate 80. Black line: conventional method (n = 3). Blue and orange line: light
scattering method (n = 6). Standard deviations not shown for clarity reasons. Grey lines: smoothed light
scattering signal (running mean, 75 data points).
3.6.2 Comparison of light scattering and conventional dissolution method
For two nanosuspension a direct comparison of both techniques was made (Fig. 3.16). Overlays of both
dissolution diagrams were designed by plotting the undissolved concentration determined by conven-
tional paddle dissolution and the recorded scattering intensity determined by the scattering method. The
resulting dissolution curves share the first data point at 2.5 min and the last data point at 120 min. The
Y-axes were scaled so that the diagrams overlap at 2.5 min and 120 min. The values at time point 0 min
could not be used to adjust the scales, because it was not possible to measure the scattering intensity at
time 0 min.
The overlays illustrate a good correlation of both techniques. For FF NS 1070nm especially the initial
high dissolution rate (0 − 10 min) is correlated very well (Fig. 3.16(a)). In the middle part (10 − 60 min)
the dissolution process is slowed down and the scattering result has a decreasing tendency with many
spikes. In the conventional experiment 92 % are dissolved after 60 min and the dissolution curve slowly
approaches the level of complete dissolution. In the scattering result this process is indicated by a con-
tinuous reduction in the number of intensity spikes. The fluctuations of the scattering signal and the
intensity spikes can be explained by number fluctuations in the scattering volume. Due to the small scat-
tering volume and the decrease in particle concentration, when the dissolution process reaches its end,
the probability of remaining particles to be detected is low. The spikes represent remaining undissolved
particles passing the scattering volume, which probably belong to micron sized particle fractions. To
optimize the comparability of both dissolution graphs a further step of data analysis was performed on
the scattering diagram. The scattering intensity data were smoothed by the running mean algorithm with
75 data points.
For AS NS 860nm an overall good correlation of both techniques and a smoother scattering graph with
less intensity spikes was observed (Fig. 3.16(b)). The nanosuspension NS 860nm (SLS D90 = 1.3 µm)
is better suitable for a dissolution determination by the scattering method than the fenofibrate suspension
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(a) Variation of size. c = 5.5µg/ml. (b) Variation of concentration. NS 140nm.
Figure 3.17: Fenofibrate nanocrystal dissolution measured by light scattering method. (a) Variation of
particle size at fixed concentration. (b) Variation of concentration of NS 140nm. Concentrations given
in µg/ml and in % of the apparent solubility S NS 140nm (n = 4).
NS 1070nm (SLS D90 = 2.1 µm), due to its lower particle size and narrower size distribution. The
applicability of the light scattering method and the preferred particle size range of suspensions will be
discussed below (section 3.6.5).
Analysis of the FF and AS dissolution graphs by (bi-)exponential function fitting and calculation of DT
(Table 3.4 and 3.5) shows a very good fit of the biexponential model (R2ad justed = 0.995 and 0.998) to the
conventional dissolution graph compared to the exponential model (R2ad justed = 0.930 and 0.971).
For FF NS 1070nm a shorter dissolution time was derived from the scattering method as from the conven-
tional method (DT = 76 ± 21 min (scattering) and DT = 132 ± 8 min (conventional)). This discrepancy
is probably attributed to an inappropriate representation of the intensity spikes at advanced dissolution
state by the applied evaluation method. For AS NS 860nm a smaller discrepancy in dissolution times
was observed (DT = 57 ± 13 min (scattering) and DT = 40 ± 6 min (conventional)). The scattering
method is more suitable for the smoother dissolution profiles of smaller particles and more appropriate
dissolution times are calculated.
3.6.3 Fenofibrate nanocrystal dissolution
Figure 3.17(a) presents the experimental dissolution curves for NS 120nm to NS 270nm. From the
Noyes-Whitney equation (Eq. 1.2) it is predicted that the smaller nanosuspensions with their higher sur-
face area exhibit higher dissolution rates and therefore shorter dissolution times. In Figure 3.17(a) this
dissolution time vs particle size ranking can be seen. For the sake of clarity results for bigger sized sus-
pensions NS 650nm to NS 1070nm are not included in Figure 3.17(a). However, Figure 3.16(a) shows
the dissolution curve of NS 1070nm. Table 3.4 summarizes the dissolution times for all formulations.
The slower dissolution rates of NS 650nm to NS 1070nm can be explained by micron sized particle
fractions present in this formulations (D90 > 1µm, Tab. 3.1).
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Table 3.4: Fenofibrate dissolution: Fitting of exponential (ExpDec1) and biexponential (ExpDec2) func-
tions to dissolution curves and calculation of dissolution time (DT ).
Experimental parameters ExpDec 1 fitting ExpDec 2 fitting
Formulation Concentration R2ad justed DT R
2
ad justed DT
[µg/ml] [%S NS ] [min] [min]
Scattering method
NS 140nm 3.9 40 0.975 1.5 ± 0.4 0.985 1.7 ± 0.3
4.7 48 0.976 1.8 ± 0.3 0.981 2.2 ± 0.4
5.5 56 0.983 2.2 ± 0.5 0.990 2.9 ± 1.1
6.9 70 0.968 3.1 ± 0.3 0.977 3.4 ± 1.0
8.6 87 0.932 5.1 ± 0.7 0.943 6.8 ± 0.6
NS 120nm 5.5 0.990 1.6 ± 0.1 0.993 1.9 ± 0.3
NS 140nm 5.5 56 0.983 2.2 ± 0.5 0.990 2.9 ± 1.7
NS 160nm 5.5 0.978 3.3 ± 0.3 0.984 4.7 ± 1.0
NS 180nm 5.5 0.987 6.3 ± 0.4 0.995 7.1 ± 0.7
NS 270nm 5.5 0.969 10.5 ± 0.6 0.974 12.3 ± 0.3
NS 650nm 5.5 0.827 15.3 ± 3.6 0.861 18.2 ± 1.2
NS 800nm 5.5 0.675 31.0 ± 5.4 0.698 60.3 ± 11.8
NS 1070nm 5.5 0.600 36.6 ± 6.2 0.623 76.4 ± 21.2
Conventional method
NS 1070nm 5.5 0.930 43.3 ± 1.0 0.995 132.2 ± 8.4
MS 7.9µm 5.5 0.955 274.5 ± 6.6 0.996 439.0 ± 42.6
Figure 3.17(b) presents the experimentally obtained dissolution curves for different particle concentra-
tions. For steeper concentration gradients higher dissolution rates and therefore shorter dissolution times
are observed, which corresponds to the ranking as expected from the Noyes-Whitney equation. In phar-
maceutical dissolution testing it is favored to minimize the concentration gradient effect by choosing sink
conditions, which means that the total drug concentration C0 is less than 10−30 % of saturation solubility
CS (Dressman et al. 1998; Jamzad and Fassihi 2006). For sink conditions the decrease in concentration
gradient with increasing dissolved concentration can be neglected and the process can be regarded as
only dependent on the constant CS . However, in the presented experiment concentrations above 30% of
apparent nanosuspension solubility are analyzed. Due to the rapid process of nanocrystal dissolution, too
few data points for dissolution under sink conditions were obtained for a satisfying data interpretation.
Table 3.4 summarizes the results of the fitting of (bi-)exponential models to experimental dissolution
graphs and the calculated dissolution times. In general the tendency for a slightly better fit of ExpDec2
(Eq. 2.2) was observed. The function fitting to dissolution curves of bigger sized suspensions (NS 650nm
- NS 1070nm) and of higher concentrations (8.6 µg/ml) resulted in lower coefficients of determination.
However, this should not necessarily be interpreted as a poor correlation, since the relatively high noise
of these dissolution curves (Fig. 3.16(a), blue line) inevitably results in high deviations between the mea-
sured signal and the fitted curve.
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(a) Variation of size: Smaller particles. c = 2.7µg/ml. (b) Variation of size: Larger particles. c = 2.7µg/ml.
Figure 3.18: Compound AS nanocrystal dissolution measured by light scattering method. Variation of
particle size (n = 4).
3.6.4 Compound AS nanocrystal dissolution
Table 3.5 summarizes the results of the fitting of (bi-)exponential models to experimental dissolution
graphs and the calculated dissolution times. All observations made for the dissolution of AS formulations
are the same for the FF formulations: A clear ranking with the shortest dissolution times for the smallest
particles and the lowest concentrations was observed. Smoother dissolution profiles are achieved for the
smaller sized suspensions and the lower concentrations. All dissolution data are presented in Figure 3.18
and Figure 3.19.
3.6.5 Nanocrystal dissolution by light scattering method: Discussion
It was demonstrated that the light scattering method is applicable to measure the dissolution of nanosus-
pensions. The preferred nanocrystal size is in the lower nanometer range (mean particle size < 500 nm).
For very short dissolution times (DT < 1.5 min) the 25 s interval between dilution and first data point
might lead to a insufficient number of collected data points, which limits the applicability for extremely
rapid processes. In the upper nanometer range (500 − 1000 nm) it was possible to measure dissolution
with the applied setup although the method is less suitable with increasing particle size fractions in the
lower micron scale.
Compared to the conventional method, in which dissolved concentrations are measured quantitatively,
the light scattering setup primarily provides relative dissolution profiles. When the scattering intensity
approaches a constant level, it can be concluded that the number and size of particles are at a constant
level, but information about the amount of undissolved drug cannot be derived directly. In this study
for all samples at the end of the dissolution process a ∆MeanCountRate of 0 ± 10 kcps was reached
(Fig. 3.17). This indicates that light was scattered only by the micelles of the dissolution medium and
not by nanocrystals. A DLS size measurement at the end of each dissolution experiment confirmed that
apart from micelles no particles were detectable. Thus it was possible to add quantitative information
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(a) NS 100nm: lower concentrations (b) NS 100nm: higher concentrations
(c) NS 150nm: lower concentrations (d) NS 150nm: higher concentrations
(e) NS 860nm: lower concentrations (f) NS 860nm: higher concentrations
Figure 3.19: Compound AS nanocrystal dissolution measured by light scattering method. Variation
of concentration. The dissolution curves for each formulation are displayed in two separate panels to
provide a better overview (n = 4).
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Table 3.5: Compound AS dissolution: Fitting of exponential (ExpDec1) and biexponential (ExpDec2)
functions to dissolution curves and calculation of dissolution time (DT ).
Experimental parameters ExpDec 1 fitting ExpDec 2 fitting
Formulation Concentration R2ad justed DT R
2
ad justed DT
[µg/ml] [%S NS ] [min] [min]
Scattering method
NS 100nm 1.7 30 0.979 1.4 ± 0.1 0.983 1.4 ± 0.2
2.3 40 0.978 2.0 ± 0.4 0.979 2.2 ± 0.4
2.8 48 0.982 2.0 ± 0.2 0.990 2.4 ± 0.7
3.2 56 0.986 2.2 ± 0.4 0.989 2.6 ± 0.4
4.0 70 0.973 3.5 ± 0.4 0.987 4.5 ± 1.0
5.0 87 0.922 7.2 ± 0.5 0.965 14.1 ± 4.5
NS 150nm 1.5 30 0.972 3.2 ± 0.4 0.980 3.0 ± 0.6
2.0 40 0.988 3.6 ± 0.4 0.989 4.1 ± 0.1
2.4 48 0.983 3.8 ± 0.3 0.990 3.9 ± 0.9
2.8 56 0.984 4.9 ± 0.2 0.987 7.2 ± 1.6
3.1 0.984 6.6 ± 0.6 0.991 9.2 ± 1.2
3.5 70 0.973 6.5 ± 0.5 0.989 9.3 ± 2.4
3.9 0.960 11.8 ± 1.2 0.987 18.9 ± 3.2
4.4 87 0.949 13.2 ± 0.9 0.981 22.4 ± 3.1
NS 860nm 1.4 30 0.817 10.1 ± 1.1 0.842 10.7 ± 0.2
1.8 40 0.928 13.4 ± 0.9 0.925 14.0 ± 0.9
2.2 48 0.910 12.7 ± 1.2 0.903 12.9 ± 1.7
2.6 56 0.894 14.6 ± 1.9 0.907 36.9 ± 10.5
3.2 70 0.927 20.2 ± 1.1 0.937 36.9 ± 3.1
4.0 87 0.673 68.1 ± 29.7 0.720 164.5 ± 15.4
NS 100nm 2.7 47 0.984 2.7 ± 0.3 0.995 3.0 ± 1.8
NS 130nm 2.7 0.984 4.4 ± 0.3 0.988 5.9 ± 0.8
NS 150nm 2.7 54 0.984 6.0 ± 0.1 0.996 7.8 ± 0.5
NS 860nm 2.7 59 0.898 23.7 ± 1.6 0.913 57.4 ± 13.0
NS 1320nm 2.7 0.755 29.6 ± 4.9 0.757 86.4 ± 30.6
Conventional method
NS 860nm 2.7 0.971 15.1 ± 0.2 0.998 39.6 ± 5.7
MS 3.4µm 2.7 0.876 148.0 ± 9.6 0.988 369.7 ± 27.7
MS 6.8µm 2.7 0.745 340.5 ± 25.4 0.975 603.7 ± 74.7
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regarding the end of the process.
In this study a linear correlation of scattering signal and particle concentration was shown exemplar-
ily (section 3.3.1). This allowed the simplified assumption that during dissolution decreasing scattering
intensity corresponds to decreasing particle concentration. However, scattering depends not only on
particle concentration, but also on size (section 1.3). To deal with the effect of differences in scattering
patterns of different sized nanocrystal formulations the comparison of their dissolution profiles was done
on the basis of a relative dissolution endpoint (time when 1% of initial scattering intensity remains). The
influence of absolute differences in scattering intensity between formulations on data interpretation was
minimized by this approach. The applied interpretation is valid under the assumption that a change in
scattering intensity during dissolution is dominated by the reduction in particle number. Consideration
of particle shrinking or alterations in particle size distribution would require more complex data analysis.
A similar method to assess small particle dissolution was introduced by Tucker (2002) and Crisp et al.
(2007), who used turbidimetric measurements at an angle of 0◦ to monitor dissolution of particles with
sizes of 0.24 − 5 µm. An interesting approach was chosen by starting the dissolution process by the
addition of surfactants (and a resulting increase in solubility) during the measurement. This procedure
enables a determination of the initial absorbance of undissolved particles. Crisp developed a model for
the solid mass decay and regarded the particle dissolution process as the shrinking of a sphere. For the
case of scattering intensity being proportional to the particle volume he modified his mass decay model
towards a turbidity decay model. Both, the dissolution and turbidity based models fit experimental curves
well and it is concluded, that ‘the assumption that turbidity scales as particle volume fraction (concen-
tration) produces reasonable accuracy’ (Crisp et al. 2007).
Tucker (2002) reported dissolution times shorter than 60 s for naproxen nanosuspensions (266 nm and
656 nm; concentration of about 15 % of the equilibrium solubility). The same author described that
danazol nanosuspensions (Mean 356 nm and 820 nm, 40 % of the equilibrium solubility) dissolve in
aqueous sodium lauryl sulfate solution in about 150 s. Crisp came to a similar result (< 120 s) for dana-
zol nanosuspensions (D50 300 nm and 400 nm, 10 % of the equilibrium solubility) in aqueous sodium
lauryl sulfate solution (0.3 wt %) (Crisp et al. 2007). On the other hand the dissolution time for an
itraconazole nanosuspension (D50 240 nm, 10 % of the equilibrium solubility) was found to be 60 min,
which is explained by a lower micellar solubility and a lower rate constant of interfacial reaction for the
bigger and more lipophilic itraconazole molecules. The dissolution time for the fenofibrate nanosuspen-
sion NS 140nm (D50 130 nm, 40 % of solubility S NS 24h) of 91 s / 101 s (ExpDec1 / ExpDec2) stated in
this study fits well into the range given by Tucker and Crisp.
3.6.6 Data evaluation according to the Noyes-Whitney dissolution model
Theory
The Noyes-Whitney dissolution model describes the dissolution process as being determined by diffusion
of dissolved molecules through the diffusion layer adjacent to the solid surface. In strict interpretation
its validity is limited to a constant surface area, a bulk concentration being considerably lower than the
solubility of the API and to surfactant free dissolution media. In practice the Noyes-Whitney model
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has been successfully applied to model dissolution curves, which were obtained under experimental
conditions where not all of the above mentioned criteria were fulfilled (Tinke et al. 2005; Gao 2011;
Dokoumetzidis et al. 2006). This indicates the usefulness of the model even under non perfect conditions
and motivated the use of the Noyes-Whitney equation as a first approach in this study. For that purpose
the Hixson and Crowell equation was used, which is a transformation of the Noyes-Whitney equation
Eq. 1.2 (Costa and Sousa Lobo 2001).
Wd = VCS (1 − e−Kt) (3.1)
Wd is the mass dissolved, CS the saturation solubility, V the volume of dissolution medium, t the
time and K is a coefficient with
K =
DA0
hV
(3.2)
where D is the diffusion coefficient, A0 is the total surface area and h is the effective boundary layer
thickness. The total initial surface area A0 of the suspensions is estimated with following assumptions:
(1) Particles have a spherical shape and the radius r. (2) Particle size distributions are neglected. (3)
Due to the extremely poor solubility of the considered APIs it is neglected that the aqueous medium is
saturated with dissolved API. All drug substance is considered to be in the solid nanocrystalline state. (4)
The densities ρ of crystalline drug substance was predicted by I-Lab 2.0 software (ACD/Labs, Toronto,
Canada) (Tab. 2.1). (5) As an approximation the shrinking of particles and the change of surface area
during the dissolution process were not taken into account.
A0 = N ∗ AP = V0APVP =
W0
ρ
3
r
(3.3)
N represents the number of particles, V0 and W0 the total volume and mass of particles and VP and AP
the volume and surface area of an individual particle. Equation 3.1 is transformed by applying logarithms
and by substituting WS = VCS and Wd = W0−Wu (W0 is the total drug amount and Wu is the undissolved
drug mass):
ln
Wu + (WS −W0)
WS
= −Kt (3.4)
WS −W0 is the gradient ∆W. The time, when dissolution terminates DT is characterized by Wu = 0.
The total drug concentration is C0 (C0 = W0/V). Eqs. 3.5 and 3.6 can be obtained by transformation of
Eq. 3.4 and insertion of Eqs. 3.1, 3.2 and 3.3:
DT = −ln∆W
WS
1
K
= −lnWS −W0
WS
hV
DA0
= −lnCS −C0
CS
hρr
3DC0
(3.5)
−ln∆W
WS
V
A0
= kDT (3.6)
Eq. 3.6 denotes that the −ln(∆W/WS ) ∗ V/A0 vs DT diagram has a slope of k = D/h, where k is the
dissolution rate constant and where the y-intercept is zero.
3.6 Dissolution by light scattering 69
(a) Variation of size. c = 5.5µg/ml. (b) Variation of concentration. NS 140nm.
Figure 3.20: Fenofibrate: Plot of dissolution times DT vs − ln(∆W/WS ) ∗ V/A0. Dissolution times were
experimentally determined by light scattering dissolution method and fitting of the biexponential model.
(a) The data points (from left to right) denote dissolution results of NS 120nm, NS 140nm, NS 160nm,
NS 180nm, NS 270nm, NS 650nm, NS 800nm and NS 1070nm. (b) The data points (from left to right)
denote dissolution results of concentrations 40 %, 48 %, 56 %, 70 % and 87 % of S NS 140nm.
Application of the Noyes-Whitney dissolution model to experimental data
Figure 3.20(b) shows the DT vs − ln(∆W/WS ) ∗ V/A0 diagram for the dissolution of FF NS 140nm at
different concentrations and the result of linear regression. From the reciprocal slope a dissolution rate
constant of 9.4 ∗ 10−4 cm/s is derived. For the experimental data an offset was observed, thus for the
linear regression analysis the y-intercept was not forced to be zero (discussed in section 3.6.6).
Figure 3.20(a) shows the DT vs − ln(∆W/WS ) ∗V/A0 diagram for the dissolution of different fenofibrate
formulations at a constant concentration and the result of linear regression. Here for the calculation of
the term −ln(∆W/WS ) ∗ V/A0 differences in the nanosuspension solubilities (S NS or WS ) were not con-
sidered, since their contribution to the term −ln(∆W/WS ) ∗V/A0 is small compared to the contribution of
particle size. Instead as an approximation the value of S NS 24h for NS 140nm (Tab. 3.3) was assumed for
all calculations. From the reciprocal slope a dissolution rate constant of 5.1 ∗10−4 cm/s is derived, which
is in a similar range as determined by variation of concentration.
Figure 3.21 summarizes the application of the Noyes-Whitney model to the dissolution results of com-
pound AS formulations. Again the particle size and the concentration gradient were varied. From the
variation-of-size experiment a dissolution rate constant of 17.5 ∗ 10−4 cm/s is derived. The variation-of-
concentration experiment was performed for three formulations and the same result was found for all
formulations: The dissolution rate constant is 5.3 ∗ 10−4 cm/s.
Data evaluation according to the Noyes-Whitney dissolution model: Discussion
The Noyes-Whitney model describes the fundamental principles of diffusion controlled dissolution and
has been applied for basic and advanced dissolution modeling extensively. In this work as a first approach
it proved to be useful to check plausibility of experimental data and to gain some mechanistic insight.
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(a) Variation of size. c = 2.7µg/ml. (b) Variation of concentration. NS 100nm.
(c) Variation of concentration. NS 150nm. (d) Variation of concentration. NS 860nm.
Figure 3.21: Compound AS: Plot of dissolution times DT vs − ln(∆W/WS ) ∗ V/A0. Dissolution times
were experimentally determined by light scattering dissolution method and fitting of the biexponential
model. (a) The data points (from left to right) denote dissolution results of NS 100nm, NS 130nm, NS
150nm, NS 860nm and NS 1320nm. (b) The data points (from left to right) denote dissolution results of
concentrations 30 %, 40 %, 47 %, 48 %, 56 %, 70 % and 87 % of S NS 100nm. (c) The data points (from left
to right) denote dissolution results of concentrations 30 %, 40 %, 48 %, 54 %, 56 %, 61 %, 70 %, 76 %
and 87 % of S NS 150nm. (d) The data points (from left to right) denote dissolution results of concentrations
30 %, 40 %, 48 %, 56 %, 59 %, 70 % and 87 % of S NS 860nm.
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By transformation of the Noyes-Whitney equation a linear relation between the dissolution time DT and
the term −ln(∆W/WS ) ∗ V/A0 was obtained.
In accordance with the Noyes-Whitney model a linear relation DT vs − ln(∆W/WS )∗V/A0 was observed
for a wide concentration range of fenofibrate and compound AS dissolution – although nonsink condi-
tions were applied. This observation suggests that the sink classification might be of minor relevance
for the dissolution of crystalline nanosuspensions. Their outstanding characteristic, an enhanced surface
area, appears to predominate over the influence of concentration gradient in the Noyes-Whitney model.
A linear relationship could also be demonstrated for the variation of particle size, despite the assumptions
made in the calculation of total initial surface area A0 and despite the disregard of solubility dependence
on particle size.
Fenofibrate dissolution rate constants of 9.4 ∗ 10−4 cm/s (variation concentration) and of 5.1 ∗ 10−4 cm/s
(variation particle size) were calculated. Compound AS dissolution rate constants of 5.3 ∗ 10−4 cm/s
(variation concentration) and of 17.5 ∗ 10−4 cm/s (variation particle size) were calculated respectively.
We assume that the dissolution rate constants calculated from dissolution at different concentrations are
more reliable, since assumptions are made for the calculation of the surface area (e.g. sphericity of parti-
cles and disregard of polydispersity). The error deriving from this is constant when a single suspensions
is diluted to different concentrations but varies between different formulations (variation-of-particle-size
experiments). Nevertheless all values are in a similar range, which means that the dissolution of the
investigated systems seem to follow a similar mechanism regardless of changes in particle size or con-
centration. The determined dissolution rate constants fit well into the range given by Crisp et al. (2007),
who calculated effective dissolution rate constants of 6−357∗10−4 cm/s. This comparison confirms that
the applied method and data evaluation lead to reliable results. However, for the interpretation of results
it is important to mention that neither particle shrinking nor associated changes of effective boundary
layer or solubility during dissolution are considered (Galli 2006; Judefeind and Villiers 2009). The ap-
plied method therefore yields an averaged value for the dissolution rate constant over the entire time of
the process.
Shortcomings are associated with the determination of dissolution rate constants in this study and might
explain the observed y-offset in our data (Fig. 3.20 and 3.21). From the experimental point of view two
arguments could be stated. On the one hand for small particle sizes or low concentration gradients the
loss of dissolution information during the first 25 s might influence data interpretation essentially. On the
other hand for bigger particle sizes the applied data evaluation method might have the tendency to un-
derestimate dissolution times (discussed in section 3.6.2). From the theoretical point of view the choice
of the basic Noyes Whitney dissolution model could be discussed. The Noyes-Whitney equation neither
takes into account particle size distributions, nor changes in particle size, surface area, diffusion layer
thickness or particle solubility during the dissolution process. For that purposes more complex models
of particle dissolution are available (Johnson 2012). Furthermore, the general suitability of diffusion
controlled models (like the Noyes-Whitney model) for nanoparticle dissolution has been discussed in
literature (Crisp et al. 2007; Judefeind and Villiers 2009). It has been proposed that for nanoparticle
dissolution the rate limiting process is not diffusion of dissolved molecule into the bulk solution. Instead
the prior solvation step at the solid-liquid interface (the dissociation of drug molecules from the solid)
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Table 3.6: Prediction of dissolution data by extrapolation of the Noyes-Whitney evaluated nanocrystal
dissolution data.
Formulation Measured DT Predicted DT Deviation∗
[min] [min]
FF MS 7.9µm 439 588 +33 %
AS MS 3.4µm 370 236 −36 %
AS MS 6.8µm 604 316 −48 %
∗
Deviation = (PredictedDT − MeasuredDT )/MeasuredDT ∗ 100%
becomes more important for the dissolution process. However, in spite of various simplifications, an
approach using the Noyes-Whitney model seems to enable a description of the dissolution process of
nanocrystals in a meaningful way.
3.6.7 Are nanocrystal dissolution data recorded by the light scattering method predictive
for microcrystal dissolution?
It was tested if the linear relations between term −ln(∆W/WS ) ∗ V/A0 and the dissolution time DT mea-
sured by light scattering of nanocrystals (Fig. 3.20 and 3.21) were predictive for the dissolution times of
microcrystals (Fig. 3.5.1). However, the success of this approach was limited as can be seen in Table 3.6.
The points discussed in section 3.6.6 regarding experimental and theoretical considerations might be
reasons for the missing predictive strength of the applied approach. Shortly differences between the ex-
perimental method on the one hand and between the mechanism of dissolution on the other hand might
be responsible.
3.6.8 Application to a market drug product
So far in this chapter dissolution measurements on nanosuspensions have been presented. However, in
general nanosuspensions are further processed in order to yield a market product based on nanocrystals.
EMEND R© 80 mg capsules are one example of a nanocrystal based market product of the API aprepitant.
Aprepitant nanosuspensions are manufactured by wet milling and by a column-coating process coated
beads are generated. The pellets are then filled into a gelatin capsule (Olver et al. 2007).
The feasibility of the light scattering dissolution method to monitor dissolution of nanocrystals released
from EMEND R© pellets was evaluated. Since the formulation contains the undissolvable excipient mi-
crocrystalline cellulose, which disturbs light scattering measurements, a filtration step was added to the
dissolution protocol. In the predilution step pellets were dispersed and after filtration a stable nanopar-
ticulate dispersion resulted (DLS Z average 203nm, PDI 0.177). This dispersion was finally diluted to a
concentration lower than saturation concentration and it was possible to monitor nanocrystal dissolution
by the light scattering setup (Fig. 3.22). For aprepitant concentrations 45−50 µg/ml a complete nanocrys-
tal dissolution was observed, with a dissolution time depending on concentration. For the concentration
55 µg/ml dissolution was much slower, which indicated that this concentration is close to the saturation
level of aprepitant in the dissolution medium. The saturation concentration could not be measured, since
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Figure 3.22: EMEND R© nanocrystal dissolution in SGF + 0.1 %Tween 80 at different API concentrations
followed by light scttering intensity measurements (n = 3).
the API aprepitant is not commercially available and is protected by a patent. However, the proposed
estimate fits well into the range of aprepitant solubility published by Shono et al. (2010).
It was demonstrated that the light scattering based nanocrystal dissolution method was applicable to a
market product. The removal of undissolvable excipients by filtration at the predilution level was a suc-
cessful strategy to enable nanocrystal dissolution measurements by means of light scattering intensity
monitoring. However, this experiment should merely be regarded as a preliminary study, since only one
market formulation has been tested.
3.6.9 The use of the biorelevant dissolution medium FaSSIF
It was evaluated whether the use of the dissolution medium fasted-state simulated intestinal fluid (FaS-
SIF) was possible within the light scattering dissolution setup. The mixed micelles present in FaSSIF
have clearly stronger light scattering properties than the Tween micelles in the standard medium SGF
+ Tween. At the standard attenuator setting 10 the scattering intensity of FaSSIF was approximately
4000 kcps. Since this is outside the linear range (section 3.3.1) the attenuator setting 7 was chosen. At
attenuator 7 the scattering intensity of the used FaSSIF batch was 169 ± 5 kcps. It was possible to
measure fenofibrate NS 140nm dissolution curves in FaSSIF (Fig. 3.23). Dissolution curves at different
concentrations could be correctly ranked. The ∆MeanCountRate values were clearly lower compared to
values measured with SGF + Tween as dissolution medium.
The dissolution times were calculated to be 3.0 min for c = 55 % S API (R2ad justed = 0.982, Ex-
pDec1), 4.5 min for c = 77 % S API (R2ad justed = 0.986, ExpDec1) and 4.9 min for c = 88 % S API
(R2ad justed = 0.982, ExpDec1). As can be seen from Table 3.4 the dissolution times for NS 140nm in
SGF + Tween were in the same range for similar concentrations used (2.2 − 5.1 min). More data will be
necessary to enable a general conculsion regarding differences and similiarities of fenofibrate nanocrystal
dissolution in both dissolution media.
74 Results and Discussion
Figure 3.23: Fenofibrate NS 140nm dissolution in FaSSIF measured by light scattering. Measurement
parameters: 2 runs at 10 s, measurement position 4.65 mm, attenuator 7, 25◦C (n = 4).
3.6.10 Summary and conclusions
Manifold shortcomings are associated to conventional and published alternative dissolution methods to
assess nanocrystal dissolution. This triggered the development of an alternative nanocrystal dissolution
method. The approach to probe the presence of nanoparticles by monitoring light scattering intensities
was followed and its applicability was demonstrated.
The new method can be described as a straightforward dilution and in situ-measurement technique. All
sampling, separation and chromatographic quantification steps are avoided. The elimination of the sep-
aration step is especially favorable for nanocrystal dissolution due to its inefficiency, slowness and inva-
sive character. A continuous and fast data acquisition offers a much higher information density as can be
achieved with the conventional method. An additional feature of the presented method is its small scale
setup. By operating with a nanosuspension volume of a few µl, dissolution experiments could easily be
integrated in early formulation development studies with typically limited availability of API. In a direct
comparison a light scattering dissolution curve matched a conventionally generated dissolution curve
remarkably well, which demonstrates the eligibility of the alternative technique. The new approach was
applicable to differentiate between different particle sizes and concentration gradients with a satisfying
sensitivity and reproducibility. The nanocrystal size most suitable for the light scattering method is in
the lower nanometer range (mean particle size < 500 nm).
So far only nanosuspensions, which are used in preformulation studies, were investigated. However, in
market products the nanosuspensions are usually further processed and more excipients are added to the
formulation. A transfer of the scattering dissolution method to later development phases would require
an implementation of strategies to cope with undissolvable excipients due to their influence on light scat-
tering measurements. For example prefiltration steps could be included, which we successfully applied
to measure nanocrystal dissolution of the market product EMEND R©. Finally it should be noted that the
measurement of particle dissolution by light scattering techniques will only allow straightforward data
interpretation, if no absorption of light occurs at the selected wavelength.
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Experimentally determined dissolution times of nanosuspensions showed a linear correlation to concen-
tration gradient and initial particle surface area as predicted by the Noyes-Whitney dissolution model.
Despite being designed for constant particle surface area and sink conditions the Noyes-Whitney disso-
lution model was applicable for a wide concentration range in this study. Evaluation of results on the
basis of advanced dissolution models, which consider further parameters relevant for particle dissolution,
will help to gain further mechanistic insight from experimental data.
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3.7 In vitro permeability
Many studies demonstrated that particle size reduction can be a successful strategy to increase the
bioavailabiliy of poorly water soluble drugs. The main mechanisms are an enhancement in dissolu-
tion rate and solubility for small particles (Van Eerdenbrugh et al. 2010). After oral administration both
lead to a steeper concentration gradient across the gastrointestinal epithelial barrier and if BCS class II
drugs are considered, full advantage of their high drug permeability can be taken. A higher drug flux
across the epithelial barrier is enabled. This permeation enhancing effect of particle size reduction was
experimentally observed by Langguth et al. (2005); Buch et al. (2009); Wang et al. (2010); Rao et al.
(2011) and others.
The aim of the presented permeability studies was to evaluate the effect of nanocrystal formulations with
various particle sizes on the permeability of fenofibrate and compound AS. Nano to micron sized par-
ticles were used to cover a wide particle size range and the concentration of the stabilizers DOSS and
HPMC was equal in all formulations.
The transport studies were conducted across confluent monolayers of Caco-2 cells in apical (pH 6.5) to
basolateral (pH 7.4) direction. Transport-FaSSIF (tFaSSIF) was used as an alternative apical transport
medium. tFaSSIF was prepared by supplementing HBSS++ with lecithin and sodium taurocholate to
obtain a more physiologically relevant medium. The presented results subdivide into three parts: (I) an
assay validation, (II) a comparison of permeability assays and (III) a permeability study with different
sized crystalline micro- and nanosuspensions.
3.7.1 Validation
For permeabilities determined by Caco-2 transport studies a high variability is reported in literature. The
heterogeneity of cell lines as well as varying culture conditions, passage numbers, seeding densities,
filter supports and monolayer ages contribute to different transport and metabolic properties of the cells.
During the transport experiment absorption properties can be influenced by the transport buffers (cosol-
vents/additives), substrate concentrations and the sampling protocol. Also differences in the calculation
of Papp are reported (Volpe 2008).
In this study the permeabilities of reference substrates have been determined and are compared to litera-
ture. The aim was to improve the comparability of the presented data to published data. Lucifer Yellow is
absorbed exclusively through a paracellular route and served as a marker of monolayer and tight junction
integrity (Takahashi et al. 2002; Konishi et al. 2002). Griseofulvin (GF) and ketoconazole (KC) were
used due to their BCS II classification and their low solubility, which provide a good comparability to
fenofibrate. As apical medium HBSS++ was used.
Table 3.7 summarizes measured and previously published permeabilities of the reference substrates. Papp
values determined for Lucifer Yellow (applied as solution) fit well into the range given in literature. The
values for GF and KC (applied as coarse suspensions of pure crystalline API) seem to be lower than pub-
lished values. However, a careful look into reported methods reveals that lower concentrations of APIs
or the cosolvent DMSO were used in apical media. Whereas in the presented protocol API suspensions
in cosolvent free medium at concentrations approximately 20 − 60 fold above saturation concentration
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Table 3.7: Validation of Caco-2 permeability assays by determination of apparent permeability coeffi-
cients (Papp) of reference substrates. For griseofulvin and ketoconazole an alternative calculation of Papp
was applied by inserting the solubility in water CS instead of the total initial donor concentration C0.
Horizontal assay Vertical assay Reference values
Substance Papp [∗ 10−6 cm/s]
Lucifer Yellow 0.27 ± 0.14 0.21 ± 0.03 0.22 1; 0.65 2
Griseofulvin 1.62 ± 0.20 2.53 ± 0.18
58 2; 37 3
Griseofulvin alternative Papp
∗
34 ± 4 51 ± 4
Ketoconazole 0.51 ± 0.03 1.04 ± 0.40
66 2; 10 4; 15 5
Ketoconazole alternative Papp
∗
29 ± 2 59 ± 23
∗ CS (GF) = 8.6µg/ml, CS (KC) = 4.7µg/ml taken from DrugBank database (www.drugbank.ca)
1 Takahashi et al. (2002) 2 Takano et al. (2006) 3 Yazdanian et al. (1998) 4 Marino et al. (2005)
5 Ingels et al. (2004)
were applied. In the literature protocols a higher amount or percentage of API is expected to be in solu-
tion and consequently to be available for absorption. The use of the total initial concentration C0 in the
calculation of Papp can lead to an underestimation of permeability, since only the dissolved fraction of
API is absorbable. Therefore we used the solubility CS of APIs instead of the total initial concentration
C0 in the calculation of Papp. CS reflects a more realistic estimation of the API concentration available
for permeation. Papp values calculated by this method are in good accordance with literature.
3.7.2 Comparison of permeability assays
The vertical permeability assay
A vertical permeability setup with Caco-2 monolayers grown on permeable SnapwellTM filter supports
mounted between side-by-side diffusion chambers was used (section 1.2.2).
The influence of gas flow on pH and TEER was evaluated in a placebo experiment with HBSS++ as
apical transport medium (Fig. 3.24). All steps except the addition of a substrate to the apical chamber at
time zero were performed according to the standard protocol. A moderate drop of pH was observed with
gas flow, which was more pronounced for the basolateral medium. Carbonic acid formation out of CO2
in the carbogen gas (5% CO2 / 95% O2) might be responsible. However, the TEER drop over time is a
more relevant issue for transport studies, since it indicates a loss of integrity of cell monolayers. It was
observed with and without gas flow. Most probably the reason for the TEER drop is the stressful transfer
of the filter support with the monolayer from the cell culture plate into the diffusion chamber. It includes
SnapwellTM filter removal from the cell culture plate supports, assembly of chambers and filling of the
chambers with medium. The monolayers are subjected to mechanical stress and are without medium for
a few minutes. Sometimes medium leakage appears in the case of inappropriate O-ring seal attachment
and the necessity of repeated chamber assembly was observed to adversly influence TEER values.
Additional drawbacks of the vertical permeability system are a lack of quantitative and reproducible gas
flow adjustment, difficult control of temperature and a large inner device surface area. It was estimated
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(a) pH (b) TEER
Figure 3.24: Vertical permeability assay: Monitoring of pH (a) and TEER (b) during a placebo exper-
iment in side-by-side diffusion chambers with gas flow (closed symbols) and without gas flow (open
symbols). The chambers were assembled at the time -120 min. (a) Apical pH (circles), basolateral pH
(squares). (b) Marked TEER values (∗) were determined in SnapwellTM cell culture plates prior to cham-
ber assembly (n = 3).
to be 22 cm2 for one chamber (acrylic glass) compared to an estimated inner surface area of 3 cm2
(polystyrene) of the apical chamber in the horizontal permeability setup. Adsorption of large amounts of
poorly water soluble API onto the device surface might be the consequence.
Comparison of horizontal and vertical permeability assay
A direct comparison of both permeability assays was performed and fenofibrate was applied as
• FF: pure crystalline FF suspended in apical transport medium
homogenized by magnetic stirring (SLS D50 11 − 18 µm)
• rawNS: coarse crystalline FF suspended in an DOSS/HPMC solution
homogenized by magnetic stirring (SLS D50 11 − 13 µm)
• NS: FF nanosuspension NS 160nm
obtained by wetmilling of rawNS (SLS D50 138 nm)
Figure 3.25(a) displays the permeated amounts of API over time and Table 3.8 summarizes the apparent
permeability coefficients. Rapid metabolization of fenofibrate by Caco-2 esterases occurred and only
fenofibric acid was detectable in the receiver compartment. After 120 min FFA was also detected in the
donor compartment.
Figure 3.25(a) shows that in general lower amounts of API in the receiver compartment were detected in
the vertical setup. A higher permeability of NS and raw NS compared to FF drug substance was seen for
both assays. A significantly higher permeability was measured for rawNS than for NS in the horizontal
assay. An explanation might be that the bigger particles sediment in the horizontal assay, which increases
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Table 3.8: Permeabilities of fenofibrate drug substance and fenofibrate formulations determined by hor-
izontal and vertical permeability assay.
Horizontal assay Vertical assay
Formulation Papp [∗ 10−6 cm/s]
pure crystalline substance 0.64 ± 0.07 0.35 ± 0.08
coarse suspension (rawNS) 3.74 ± 0.26 2.00 ± 0.14
nanosuspension NS 160nm 2.61 ± 0.22 2.34 ± 0.33
the concentration gradient at the monolayer and consequently enhances permeability. A higher Papp was
measured for NS than for rawNS in the vertical setup which was, however, not significant. No significant
difference in the permeability of the nanosuspension was observed in the vertical vs horizontal assay (p
< 0.05 for all tests).
The comparison of API recovery (Fig. 3.25(b)) reveals a much better mass balance for formulated fenofi-
brate (rawNS and NS). The stabilizers DOSS and HPMC prevent adsorption to plastic surfaces and
improve particle wettability. A tendency for a lower recovery of API from the vertical system could be
observed due to a higher device surface area. Adsorptive loss might contribute to lower permeated API
amounts measured in the vertical assay.
The development of pH and TEER in the vertical assay (Fig. 3.25(d)) are the same as seen in the placebo
experiment (Fig. 3.24). On the contrary stable TEER values were measured in the horizontal assay
(Fig. 3.25(c)). The simultaneous monitoring of cell capacitance CCl provides insight into changes of the
cell membrane surface area. A stable cell capacitance demonstrates that cells were not adversely affected
during the experiment.
Comparison of permeability assays: Summary and conclusions
The aim of the permeability studies was to determine the permeability of APIs formulated as particle
suspensions. Since gentle horizontal shaking in the horizontal assay cannot completely compensate for
sedimentation of larger particles, a vertical permeability setup was evaluated. Not only the positioning
of the cell monolayer, but also hydrodynamic conditions which create a minimized unstirred water layer
(UWL) might be advantageous for permeability assessment of suspensions of poorly water soluble com-
pounds.
Indeed the finding of a higher permeability from a micron versus a nano sized suspension in the hori-
zontal setup might indicate that sedimentation influences permeability. On the other hand the expected
permeability enhancing effect of particle size reduction could also not be seen in the vertical setup. Re-
garding the criterion of providing a good distinguishability between formulations none of the systems
did offer clear advantages. As expected the API recovery from the side-by-side diffusion chambers was
lower, even though the differences were small.
The main drawback of the vertical system is a decrease of TEER over time indicating a loss of cell mono-
layer integrity, which is a prerequisite for successful transport studies. Other shortcomings are leakage
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(a) Permeation (b) API recovery
(c) IPC horizontal assay (d) IPC vertical assay
Figure 3.25: Comparison of horizontal (closed symbols) and vertical (open symbols) permeability assay
for pure FF crystalline suspension (black), FF nanosuspension NS 160nm (light blue) coarse FF crys-
talline suspension (blue). (a) Permeated amount of FFA versus sampling time. (b) API recovery. (c)
In-process control (IPC) of capacitance CCl (compact lines) and TEER (dashed lines) for the horizontal
assay. (d) IPC of apical pH (circles), basolateral pH (squares) and TEER (dashed lines) for the vertical
assay. Marked TEER values (∗) were determined in SnapwellTM cell culture plates prior to chamber
assembly (n = 4 − 5).
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and difficulties in adjustment of a standardized gas flow and temperature. The CellZscope R© device used
for horizontal permeability studies offers clear experimental advantages, like an automated monitoring of
TEER and capacitance in parallel. Additionally simultaneous experiments in 24 wells can be performed
under easily adjustable temperature and shaking conditions. This optimizes throughput and repeatability.
The horizontal system was selected for further studies due to the experimental drawbacks of the vertical
setup. The vertical setup did not improve the permeation ranking of formulations.
3.7.3 Permeability of APIs formulated as crystalline micro- and nanosuspensions
Stability of nanosuspensions in transport media
The stability of selected nanosuspensions of FF and AS in apical transport media was evaluated with
respect to particle size. The aim was to identify stable formulations suitable to study the effect of particle
size on permeation. Selection of formulations was governed by the intention to cover a wide particle size
range.
Figure 3.26(a,b) shows that the fenofibrate suspension NS 140nm was not stable in HBSS++, but was
in tFaSSIF. Salts are responsible for rapid particle agglomeration. Since the salt concentration in both
media is equal, the better stability in tFaSSIF can be attributed to the phospholipid lecithin and the bile
salt sodium taurocholate. As amphiphilic molecules they exhibit a particle stabilizing effect through
adsorption to the particle surface area. No instabilities were observed for fenofibrate formulations NS
270nm and NS 1070nm.
The compound AS nanosuspension NS 100nm agglomerated immediately after dilution, whereas NS
150nm and NS 860nm were found to be stable in both media and were selected for further studies
(Fig. 3.26(c,d)).
Permeability of APIs formulated as crystalline micro- and nanosuspensions
The fenofibrate permeability from formulations NS 140nm, NS270nm, NS1070nm and MS 7.9µm and
the compound AS permeability from NS 150nm, NS 860nm and MS 6.8µm were determined by the
horizontal permeability assay. The apical medium was varied and all experiments were performed with
Caco-2 cells grown on permeable filter supports and with empty filters. In-process controls of TEER and
capacitance were performed and the recovery of API at the end of each experiment was determined. All
results can be found in Figure 3.27 and 3.28. The calculated Papp values are listed in Table 3.9. Table 3.10
summarizes all experiments and the effects of experimental conditions on the measured permeability and
recovery.
Prior to experiments with formulations the effect of pure transport media on Caco-2 cells was stud-
ied in a placebo experiment. TEER and capacitance were stable for 180 min within ± 10% of the start
value (data not shown). Stable TEER and capacitance was also given in experiments with formulations
(Fig. 3.27(c,d) and 3.28(c,d)).
In assays performed with fenofibrate and with Caco-2 cells fenofibric acid was the only detectable sub-
strate in the receiver compartment.
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(a) FF nanosuspensions in HBSS++ (b) FF nanosuspensions in tFaSSIF
(c) AS nanosuspensions in HBSS++ (d) AS nanosuspensions in tFaSSIF
Figure 3.26: Stability of fenofibrate and compound AS suspensions in HBSS++ and tFaSSIF at a con-
centration of 0.5 mM. The particle size was measured by dynamic light scattering and is reported as Z
average diameter. At 0, 1, 2 and 18 h after dilution the particle size was measured. As reference values
the particle sizes measured in water are displayed (black columns) (n = 1).
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(a) Apical medium: HBSS++ (b) Apical medium: tFaSSIF
(c) IPC: HBSS++ / Caco-2 (d) IPC: tFaSSIF / Caco-2
(e) Recovery: HBSS++ (f) Recovery: tFaSSIF
Figure 3.27: Permeability of fenofibrate suspensions determined by horizontal permeability assay. The
apical medium was varied: HBSS++ (a,c,e) and tFaSSIF (b,d,f) were used. Caco-2 monolayers grown
on filters (squares) and empty filters (crosses) were evaluated as permeation barrier. Panels (c) and (d)
show in-process controls (IPC) of capacitance (compact lines) and TEER (dashed lines). The permeation
experiment was started at time zero and earlier data points represent the equilibration phase. Panels (e)
and (f) show the total API recovery (n = 3).
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(a) Apical medium: HBSS++ (b) Apical medium: tFaSSIF
(c) IPC: HBSS++ / Caco-2 (d) IPC: tFaSSIF / Caco-2
(e) Recovery: HBSS++ (f) Recovery: tFaSSIF
Figure 3.28: Permeability of compound AS suspensions determined by horizontal permeability assay.
The apical medium was varied: HBSS++ (a,c,e) and tFaSSIF (b,d,f) were used. Caco-2 monolayers
grown on filters (squares) and empty filters (crosses) were evaluated as permeation barrier. Panels (c)
and (d) show in-process controls (IPC) of capacitance (compact lines) and TEER (dashed lines). The
permeation experiment was started at time zero and earlier data points represent the equilibration phase.
Panels (e) and (f) show the total API recovery (n = 3).
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Table 3.9: Apparent permeability coefficients (Papp) of fenofibrate and compound AS suspensions de-
termined by in the horizontal permeability assay. The apical medium was varied: HBSS++ and tFaSSIF
were used. In addition to Caco-2 monolayers grown on Transwell R© filter inserts (Caco-2), the barrier
properties of empty Transwell R© filters (empty filter) were evaluated.
HBSS++ tFaSSIF
Caco-2 empty filter Caco-2 empty filter
Formulation Papp [∗ 10−6 cm/s]
Fenofibrate formulations
NS 140nm 2.66 ± 0.33 0.14 ± 0.10
NS 270nm 2.21 ± 0.19 0.00 ± 0.00
NS 1070nm 4.20 ± 0.06 0.00 ± 0.00 5.61 ± 0.08 0.08 ± 0.04
MS 7.9µm 3.69 ± 0.52 0.00 ± 0.00 5.60 ± 0.18 0.28 ± 0.06
Compound AS formulations
NS 150nm 0.25 ± 0.01 1.52 ± 0.09 0.31 ± 0.03 1.98 ± 0.09
NS 860nm 0.10 ± 0.00 1.05 ± 0.08 0.25 ± 0.01 1.52 ± 0.14
MS 6.8µm 0.10 ± 0.00 1.00 ± 0.12 0.22 ± 0.00 1.50 ± 0.30
Effect of particle size. In the present study a positive effect of size reduction on permeability was seen
for AS suspensions. For FF the smallest suspensions NS 140nm and NS 270nm had the significantly
lowest permeabilities (p < 0.05), despite the fact that a solubility enhancing effect was demonstrated for
NS 140nm (section 3.4.2). No permeability enhancing effect was observed for particles with a size of
approx. 1 µm (FF NS 1070nm, AS NS 860nm) with reference to particles with approx. 7− 8 µm (FF MS
7.9µm, AS MS 6.8µm) (p < 0.05). Expected equal solubilities for formulations in both size ranges can
explain this result.
A specific feature of permeability studies on the ester prodrug fenofibrate is that fenofibrate is hydrolyzed
during the assay by Caco-2 esterases. After 120 min the fenofibric acid concentrations in the apical com-
partment were approximately 11 − 22 µg/ml (Fig. 3.29). This corresponds to a metabolized fraction of
6− 12 % (relating to the total apically applied API (FF)) or 5− 30 % (relating to the total apically recov-
ered API (FF+FFA)). A rapid hydrolysis and a more than 100-fold higher water solubility of fenofibric
acid suggests a negligible fraction of dissolved fenofibrate present in the donor compartment. It is proba-
ble that higher concentrations of dissolved fenofibric acid prevail and that fenofibric acid is consequently
the substrate mainly permeating across the Caco-2 monolayer. In that case the hydrolysis rate would
control the diffusion rate. This hypothesis is supported by a good correlation between Papp values and
the fenofibric acid concentrations in apical compartment after 120 min (Fig. 3.29). It seems that not the
particle size or solubility did control permeabilities, but the rate of fenofibrate hydrolysis.
This hypothesis is supported by two published studies. Linn et al. (2012) studied the Caco-2 permeability
of fenofibrate drug substance and a fenofibrate solid dispersion. The assumption that transport is con-
trolled by hydrolysis is discussed in order to explain some of the experimental findings. Zhu et al. (2010)
studied the site-specific absorption of fenofibrate versus fenofibric acid in humans by delivering FF and
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Figure 3.29: Correlation of apparent FF permeability Papp and fenofibric acid concentration in apical
compartment. Included are experiments with different fenofibrate formulation, transport assay (H: hori-
zontal, V: vertical) and transport medium.
FFA nanocrystal dispersions specifically to the stomach, proximal small bowel, distal small bowel and
the colon. Higher Cmax, lower Tmax and higher bioavailability of FFA at all regions of the GI tract and
especially at the colon suggest that FFA has improved absorption characteristics over FF.
Effect of Caco-2 monolayer compared to empty filter. No permeation of fenofibrate across empty
filters was observed in the case of HBSS++ used as apical medium. This result is in contrast to expected
higher permeabilities when the cell monolayer as permeation barrier is missing (Hidalgo et al. 1991; Yu
and Sinko 1997). It seems that fenofibrate itself does not diffuse across the filter support. In the case of
tFaSSIF as apical medium little amounts of fenofibrate pass the filter. Mixed micelles might function as
carriers which transport fenofibrate through the pores.
In empty filter experiments better recoveries with tFaSSIF than with HBSS were observed, which indi-
cates a lower absorptive loss caused by solublizing agents. With HBSS better recoveries were observed
with Caco-2 cells than with empty filters, which indicates a higher absorptive loss when the plastic sur-
face area is increased due to the missing cell monolayer. It can be concluded that FF adsorption to the
apical filter surface or pores is most likely responsible for low permeabilities with empty filters. As well
blocking of filter pores by particles might occur.
For AS particle suspensions the barrier properties of the cell monolayer become visible. With empty
filters higher amounts of API are detected basolaterally. While the suspensions with medium and large
particles are not distinguishable, clearly more API passes the filter when the smallest sized suspension
is employed. Diffusion of the nanocrystals in NS 150nm through the 0.4 µm-pores and an improved
solubility explain higher permeabilities.
Effect of apical transport medium. Higher Papp values can be measured for FF formulations in tFaS-
SIF than in HBSS++. While the effect is not significant for the smallest sized suspensions, tFaSSIF
enhances the permeability significantly for the medium and large sized suspensions (p < 0.05). A higher
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Table 3.10: Overview of effects of experimental conditions on permeability and recovery.
Given Measured FF/FFA AS
parameter parameter
particle size
∗ permeability large = medium > small small > medium = large
recovery small > medium > large small > medium > large
Caco-2 vs empty filter permeability Caco-2 > empty empty > Caco-2
recovery Caco-2 = empty empty ≥ Caco-2
HBSS vs tFaSSIF
permeability tFaSSIF > HBSS tFaSSIF > HBSS
recovery tFaSSIF ≥ HBSS tFaSSIF ≥ HBSS
∗ Small particle size refers to formulations FF NS 140nm and AS NS 150nm, medium particle size to FF NS
1070nm and AS NS 860nm and large particle size to FF MS 7.9µm and AS MS 6.8µm.
solubility in tFaSSIF might explain this finding. Additionally with tFaSSIF higher concentrations of
fenofibric acid were found in the apical compartment. A good overall correlation of Papp and fenofibric
acid concentration (Fig. 3.29) for both media might suggest that not the solubility enhancing effect, but
a hydrolysis enhancing effect of tFaSSIF gives the main contribution.
The interpretation of AS permeation data is not complicated by simultaneous API metabolization. Here
higher Papp values in tFaSSIF than in HBSS++ can be attributed to a higher solubility of AS in tFaSSIF.
In literature diverse effects of solubilization by micellar encapsulation on permeability are discussed
(Kleberg et al. 2010). A parallel increase of permeability with micellar solubility, like demonstrated in
this study, is reported in literature. Brouwers et al. (2006) observed a 60 % increase in permeabiliy of
amprenavir (poorly water soluble, logP 2.43) when using FaSSIF or human intestinal fluids compared
to HBSS. On the contrary also a decreasing effect on permeability has been observed manifold and was
explained by an entrapment of drug molecules in micelles and a reduction of free drug concentration
(Ingels et al. 2004; Fossati et al. 2008; Yano et al. 2010).
A trend to better recoveries in tFaSSIF especially for the formulations with larger particles was observed
for both APIs and is in good accordance with literature (Ingels et al. 2004; Fossati et al. 2008).
3.7.4 Permeability of fenofibrate formulations in literature
To the best knowledge of the authors only two studies investigating formulation effects on the permeabil-
ity of fenofibrate in Caco-2 transport assays are published (Buch et al. 2009; Linn et al. 2012). Table 3.11
provides an overview of the here presented and previously published results and methods.
In both literature studies the permeability of pure crystalline fenofibrate was determined. Also the com-
parability is hampered by the usage of different experimental methods very similar fenofibrate permeabil-
ities were determined. Positive effects on the permeability of fenofibrate formulated as solid dispersions
could be demonstrated by both authors. Furthermore Buch et al. (2009) used a powderized TriCor R©
145mg tablet as a nanoparticulate formulation and reports an approximately 10-fold permeability in-
crease. However, this is not the ideal formulation to study the sole effect of particle size reduction. The
reason is that the TriCor R© tablet contains the ionic surfactant sodium lauryl sulfate (SLS) at unknown
concentration. SLS can improve the solubility of fenofibrate strongly (Granero et al. 2005).
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Table 3.11: Permeabilities of fenofibrate drug substance and fenofibrate formulations determined by
horizontal and vertical permeability assay and comparison with reference values from literature.
Horizontal assay Vertical assay
Formulation Papp [∗ 10−6 cm/s]
Comparative study of permeability assays and particle sizes 1
pure crystalline substance 0.64 ± 0.07 0.35 ± 0.08
nanosuspension NS 160nm 2.61 ± 0.22 2.34 ± 0.33
nanosuspension NS 270nm 2.21 ± 0.19
nano/microsuspension NS 1070nm 4.20 ± 0.06
microsuspension MS 7.9µm 3.69 ± 0.52
coarse suspension with HPMC and DOSS 3.74 ± 0.26 2.00 ± 0.14
Permeability of FF and FF formulations reported by Linn et al. (2012) 2
pure crystalline substance 0.86
physical mixture: 20% FF in Soluplus R© 1.35
solid dispersion: 20% FF in Soluplus R© 2.48
Permeability of FF and FF formulations reported by Buch et al. (2009) 3
pure crystalline substance 28µm / 5µm ∗ 0.13 / 0.19
powderized nanoparticulate tablet formulation ∗∗ 1.11
powderized solid dispersion tablet formulation 1.91
Linn et al. (2012) and Buch et al. (2009) did not calculate Papp values. On the basis of the provided
information Papp values were derived.
Experimental setup: membrane material and pore size, initial concentration in donor compartment, apical
(A) and basolateral (B) transport medium.
1 polyester 0.4µm, c0 = 0.181 mg/ml, A: HBSS pH 6.5, B: HBSS pH 7.4.
2 polyester 0.4µm, c0 = 1.0 mg/ml, A: KRB pH 7.4, B: KRB pH 7.4 + 0.2% vitamin E TPGS 1000.
3 polycarbonate 0.3µm, c0 = 0.181 mg/ml, A: HBSS + 3mM NaTC + 0.75mM lecithin, pH 6.5 B: HBSS
+ 4.5% BSA pH 7.4. ∗ average particle size. ∗∗ TriCor R©, Abbott Laboratories, Abbott Park, IL, USA.
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3.7.5 Summary and conclusions
The aim of the permeability studies was to evaluate the effect of particle size on the permeability of two
APIs. Nano to micron sized particles were used to cover a wide particle size range and the concentrations
of stabilizers DOSS and HPMC were equal for all formulations. A horizontal permeability assay was
used with different apical media, one of which was a biorelevant transport medium. The permeabilities
of pure crystalline fenofibrate, ketoconazole and griseofulvin drug substances determined in this study
were in good accordance with literature.
The results for AS formulations meet the expectations and are in accordance to findings in literature:
A smaller particle size improves the permeability, the Caco-2 monolayer and not the empty filter is the
main permeation barrier and the micellar medium tFaSSIF improves the API recovery from the assay.
On the contrary, for fenofibrate unexpected findings were identified: A smaller particle size negatively
affected permeation and lower permeabilities were seen with empty filters than with filters covered over
by a Caco-2 monolayer. The latter indicates that adsorptive loss of API is an issue which has to be
carefully considered in fenofibrate transport studies. In the discussion about the permeability results for
fenofibrate formulations further aspects can be mentioned. The FF permeability can be influenced by the
formulation, hydrolysis and micellar encapsulation. The interplay of all aspects makes the interpretation
of results difficult. However, the data suggest that API hydrolysis of fenofibrate to fenofibric acid is
a crucial parameter. Taking into account Papp values measured under various conditions (vertical vs
horizontal assay, particle size, transport medium) an overall tendency for higher permeabilities with
higher fenofibric acid concentrations was observed (Fig. 3.29).
To support this hypothesis and to gain further insight into the mechanism and influencing parameters
of fenofibrate permeation more reference experiments are required. An evaluation of esterase activity
under different conditions and transport experiments with an inhibition of hydrolytic enzymes will help
to analyze the effect of hydrolysis systematically. Recently Ohura et al. (2010) highlighted the role of
carboxylesterases in the assessment of transepithelial transport of ester prodrugs. With bis-p-nitrophenyl
phosphate (BNPP) he describes a specific carboxylesterase inhibitor. Additional experiments to study the
mechanism of fenofibrate/fenofibric acid permeation applied as nanocrystal formulation might cover:
(I) a concentration titration of biorelevant surfactants to quantitatively estimate the effect of micellar
solubilization on permeation, (II) the quantification on intracellular uptake into recovery calculations
and (III) identification of transporters possibly involved in FF and FFA absorption.
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3.8 In vivo pharmacokinetics
The aim of this in vivo pharmacokinetic study was to evaluate the effect of particle size on the bioavail-
ability. Therefore suspensions of fenofibrate and compound AS were orally administered to rats. Solu-
tions of both APIs were furthermore administered intravenously. The correlation between in vitro dis-
solution data and in vivo bioavailability was investigated. In addition it was evaluated whether in silico
simulation can predict concentration-time profiles of nano and micron sized formulations correctly.
3.8.1 The effect of fenofibrate and compound AS particle size reduction on pharmacoki-
netics
The observed plasma concentration-time profiles and pharmacokinetic parameters for all formulations
are summarized in Figure 3.30 and Table 3.12. After oral administration of fenofibrate only the metabo-
lite fenofibric acid was detected in all plasma samples.
For fenofibrate crystal size reduction a trend towards shorter Tmax, higher Cmax and higher AUC values
was observed. All pharmacokinetic parameters indicate that particle size reduction can improve the rate
and extent of FF absorption from the GI tract. A 1.5-fold increase in bioavailability was achieved by
particle size reduction from 7.9 µm to 140 nm and the absolute bioavailability was raised from 57 % to
83 % (Fig. 3.31(a)).
A similar effect of particle size reduction was observed for compound AS. Higher Cmax and higher AUC
values were achieved, while the size reduction had no effect on Tmax. It seems that the extent, but not the
rate of absorption is enhanced with decreasing particle size. An overall trend towards higher bioavail-
ability for smaller particles can be assumed, although the formulation NS 1320nm does not fit into this
tendency (Fig. 3.31(b)). A 1.8-fold increase in bioavailability was achieved by particle size reduction
from 6.8 µm to 100 nm and the absolute bioavailability could be raised from 28 % to 50 %. Compared
to fenofibrate lower absolute bioavailabilities were observed, which indicates a lower permeabiliy of
compound AS. A lower permeability of AS was also found in in vitro studies on Caco-2 monolayers
(Tab. 3.9). The nanosuspensions FF NS 140nm and AS NS 150nm exhibited similar particle size and
showed a similar relative bioavailabiliy of 145 % and 135 %, respectively.
3.8.2 The in vivo effects of particle size reduction: Discussion
It has been described manifold that nanocrystal formulations can help to increase the oral bioavailability
of poorly water soluble drugs. Here only few examples from literature are given: Wu et al. (2004); Jinno
et al. (2006, 2008); Wang et al. (2010); Xia et al. (2010); Sigfridsson et al. (2011); Quinn et al. (2012).
Some of their results are: The strategy of particle size reduction, surface area enhancement, dissolution
rate enhancement leading to a higher systemic exposure is successful for dissolution rate-limited absorp-
tion. If the conditions for a dissolution rate-limited absorption are met, for example, depends on the
applied dose and the absorption window of the drug substance. At low doses or with a broad absorption
window a particle size reduction will not always lead to a higher systemic exposure (Wu et al. 2004;
Sigfridsson et al. 2011).
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(a) Fenofibrate / Fenofibric acid: p.o. (b) Compound AS: p.o.
(c) Fenofibrate / Fenofibric acid: i.v. (d) Compound AS: i.v.
Figure 3.30: (a+b) Plasma concentration-time profiles of orally administered suspensions. (a) FF dose
2.1 mg/kg. (Only FFA found in plasma). (b) AS dose 2.7 mg/kg. (c+d) Plasma concentration-time
profiles after i.v. administration of API solutions. (c) FFA dose 2.1 mg/kg. (d) AS dose 1.0 mg/kg. All
data expressed as arithmetic mean + /± standard error of the mean (n = 3).
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Table 3.12: Pharmacokinetic parameters of FF and AS p.o. and i.v. administration. FFA dose i.v.
2.1 mg/kg, FF dose p.o. 2.1 mg/kg, AS dose i.v. 1.0 mg/kg, AS dose p.o. 2.7 mg/kg.
Formulation Route Dose Tmax Cmax AUC0→25h Fabs Frel
∗
[mg/kg] [h] [ng/ml] [ng/ml∗h] [%] [%]
Fenofibrate
FFA solution i.v. 2.1 0.2 14733 41711 100 –
NS 140nm p.o. 2.1 0.5 6511 34532 83 145
NS 270nm p.o. 2.1 1.0 3853 29276 70 123
NS 1070nm p.o. 2.1 3.0 2881 25009 60 105
MS 7.9µm p.o. 2.1 3.0 3168 23850 57 100
Compound AS
AS solution i.v. 1.0 0.2 5880 21972 100 –
NS 100nm p.o. 2.7 3.0 3090 29658 50 181
NS 150nm p.o. 2.7 3.0 2530 22240 37 135
NS 860nm p.o. 2.7 3.0 2040 18701 32 114
NS 1320nm p.o. 2.7 3.0 1853 22979 39 140
MS 6.8µm p.o. 2.7 5.0 1375 16420 28 100
∗ The relative bioavailabilities Frel of the nanosuspensions (NS) were calculated with reference to the AUC of the
microsuspensions (MS).
(a) Fenofibrate (b) Compound AS
Figure 3.31: FF and AS bioavailability as a function of particle size.
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An improvement of the oral bioavailability of fenofibrate by particle size reduction was for example
demonstrated by Li et al. (2009) (amorphous nanosuspensions), by Chen et al. (2009) (liposomes), by Jia
et al. (2011) (silica/polymethylacrylate nanomatrix) and by Hanafy et al. (2007) (DissoCubes R© nanosus-
pension and solid lipid nanoparticles). Crystalline nanosuspensions were used in the studies of Buch et al.
(2009).
While in the majority of studies only one nano-formulation is evaluated against a larger sized reference
formulation (microsuspension or coarse suspension), only few studies deal with a incremental particle
size reduction. Examples for the latter can be found in Wu et al. (2004); Li et al. (2009); Xia et al. (2010);
Wang et al. (2010) and will be shortly summarized below.
Wang et al. (2010) used silybin nanocrystal suspensions with particle sizes of 127 nm and 642 nm (DLS
Z average, PDI 0.30 and 0.38) and compared it to an un-milled silybin suspension in a PK study on
beagle dogs. A 2.9-fold and 2.3-fold bioavailability enhancement was observed for the nanocrystal for-
mulations. No significant difference between both nanosuspensions was observed.
Li et al. (2009) performed a bioavailability study in rats with amorphous fenofibrate nanosuspensions
(FF dose 27 mg/kg). The particle sizes were 194 nm and 356 nm (DLS Z average, PDI 0.25 and 0.19).
Micronized and coarse drug powders with sizes of 5− 10 µm and 120− 150 µm were used as references.
While micronization resulted in a 8-fold AUC enhancement with reference to the coarse suspension, an
additional 2-fold AUC enhancement was observed for the nanosuspensions with reference to the micro-
suspension. Larger Cmax and shorter Tmax of nanosuspensions indicated more rapid absorption of FF
from the colloidal suspensions. This is a result which was likewise found in the present study. Li et al.
(2009) report a lack of statistically significant differences in all PK parameters between the two nanosus-
pensions.
In the work of Xia et al. (2010) a wide particle size range was covered by six crystalline suspensions
of nitrendipine. Their mean particle sizes were 200 nm, 629 nm, 2.7µm, 4.1µm, 20.2µm and 36.6µm. It
could be criticized that the three smallest sized suspensions displayed very wide particle size distribution
with clearly bi- or multimodal distributions. A PK study on rats was performed and incremental im-
provements in systemic exposure by a reduction in particle size were observed. AUC and Cmax values of
crystals with 200 nm to 20.2µm were significantly increased. The absolute bioavailabilities were 62 %,
52 %, 29 %, 27 %, 25 % and 10 % in order of increasing size.
Finally Wu et al. (2004) administered aprepitant suspensions with mean particle sizes of 120 nm, 480 nm,
1.9µm and 5.5µm to dogs. Incremental improvements in oral absorption correlated well with a reduc-
tion of particle size. A four-fold increase in AUC of the smallest suspension compared to the largest
suspension (45-fold larger particles) was seen. Also the suspension with 480 nm particle size was able
to increase the bioavailability, however, only a two-fold increase was observed. Hence the 120 nm sus-
pension caused an additional two-fold bioavailability improvement compared to the 480 nm suspension.
This result is in contrast to the studies of Wang et al. (2010); Li et al. (2009); Xia et al. (2010). They did
not report an additional effect on systemic exposure once the crystal size reached the nanometer range.
The present study contributes two more investigations on the in vivo effects associated with incremental
particle size reduction. The fenofibrate nanosuspension NS 140nm had significantly higher Cmax than all
other formulations. For compound AS suspensions a significantly higher Cmax for NS 150nm compared
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Figure 3.32: In vitro-in vivo correlation: Linear relationship between logarithmic dissolution time (LOG
DT ) and the AUC of fenofibrate (blue) and compound AS (orange) crystalline suspensions.
to the microsuspension was observed. Cmax of NS 100nm was not significantly different from the mi-
crosuspension, however, the plasma concentration at 5 h was. No statistical differences were identified
between NS 100nm and NS 150nm. Particle size reduction to a size of about 1 µm did not improve the
bioavailability with reference to a particle size of about a size of 7 − 8µm for both APIs (p < 0.05 for all
tests).
In summary the presented studies demonstrated that a crystal size reduction to the nanometer scale im-
proved the bioavailability of fenofibrate and compound AS. An additional effect in the comparison of
two nanosuspensions was observed for fenofibrate, but not for compound AS.
3.8.3 In vitro-in vivo correlation
Following the concept of Xia et al. (2010) a linear regression analysis was performed on the logarithmic
dissolution times (Log (DT)) with the AUC as a measure of bioavailability (Fig. 3.32). A good linear
relationship was observed for fenofibrate (R2 = 0.918). For compound AS the deviations between
measured and fitted data are higher (R2 = 0.682). However, the data points are evenly distributed around
the fitted linear relation which suggests the possibility that a linear correlation might actually model the
experimental data correctly.
3.8.4 Pharmacokinetic modeling & simulation
The effect of particle size reduction on in vivo PK was modeled with the GastroPlusTM software. The aim
was to evaluate whether PK profiles could be correctly simulated and whether the nanofactor effect im-
proves the simulation. The possibility to include the nanofactor effect into the ACAT model was offered
by Simulations plus, Inc., because a faster dissolution and/or an enhanced solubility alone did not cor-
rectly simulate the absorption from nano-sized particles (section 1.2.3). The nanofactor effect allows for
a local supersaturation at the apical membrane, leading to a steeper concentration gradient and thereby
increasing absorption. It is based on the empirical model adjustment for each API.
Table 3.13 summarizes the simulation input parameters and some comments on the simulations setup are
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Table 3.13: PK simulation with GastroPlusTM: input parameters.
Parameter Fenofibrate / fenofibric acid Compound AS
logP 5.29 calc 2.17 obs
pKa – calc1
Reference solubility [mg/ml] 0.00029 obs 0.011 obs
Reference solubility pH 7.0 calc 5.8 calc
SGF solubility [mg/ml] 0.00012 obs 0.0073 obs
FaSSIF solubility [mg/ml] 0.01126 obs 0.0093 obs
FeSSIF solubility [mg/ml] 0.03679 obs 0.03 obs
Bile salt solubilization ratio2 408000 calc 6928 calc
Caco-2 Papp [cm/s ∗ 105] 0.064 or 0.2 obs 0.031 obs
Simulated Pe f f (Rat) [cm/s ∗ 104] 0.1500 or 0.3089 calc 0.0947 calc
Dose [mg] 0.518 0.675
Dosage Form Immediate release: Suspension
Particle density [g/ml] 1.2 calc 1.2 calc
Particle size distribution obs3 obs3
Dissolution model Johnson4 Wang-Flanagan4
Nanofactor5 0.2 0.1
Diffusion coefficient [cm2/s ∗ 105] 0.67 calc 0.59 calc
Liver first pass extraction (FPE) [%] 3.9721 calc6 2.7072 calc
Fraction unbound in plasma (Fup) [%] 1.28 calc6 3.13 calc
Blood/Plasma concentration ratio 0.55 calc6 0.6 calc
Clearance CL [l/h] 0.01277 fit 0.01279 fit
Volume of distribution Vc [l/kg] 0.03631 fit 0.14417 fit
K12 [1/h] 9.2383 fit 0.51529 fit
K21 [1/h] 2.8343 fit 1.7645 fit
K13 [1/h] 0.3937 fit 0.00779 fit
K31 [1/h] 0.07277 fit 0.20788 fit
Compartmental PK model 3 compartments 3 compartments
ASF model7 Opt logD Model SA/V 6.1
ACAT model Rat - physiological - fasted8
with stomach transit time 0.05 h
obs: observed/experimental value
calc: calculated by GastroPlusTM
fit: fitted by the GastroPlusTM PKPlusTM module from FFA/AS i.v. experimental profiles
1 GastroPlusTM built in solubility-pH function
2 solubility and diffusion coefficient adjusted for bile salt effect
3 SLS particle size distribution with 9 − 16 bins
4 diffusion layer thickness adjusted to changing radius up to maximum 30 µm, particle shape factor 1
5 manually adjusted with GastroPlusTM default for interfacial tension 0.05 J/m2
6 calculated by GastroPlusTM for FFA molecule
7 The absorption scale factor (ASF) provides the absorption model. The applied model (default) incorporates a logD-
dependent calibration of ASF based on human and rat permeability/fraction absorbed data.
8 animal weight 0.25 kg
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given here. The orally administered suspensions were characterized by SLS particle size measurements
(section 3.1.1) and the obtained particle size distributions are used in the simulations. Experimental val-
ues for the physiochemical properties of APIs (solubility, permeability) were used as far as available and
all other values were predicted by the ADMET PredictorTM. The Johnson and Wang-Flanagan disso-
lution models were applied to simulate in vivo dissolution in different GI compartments. The observed
i.v. concentration-time profiles were used to obtain pharmacokinetic parameters. Different settings (0-1)
were tried for the nanofactor and the value which resulted in the best simulation for the smallest nano-
sized formulations was selected for all formulations. For fenofibrate the modeling had an additional
dimension: the conversion of the prodrug fenofibrate towards fenofibric acid. In the in vitro permeabil-
ity and the in vivo PK studies the metabolization was already complete after intestinal absorption. This
observation was accounted for in the model by applying the physiochemical parameters of FF for all
steps prior to absorption and by applying the pharmacokinetic properties of FFA for all steps following
absorption (elimination).
All simulation results are shown in Figure 3.33, Figure 3.34 and Table 3.14. Fenofibrate simulations
were started using the pure crystalline API permeability Papp = 0.64 ∗ 10−6 cm/s (Tab. 3.8). Without the
nanofactor effect the AUC of all formulations was underestimated and the observed shift of Tmax could
not be modeled. The nanofactor improved the AUC prediction and a clearly better fit was achieved for
NS 140nm and NS 270nm. The discrimination between the four formulations corresponding to particle
size was much better simulated. Now Tmax decreased with deceasing particle size. It was, however, still
too long especially for NS 140nm.
Since a higher permeability in the Caco-2 model was observed for nano-sized FF formulations than for
pure crystalline API, the permeability was set to Papp = 2 ∗ 10−6 cm/s (average, rounded value measured
for NS 140nm/NS 270nm, Tab. 3.11). This improved the overall predictivity of the simulation indicated
by an average R2 = 0.761 (2 ∗ 10−6 cm/s) versus an average R2 = 0.652 (0.64 ∗ 10−6 cm/s). The
profiles of the two smaller sized suspensions with an early Tmax were much better simulated. However,
the extent of absorption (AUC, Fabs) was now overestimated for the two larger sized suspensions. In-
clusion of the nanofactor effect into the simulation greatly improved the prediction of the NS 140nm
concentration-time profile. However, the overestimation of Cmax and AUC of the other formulations,
which was already observed without the nanofactor, was amplified.
In summary it was difficult to identify the overall best model for the simulation of the FF concentration-
time profiles of all formulations. An inappropriate representation of the intestinal metabolization by the
applied model might be one reason.
Compound AS simulations were started using the permeability Papp = 0.22 ∗ 10−6 cm/s, which was
determined for the AS microsuspension (Tab 3.9). The average R2 values for all five formulations were
0.671 without the nanofactor and 0.786 with the nanofactor (data not shown). Application of the per-
meability Papp = 0.31 ∗ 10−6 cm/s which was determined for AS NS 150nm improved the correlation
of predicted and observed plasma profiles for every single formulation. The average coefficients of de-
termination were increased to R2 = 0.750 without the nanofactor and R2 = 0.840 with the nanofactor
(Tab. 3.14). The inclusion of the nanofactor effect into the model clearly improved the predictivity of the
model for NS 100nm and NS 150nm. The differences for NS 860nm, NS 1320nm and MS 6.8 µm were
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less pronounced. While the nanofactor effect caused an overestimation of the microsuspensions bioavail-
ability, it is not possible to identify the better model for medium sized formulations like NS 860nm and
NS 1320nm.
In summary the simulation of the concentration-time profiles for AS formulations was remarkably good
and the inclusion of the nanofactor effect clearly improved the overall suitability of the model.
One point which remains to be discussed is that no relevant differences between the nano-sized formula-
tions (FF NS 140nm vs FF NS 270nm and AS NS 100nm vs AS NS 150nm) were seen in the simulations.
However, they were observed in vivo (Fig. 3.30). The use of the nanofactor effect did not make a dif-
ference. A reason might be that a model adjustment allowing for supersaturation effects by nanocrystal
alone is not sufficient. It should also be kept in mind that it is an empirical approach. Recently the
challenge of nanoparticle absorption/dissolution modeling was also addressed by Johnson (2012). He
modeled dissolution by the Johnson and Wang-Flanagan dissolution models and incorporated a parti-
cle size adjusted solubility according to the Ostwald-Freundlich equation. Even though his model was
hence comprising many parameters it was not sufficient to explain observed differences between absorp-
tion from nano and micron sized particles. He confirmed that the dissolution rate enhancement alone
cannot explain nanocrystal absorption profiles.
While the theoretical implications of particle size reduction on dissolution are already quite well repre-
sented in the advanced dissolution models, it becomes obvious that the implications on API absorption
are still poorly investigated and understood. The present investigation confirms that the nanofactor effect
can greatly improve the simulation of the in vivo behavior of orally applied nano-sized rapidly dissolving
particles. However, it does not have the power to discriminate between different nano-sized formulations,
which indicates that also other effects might contribute to the observed increase in extent of API absorp-
tion. Also a more mechanistic approach of taking into account supersaturation phenomena is required.
3.8.5 Summary and conclusions
The pharmacokinetic studies on suspensions with incrementally reduced particle size are an important
contribution to the discussion about the in vivo effects of particle size reduction, since similarly designed
studies are rare. The presented studies demonstrated that a crystal particle size reduction to the nanome-
ter scale improved the relative bioavailability with reference to a microsuspension. This was true for both
APIs, fenofibrate and compound AS. An additional bioavailability enhancing effect when two nanosus-
pensions are compared was only observed for fenofibrate, but not for compound AS.
The outstanding characteristics of the presented studies are that the suspensions are narrowly distributed
and that dissolution data are available for all formulations. A good linear correlation of the logarithmic
dissolution times (Log (DT)) with the AUC was observed. The Advanced Compartmental Absorption
and Transit (ACAT) simulation model was used to simulate plasma concentration-time profiles with
GastroPlusTM. The use of the nanofactor effect, which offers an empirical model adjustment by allowing
for nanocrystal dissolution exceeding the solubility limit, improved the predictivity of the model for the
simulation of the absorption of API delivered as nano sized crystals. However, the model did not repre-
sent the in vivo observed discrimination between the smallest sized formulations.
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(a) NS 140nm (b) NS 270nm
(c) NS 1070nm (d) MS 7.9 µm
(e) FFA i.v.
Figure 3.33: FF simulated plasma concentration-time curves (lines) and experimental data (symbols).
Simulation parameters: Caco-2 Papp = 0.064 ∗ 10−5 cm/s (thin lines) or Caco-2 Papp = 0.2 ∗ 10−5 cm/s
(bold lines); with nanofactor 0.2 (compact lines) or without nanofactor (dashed lines).
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(a) NS 100nm (b) NS 150nm
(c) NS 860nm (d) NS 1320nm
(e) MS 6.8 µm (f) AS i.v.
Figure 3.34: Compound AS simulated plasma concentration-time curves (lines) and experimental data
(symbols). Simulation parameters: Caco-2 Papp = 0.031 ∗ 10−5 cm/s; with nanofactor 0.1 (compact
lines) or without nanofactor (dashed lines).
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Table 3.14: PK parameters of FF and AS formulations simulated by the ACAT model with different
settings.
Formulation R2 Tmax Cmax AUC0→25h Fabs
[h] [ng/ml] [ng/ml∗h] [%]
Small numbers denote deviations
∗
of predicted from observed value in %
Fenofibrate
FFA i.v. 0.994 0 – 57060 +287∗ 37500 -10 100 ±0
Papp = 0.064 ∗ 10−5 cm/s, without nanofactor
NS 140nm 0.376 2.2 +340 3077 -53 21500 -38 59 -29
NS 270nm 0.589 2.2 +120 3068 -20 21400 -27 59 -16
NS 1070nm 0.885 2.2 -27 3001 +4 21000 -16 58 -4 •
MS 7.9µm 0.758 2.3 -23 2419 -24 17400 -27 48 -16
Papp = 0.064 ∗ 10−5 cm/s, with nanofactor 0.2
NS 140nm 0.607 1.8 +260 5842 -10 34600 ±0 93 +12
NS 270nm 0.782 1.9 +90 5239 +36 32700 +12 88 +26
NS 1070nm 0.802 2.1 -30 4183 +45 27700 +11 76 +26
MS 7.9µm 0.854 2.3 -23 2695 -15 19100 -20 53 -8
Papp = 0.2 ∗ 10−5 cm/s, without nanofactor
NS 140nm 0.548 1.5 +200 4872 -25 30500 -12 83 -1
NS 270nm 0.867 1.6 +60 4850 +26 30400 +4 82 +18 •
NS 1070nm 0.733 1.7 -43 4719 +64 29900 +20 81 +35
MS 7.9µm 0.854 1.8 -40 3590 +13 24300 +2 67 +17 •
Papp = 0.2 ∗ 10−5 cm/s, with nanofactor 0.2
NS 140nm 0.836 1.2 +140 7339 +13 35900 +4 96 +16 •
NS 270nm 0.736 1.4 +40 6869 +78 35700 +22 96 +37
NS 1070nm 0.658 1.6 -47 5729 +99 33600 +34 90 +51
MS 7.9µm 0.843 1.9 -37 3782 +19 25200 +6 69 +21
Compound AS
AS i.v. 0.983 0 – 6936 +18 19500 -11 100 ±0
Papp = 0.031 ∗ 10−5 cm/s, without nanofactor
NS 100nm 0.569 2.9 -3 1955 -37 16200 -45 32 -37
NS 150nm 0.612 2.9 -3 1955 -23 16200 -27 32 -14
NS 860nm 0.821 2.9 -3 1921 -6 16000 -14 31 -2 •
NS 1320nm 0.881 2.9 -3 1899 +2 15800 -31 31 -20
MS 6.8µm 0.868 2.9 -42 1664 +21 14300 -13 28 ±0 •
Papp = 0.031 ∗ 10−5 cm/s, with nanofactor 0.1
NS 100nm 0.896 2.6 -13 2988 -3 26200 -12 51 +2 •
NS 150nm 0.744 2.7 -10 2913 +15 26100 +17 51 +38 •
NS 860nm 0.800 2.8 -7 2172 +6 18900 +1 37 +15
NS 1320nm 0.901 2.8 -7 2050 +11 17300 -25 34 -13 •
MS 6.8µm 0.858 2.9 -42 1751 +27 16000 -3 31 +12
∗ Deviation = (PredictedValue − ObservedValue)/ObservedValue ∗ 100% • best fit
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The presented investigations on the relation of in vitro and in vivo data and on pharmacokinetic simula-
tions are a first approach. It is planed to continue analysis of the experimental data for example by making
use of the GastroPlusTM optimization tool. It mathematically fits model parameters to experimental data
and allows for IVIVC investigations.
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4
Summary and Outlook
Summary
The aim of this thesis was a biopharmaceutical characterization of oral nanocrystal formulations includ-
ing solubility, dissolution, permeation and in vivo pharmacokinetic studies. Crystalline suspensions with
an incrementally reduced particle size were developed to explicitly study the effect of particle size on the
biopharmaceutical properties. Size reduction had by far the strongest influence on dissolution kinetics.
A linear correlation of the logarithmic in vitro dissolution times with in vivo bioavailability was observed.
In the following the results and conclusions are summarized more in detail:
Crystalline nanosuspensions and microsuspensions of two drug substances, fenofibrate and the Merck
Serono compound AS, were prepared. An incremental particle size reduction was performed by using
the method of wet media milling. Nine fenofibrate and seven compound AS suspensions were prepared
and all of them were aqueous suspensions of 20% API, 2.5% HPMC and 0.1% DOSS. The suspensions
covered a wide particle size range (100 nm to 8 µm) and exhibited narrow particle size distributions.
It was challenging to determine the solubility and dissolution of nanocrystal formulations. Very small
particles with rapid dissolution kinetics complicated the separation of solid from dissolved material.
Therefore, this work focused on noninvasive analytical techniques which avoid the critical separation
step. A method of monitoring the light scattering intensity with a Zetasizer Nano ZSTM instrument was
developed and applied to measure solubilities and dissolution kinetics of nanocrystalline API.
Also alternative methods were evaluated for their suitability to assess nanocrystal dissolution. Mod-
ifications of the conventional USP II method by using 0.02 µm syringe filters or dialysis membranes
did not improve its applicability for nanocrystal dissolution. Among the tested noninvasive in situ an-
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alytical techniques (nanoparticle tracking analysis, NMR and Raman spectroscopy, isothermal titration
calorimetry) the light scattering approach was the most promising one. It measures the drop of light
scattering intensity during dissolution, which is caused by a reduction in particle number and size.
The light scattering dissolution method allowed for a continuous and fast nanocrystal dissolution assess-
ment in a straightforward small scale experimental setup. Dissolution results were in good agreement
with a conventional dissolution technique (USP II apparatus with sample filtration). The new approach
was applicable to differentiate between different particle sizes and concentration gradients with a satisfy-
ing sensitivity and reproducibility. The nanocrystal size most suitable for the light scattering method was
100 − 500 nm (particle diameter) and the method was still applicable up to a size of 1 µm. Dissolution
times as short as 90 s could be determined.
The experimentally obtained dissolution curves were successfully fitted by a biexponential decay model.
This allowed for the calculation of dissolution times (time, when only 1 % of initial scattering intensity
remains). The results of light scattering dissolution were in good agreement with the Noyes-Whitney
dissolution model.
While a particle size reduction greatly accelerated the dissolution process, only moderately enhanced
solubilities of nanosuspensions were observed (10 − 20 % for particles < 200 nm). This result highlights
accelerated dissolution as main factor of the bioavailability enhancement through nanocrystals.
In Caco-2 permeability studies the effect of particle size on the permeability was evaluated. An assay
with vertical monolayer arrangement was compared to the classical horizontal assay. The vertical setup
did not improve the discriminative power and the adjustment of standardized experimental conditions
was difficult. Therefore, the horizontal setup was selected for further experiments. A variation of apical
transport medium by using a biorelevant medium instead of a classical buffered salt solution did not alter
the permeabilities essentially.
For compound AS it was observed that a smaller particle size improved the permeability. This is
an expected result, due to a moderately enhanced solubility and a markedly faster dissolution of the
smaller particles. A fast dissolution guarantees for a constant high concentration of dissolved API at the
absorption site and enables a good utilization of the APIs permeability potential. On the other hand a
positive effect of size reduction on the permeability was not observed for fenofibrate. The findings in
this study suggest that the enzymatic fenofibrate conversion in the Caco-2 assay might interfere with the
effects of particle size reduction. The metabolite, fenofibric acid, has a higher solubility than fenofibrate
and an equal permeability. A parallel increase of permeability with apical fenofibric acid concentration
indicates that fenofibric acid might be the substrate mainly permeating across the epithelial barrier. The
metabolization might play a crucial role and was not sufficiently investigated in this study.
In vivo pharmacokinetic studies of the oral administration of suspensions to rats completed the bio-
pharmaceutical characterization. The in vivo studies demonstrated that a crystal size reduction to the
nanometer scale improved the relative bioavailability with reference to a microsuspension. This was
true for both APIs, fenofibrate and compound AS. The presented pharmacokinetic studies on several
suspensions with incrementally reduced particle size give an important contribution to the discussion
about the in vivo effects of particle size reduction, since similarly designed studies are rare. The out-
standing characteristics of the presented studies are that the suspensions are narrowly distributed and
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that dissolution data are available for all formulations.
The presented work covers a thorough particle size distribution analysis, solubility, dissolution, perme-
ation and in vivo pharmacokinetic investigation of micro- and nanosuspensions of two drug substances.
These data are very useful to investigate the in vitro-in vivo relation of oral nanocrystal formulations.
In this work a good linear correlation of the logarithmic dissolution times to the bioavailability was
demonstrated. Furthermore plasma concentration-time profiles were successfully simulated using the
Advanced Compartmental Absorption and Transit (ACAT) model. For nanocrystal formulations the fit
of simulated to observed profiles was improved by applying the nanofactor effect implemented in the
ACAT model.
Outlook
The application of the light scattering method for nanocrystal solubility and dissolution studies of a
greater number of APIs and formulations will help to better characterize the strengths and limitations of
the new methods and to demonstrate a broad applicability.
Regarding the nanocrystal dissolution method future studies covering the following aspects would be
interesting:
• A use of the light scattering dissolution method in later development phases and for quality control
purposes would require an implementation of strategies to cope with undissolvable excipients due
to their influence on light scattering measurements. In this work the successful application of
prefiltration steps was demonstrated for the measurement of nanocrystal dissolution of the market
product EMEND R©.
• An evaluation of dissolution results on the basis of advanced dissolution models will help to gain
further mechanistic insight from experimental data. Wang-Flanagan and Johnson developed ad-
vanced dissolution models taking into account particle shrinking and associated changes of the
diffusion layer thickness and particle solubility. All these parameters are considered constant in
the Noyes-Whitney dissolution model. Furthermore calculations with particle size distributions
rather than an average particle size will help to refine the model.
• It would be interesting to theoretically model the course of light scattering intensity during dissolu-
tion. The decreasing scattering intensity is caused by changes in particle number and particle size.
Depending on size the scattering properties of a particle are likely to change during dissolution.
• Another noninvasive analytical technique, the isothermal titration calorimetry, showed a potential
for the dissolution testing of nanocrystals. Further studies with different formulations under dif-
ferent conditions will clarify the applicability of this method. A comparison of results to the light
scattering method would be interesting.
Regarding the Caco-2 permeability studies on fenofibrate formulations a thorough investigation on
the extent and influence of fenofibric acid formation during the assay is required. An evaluation of the
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esterase activity or a specific inhibition of esterases would help to analyze the hydrolytic effect and its
influence on fenofibrate permeability. Furthermore it would be interesting to extend the experiments on
particle formulations, which aggregate in the transport media. The high bioavailability of compound AS
formulation NS 100nm showed that an in vitro instability in physiologically relevant intestinal media was
not translating into poor in vivo performance. The performance of aggregated NS 100nm nanocrystals
in an in vitro permeability experiment will reveal if a disaggregation caused by the intestinal motility is
responsible for good in vivo results.
The presented investigations on the relation of in vitro and in vivo data are a first approach. A deeper
analysis is planned to be performed using the Advanced Compartmental Absorption and Transit (ACAT)
Simulation Model implemented in the GastroPlusTM software.
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List of Abbreviations
ACAT Advanced Compartmental Absorption and Transit model
AcN acetonitrile
API active pharmaceutical ingredient
AS Merck Serono Compound AS
ATP adenosine triphosphate
BCS Biopharmaceutical classification system
DLS dynamic light scattering
DMEM Dulbecco´s modified Eagle´s medium
DOSS dioctyl sulfosuccinate sodium salt
DSC differential scanning calorimetry
FaSSIF fasted state simulated intestinal fluid
FF fenofibrate
FFA fenofibric acid
GF griseofulvin
GI gastrointestinal
HBSS Hanks´ balanced salts solution
HPLC high pressure liquid chromatography
HPMC hydroxypropylmethylcellulose
i.v. intravenous
IPC in-process control
ITC isothermal titration calorimetry
120 LIST OF ABBREVIATIONS
KC ketoconazole
kcps kilo counts per second
MRP multidrug resistance protein
MS microsuspension
NMR nuclear magnetic resonance spectroscopy
NS nanosuspension
NTA nanoparticle tracking analysis
P-gp P-glycoprotein
p.o. peroral
PBS phosphate buffered saline
PDI polydispersity index
Ph. Eur. Pharmacopoeia Europaea
PK pharmacokinetic
PZN Pharma Zentral Nummer
rpm rounds per minute
SEM scanning electron microscopy
SGF simulated gastric fluid
SGF + Tween simulated gastric fluid supplemented with 0.1% polysorbate 80
SLS static light scattering
TEER trans epithelial electrical resistance
TFA trifluoroacetic acid
TOC total organic carbon
USP United States Pharmacopeia
UWL unstirred water layer
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